 
 
 
Any and all information presented in this document shall be treated as confidential and shall remain the excl usive property of S anofi (or any of its 
affiliated companies). The us e of such confidential information must be restricted to the recipi[INVESTIGATOR_21321], published or otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever without th e prior wr itten 
conse nt of [COMPANY_011] (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other entity which at the d ate 
of communication or afterwards (i) controls direc tly or indirectly [COMPANY_011] , (ii) is directly or indirec tly controll ed by [CONTACT_13225] , with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040], partnership or o ther entity  
Based on Template: [COMPANY_011] OneDocument Version 2.0, dated 14-OCT -2019  Page 1 
AMENDED CLINICAL TRIAL PROTOCOL 12  
 Protocol title:  A Phase 3, randomized, double -blind, efficacy and safety 
study comparing SAR442168 to placebo in participants 
with nonrelapsing secondary progressive multiple 
sclerosis  (HERCULES)  
Protocol number:  EFC16645  
Amendment number:  12 
Compound number 
(INN/Trademark):  SAR442168   
(tolebrutinib /not applicable ) 
Study p hase : Phase  3 
Short title:  NRSPMS  study of BTK inhibitor tolebrutinib ( SAR442168 ) 
HERCULES  
Sponsor  name:  [CONTACT_21524] * 
*[COMPANY_011] corporation organized and existing under the laws 
of [LOCATION_009] is the ultimate parent of a worldwide group of 
affiliates including [COMPANY_011] US Services Inc., [COMPANY_011] 
Genzyme, and Genzyme Corporation  
Legal registered 
address:  [ADDRESS_20213], Cambridge, MA, [ZIP_CODE], [LOCATION_003]  
Monitoring Team’s 
Representative Name 
[CONTACT_9352] 
[CONTACT_21396](s):  
IND:  [ADDRESS_20214]:  [ADDRESS_20215]: [STUDY_ID_REMOVED]  
WHO:  U1111 -1246 -7768  
EUDAMED : Not applicable  
Other:  Not applicable  
Date:  20-Dec-2023  Total number of pages:  149 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 2 PROTOCOL AMENDMENT SUMMARY OF CHANGES   
DOCUMENT HISTORY   
Document  Country /countries  
impacted by 
[CONTACT_13097], version  
Amended Clinical Trial Protocol 12  All 20 December 2023, version 1 (electronic 21.0)  
Amended Clinical Trial Protocol 11  All 20 November 2023, version 1 (electronic 20.0) 
Amended Clinical Trial Protocol 10  All 28 September 2023, version 1 (electronic 17.0)  
Amended Clinical Trial Protocol 09  [LOCATION_009]  12 July 2023, version 1 (electronic 16.0)  
Amended Clinical Trial Protocol 08  All 14 December 2022, version 1 (electronic 14.0)  
Amended Clinical Trial Protocol 07  All 13 September 2022, version 1 (electronic 13.0)  
Amended Clinical Trial Protocol 06  All 23 May 2022, version 1 (electronic 12.0)  
Amended Clinical Trial Protocol 05  All 21 December 2021, version 1 (electronic 11.0)  
Amended Clinical Trial Protocol 04  All 26 Jul y 2021, version 1 (electr onic 10.0) 
Amended Clinical Trial Protocol 03  All 03 November 2020, version 1 (electronic 7.0)  
Amended Clinical Trial Protocol [ADDRESS_20216] 2020, version 1 (electronic 5.0)  
Amended Clinical Trial Protocol 01  All 15 May 2020, version 1 (electronic 2.0)  
Original Clinical Trial Protocol   28 Feb ruary  2020, version 1 (electronic 1.0)  
Amended protocol 12 (20 December  2023 ) 
This amended protocol (amendment 12) is considered to be non-substantial based on the criteria 
set forth in Article  10(a) of Directive 2001/20/EC of the European Parliament and the Council of 
the European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is  to update the liver function test monitoring as per 
Health Authority re quest . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 3 Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.3 Schedule of activities (S oA) Week 3 added in the visit header and in footnote ‘l’.  Update . 
10.9 Appendix 9: Example of drugs 
with a potential to change 
SAR442168 metabolism or 
absorption  Table 8: removed ‘rifabutin’ from the list of potent 
CYP3A inducers. Table 9: moved ‘rifabutin’ from the 
list of potent CYP3A inducers to the list of moderate 
CYP3A inducers.  Correction of error as per  
updated guidance for CYP 
inhibitors/inducers based on 
information from DDI study.  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
Throughout the document  Reformatted existing content when necessary. Minor, 
editorial, stylistic changes as necessary. Updated 
table of contents, section numbers, abbreviations as 
necessary.  Update in accordance with 
Sponsor’s standards.  
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20217] OF FIGURES  ................................ ................................ ................................ ................................ ........  10 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............  11 
1.1 SYNOPS IS ................................ ................................ ................................ ................................ ..... 11 
1.2 SCHEMA  ................................ ................................ ................................ ................................ ........  18 
1.3 SCHEDULE OF ACTIVITIES (SOA)  ................................ ................................ ..............................  19 
2 INTRODUCTION  ................................ ................................ ................................ ............................  30 
2.1 STUDY RATIONALE ................................ ................................ ................................ ......................  30 
2.2 BACKGROUND  ................................ ................................ ................................ .............................  32 
2.3 BENEFIT/RI SK ASSESSMENT  ................................ ................................ ................................ ..... 33 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ . 37 
3.1 APPROPRIATENESS OF MEASUREMENTS  ................................ ................................ ..............  39 
4 STUDY DESIGN  ................................ ................................ ................................ ............................  40 
4.1 OVERALL DESIGN  ................................ ................................ ................................ ........................  40 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN  ................................ ................................ .........  40 
4.2.1  Justification for participant’s age and study duration  ................................ ................................ ..... 40 
4.2.2  Justification for the use of placebo ................................ ................................ ................................ . 41 
4.2.3  Participant input into design  ................................ ................................ ................................ ...........  41 
4.3 JUSTIFICATION FOR DOSE  ................................ ................................ ................................ ........  41 
4.4 END OF STUDY DEFINITION  ................................ ................................ ................................ ....... 42 
5 STUDY POPULATION  ................................ ................................ ................................ ..................  43 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ ..................  43 
5.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ................  44 
5.3 LIFESTYLE CONSIDERATIONS  ................................ ................................ ................................ ... 49 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 5 5.3.1  Meals and dietary restrictions  ................................ ................................ ................................ ........  49 
5.3.2  Caffeine, alcohol, and tobacco  ................................ ................................ ................................ ....... 49 
5.3.3  Activity  ................................ ................................ ................................ ................................ ............  49 
5.4 SCREEN FAILURES ................................ ................................ ................................ ......................  50 
5.5 CRITERIA FOR TEMPORARILY DELAYING ADMINISTRATION OF STUDY 
INTERVENTION  ................................ ................................ ................................ ............................  50 
6 STUDY INTERVENTION  ................................ ................................ ................................ ...............  51 
6.1 CRITERIA FOR TEMPORARILY DELAYING ENROLLMENT AND ADMINISTRATION OF 
STUDY INTERVENTION  ................................ ................................ ................................ ...............  51 
6.2 STUDY INTERVENTION(S) ADMINISTERED  ................................ ................................ ..............  [ADDRESS_20218]  ................................ ................................ ............................  51 
6.3 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY ................................ .......................  52 
6.4 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  ................................ ....... 52 
6.5 STUDY INTERVENTION COMPLIANCE  ................................ ................................ ......................  54 
6.6 CONCOMITANT THERAPY  ................................ ................................ ................................ ..........  55 
6.6.1  Open -label treatment  ................................ ................................ ................................ .....................  56 
6.7 DOSE MODIFICATION  ................................ ................................ ................................ ..................  57 
6.8 INTERVENTION AFTER THE END OF THE STUDY  ................................ ................................ ... 57 
7 DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........................  58 
7.1 DISCONTINUATION OF STUDY INTERVENTION  ................................ ................................ ...... 58 
7.1.1  Definitive discontinuation  ................................ ................................ ................................ ...............  58 
7.1.2  Temporary discontinuation  ................................ ................................ ................................ .............  60 
[IP_ADDRESS]  Rechallenge  ................................ ................................ ................................ ................................ ... 60 
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY  ................................ .. [ADDRESS_20219] TO FOLLOW UP  ................................ ................................ ................................ .................  62 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ ...........  63 
8.1 EFFICACY ASSESSMENTS  ................................ ................................ ................................ .........  63 
8.1.1  Expanded disability status scale  ................................ ................................ ................................ .... 64 
[IP_ADDRESS]  Confirmed disability progression  ................................ ................................ ................................ .... 64 
[IP_ADDRESS]  Confirmed disability improvement  ................................ ................................ ................................ .. 65 
8.1.2  Magnetic resonance imaging  ................................ ................................ ................................ .........  65 
8.1.3  Multiple sclerosis relapse assessment  ................................ ................................ ...........................  66 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 6 [IP_ADDRESS]  Definition of multiple sclerosis relapse  ................................ ................................ ...........................  66 
[IP_ADDRESS]  Unscheduled assessment visits  ................................ ................................ ................................ ..... [ADDRESS_20220]  ................................ ................................ ................................ ...............................  68 
8.1.6  Cognitive tests  ................................ ................................ ................................ ................................  68 
8.1.7  Composite analyses  ................................ ................................ ................................ .......................  68 
[IP_ADDRESS]  Modified Multiple Sclerosis Functional Composite -3 ................................ ................................ ..... 68 
[IP_ADDRESS]  Assessment of no evidence of disease activity  ................................ ................................ .............  [ADDRESS_20221] complaints  ................................ ................................ ..................  75 
8.4 TREATMENT OF OVERDOSE  ................................ ................................ ................................ ...... 75 
8.5 PHARMACOKINETICS  ................................ ................................ ................................ ..................  76 
8.6 PHARMACODYNAMICS  ................................ ................................ ................................ ...............  76 
8.7 GENETICS  ................................ ................................ ................................ ................................ ..... 77 
8.8 BIOMARKERS  ................................ ................................ ................................ ...............................  77 
8.9 IMMUNOGENICITY ASSESSMENTS  ................................ ................................ ...........................  77 
8.10  MEDICAL RESOURCE UTILIZATION AND HEALTH ECONOMICS  ................................ ...........  77 
8.11  USE OF BIOLOGICAL SAMPLES AND DATA FOR FUTURE RESEARCH  ................................  78 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 7 9 STATISTICAL CONSIDERATIONS  ................................ ................................ ..............................  79 
9.1 STATISTICAL HYPOTHESES  ................................ ................................ ................................ ....... 79 
9.2 SAMPLE SIZE DETERMINATION  ................................ ................................ ................................ . 79 
9.3 POPULATIONS FOR ANALYSES  ................................ ................................ ................................ . 80 
9.4 STATISTICAL ANALYSES  ................................ ................................ ................................ ............  80 
9.4.1  General considerations  ................................ ................................ ................................ ..................  80 
9.4.2  Primary endpoint  ................................ ................................ ................................ ............................  81 
9.4.3  Secondary endpoint(s)  ................................ ................................ ................................ ...................  82 
9.4.4  Tertiary/exploratory endpoint(s)  ................................ ................................ ................................ ..... 82 
9.4.5  Other safety analyses  ................................ ................................ ................................ ....................  83 
9.4.6  Other analyses  ................................ ................................ ................................ ...............................  84 
9.5 INTE RIM ANALYSES  ................................ ................................ ................................ ....................  84 
9.6 DATA MONITORING COMMITTEE (DMC)  ................................ ................................ ...................  84 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ........................  85 
10.1  APPENDIX 1: REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS  ....... 85 
10.1.1  Regulatory and ethical considerations  ................................ ................................ ...........................  85 
10.1.2  Financial disclosure ................................ ................................ ................................ ........................  86 
10.1.3  Informed consent process  ................................ ................................ ................................ ..............  86 
10.1.4  Data protection  ................................ ................................ ................................ ...............................  87 
10.1.5  Committee structures  ................................ ................................ ................................ .....................  89 
[IP_ADDRESS]  Data Monitoring Committee  ................................ ................................ ................................ ...........  89 
[IP_ADDRESS]  Scientific Advisory Committee  ................................ ................................ ................................ ....... 89 
[IP_ADDRESS]  Eligibility Adjudication Committee  ................................ ................................ ................................ .. 90 
[IP_ADDRESS]  Relapse Adjudication Committee  ................................ ................................ ................................ ... 90 
[IP_ADDRESS]  Independent Hepatology Assessment Committee  ................................ ................................ .........  90 
10.1.6  Dissemination of clinical study data  ................................ ................................ ...............................  90 
10.1.7  Data quality assurance  ................................ ................................ ................................ ..................  91 
10.1.8  Source documents  ................................ ................................ ................................ .........................  92 
10.1.9  Study and site start and closure  ................................ ................................ ................................ ..... 92 
10.1.10  Publication policy  ................................ ................................ ................................ ...........................  93 
10.2  APPENDIX 2: CLINICAL LABORATORY TESTS  ................................ ................................ .........  93 
10.3  APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING  ................................ ................  95 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............................  95 
10.3.2  Definition of SAE  ................................ ................................ ................................ ............................  97 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 8 10.3.3 Recording and follow up of AE and/or SAE  ................................ ................................ ...................  98 
10.3.4  Reporting of SAEs ................................ ................................ ................................ ........................  100 
10.4  APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PREGNANCY 
INFORMATION  ................................ ................................ ................................ ............................  100 
10.5  APPENDIX 5: GENETICS  ................................ ................................ ................................ ...........  103 
10.6 APPENDIX 6: LIVER AND OTHER SAFETY: ACTIONS AND FOLLOW -UP 
ASSESSMENTS  ................................ ................................ ................................ ..........................  104 
10.7  APPENDIX 7: MEDICAL DEVICE ADVERSE EVENTS (AES) , ADVERSE DEVICE 
EFFECTS (ADES), SERIOUS ADVERSE EVENTS (SAES) AND DEVICE DEFICIENCIES: 
DEFINITION AND PROCEDURES FOR RECORDING, EVALUATING, FOLLOW -UP, AND 
REPORTING  ................................ ................................ ................................ ................................  112 
10.8  APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENTS  ................................ ............................  112 
10.8.1  Contraception requirements in [LOCATION_006], [LOCATION_013], and Denmark  ................................ ......................  112 
10.8.2  Country -specific differences for China  ................................ ................................ .........................  113 
10.8.3  Country -specific provisions for [LOCATION_009] and Japan  ................................ ................................ ....... 113 
10.8.4  Country -specific provisions for Japan  ................................ ................................ ..........................  115 
10.8.5  Country -specific provisions for the US  ................................ ................................ .........................  115 
10.8.6  Count ry-specific provisions for the US, Israel, and sites following FDA partial clinical hold 
conditions  ................................ ................................ ................................ ................................ ..... 115 
10.9  APPENDIX 9: EXAMPLE OF DRUGS WITH A POTENTIAL TO CHANGE SAR442168 
METABOLISM OR ABSORPTION  ................................ ................................ ..............................  115 
10.10  APPENDIX 10: CONTINGENCY MEASURES FOR A REGIONAL OR NATIONAL 
EMERGENCY THAT IS DECLARED BY A GOVERNMENTAL AGENCY  ................................ . 117 
10.10.1  Informed consent  ................................ ................................ ................................ .........................  117 
10.10.2  Study procedures  ................................ ................................ ................................ .........................  117 
10.10.3  Temporary discontinuation  ................................ ................................ ................................ ...........  118 
10.10.4  Statistical analysis  ................................ ................................ ................................ ........................  118 
10.11  APPENDIX 11: IMMUNOPHENOTYPI[INVESTIGATOR_1645] (TOLEDYNAMIC SUBSTUDY)  ................................  119 
10.12  APPENDIX 12: ACTIGRAPHY SUBSTUDY  ................................ ................................ ................  121 
10.13  APPENDIX 13: ABBREVIATIONS  ................................ ................................ ...............................  122 
10.14  APPENDIX 14: PROTOCOL AMENDMENT HISTORY  ................................ ..............................  124 
10.14.1  Amended protocol 01 (15 May 2020) ................................ ................................ ...........................  124 
10.14.2  Amended protocol 02 ([ADDRESS_20222] 2020)  ................................ ................................ ......................  128 
10.14.3  Amended protocol 03 (03 November 2020)  ................................ ................................ .................  130 
10.14.4  Amended protocol 04 (26 July 2021)  ................................ ................................ ...........................  132 
10.14.5  Amended protocol 05 (21 December 2021)  ................................ ................................ .................  137 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 9 10.14.6  Amended Protocol 06 (23 May 2022)  ................................ ................................ ..........................  139 
10.14.7  Amended protocol 07 (13 September 2022)  ................................ ................................ ................  139 
10.14.8  Amended protocol 08 (14 December 2022)  ................................ ................................ .................  140 
10.14.9  Amended protocol 09 (12 July 2023)  ................................ ................................ ...........................  141 
10.14.10  Amended protocol 10 (28 September 2023)  ................................ ................................ ................  142 
10.14.11  Amended protocol 11 (20 November 2023)  ................................ ................................ .................  144 
11 REFERENCES  ................................ ................................ ................................ .............................  146  
 
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20223] OF FIGURES   
Figure  1 - Graphical study design  ................................ ................................ ................................ .................  18 
 
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 11 1 PROTOCOL SUMMARY   
1.1 SYNOPSIS   
Protocol title:  A Phase 3, randomized, double -blind, efficacy and safety study comparing 
SAR442168 to placebo in participants with nonrelapsing secondary progressive 
multiple sc lerosis  (HERCULES)  
Short title:  NRSPMS  study of BTK inhibitor tolebrutinib ( SAR442168 ) (HERCULES)  
Rationale:  
The advent of disease -modifying therapi[INVESTIGATOR_21322] (MS ) has led 
to significant strides in reducing relapse frequency and the attendant morbidity. However, chronic 
disability accumulation remains a significant unmet need for people living with MS. Individuals 
with progressive disease, including secondary progressive MS ( SPMS ), need therapi[INVESTIGATOR_21323]. The recent approval of siponimod has led to a broad relabeling of 
existing disease -modifying therapi[INVESTIGATOR_014], with an indicat ion “for the treatment of relapsing forms of 
MS, to include clinically isolated syndrome, relapsing -remitting disease, and active secondary 
progressive disease, in adults”. This label reflects the perception that drugs like ocrelizumab and 
siponimod that w ere tested in patients  with progressive disease benefits patients  with “active 
disease”, ie, they reduced acute inflammatory activity rather than directly reducing “Progression 
Independent of Relapse Activity” or PI[CONTACT_14687].  
Data from the Phase 3 EXPAND  trial of siponimod, a S1P receptor modulator, in a SPMS 
population demonstrated reduced  risk (hazard ratio [ HR]=0.79) of 3-month confirmed disability 
progression  (CDP ) (1). However, in the subgroup without activity at baseline (defined by [CONTACT_21397] 24 -month period prior to enrollment ), the effect on 3-month CDP  
was limited (HR=0.87). Likewise, d ata from ORATORIO, the pi[INVESTIGATOR_9205] 3 trial of ocrelizumab 
in a primary progressive MS ( PPMS) population, demonstrated that this anti -CD20 monoclonal 
antibody that depletes B lymphocytes provide d a small but statistically significant (HR=0.76) 
benefit in reducing the risk of disability progression (2). As with EXPAND , analysis of 
a subgroup defined by [CONTACT_21398] (in this case, the presence or ab sence of gadolinium  (Gd) 
contrast -enhancing lesions at baseline , which amounted to 199 or 533 of 732 participants , 
respectively) revealed a smaller, non -significant effect size (HR=0.84) in  patients  without this 
inflammatory magnetic resonance imaging ( MRI ) activity at enrollment. According  to these data, 
and to our working hypothesis , effective management of MS disease activity will require 
additional interventions beyond immunomodulation of perip heral immunity. Our focus is on 
targeting innate immunity, including monocytes and macrophages peripherally, as well as B cells 
in the central nervous system ( CNS ) and microglial cells that represent the resident innate immune 
system within the CNS.  
BTK inhibitors do not result in chronic B -cell depletion; SAR442168 (tolebrutinib)  inhibits 
B-cell-receptor signaling by [CONTACT_21399]’s tyrosine kinase (BTK ) activity. Furthermore, 
abundant evidence suggests that innate immunity, and specifically CNS -resident microglial cell 
activity, is a significant driver of disability accumulation in all forms of MS. The dual working 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 12 hypothesis driving developm ent of SAR442168  is based on the following: 1) modulating B cells 
to render them inert to antigenic stimulation will have an effect similar to B -cell depletion on 
progressive MS disability accumulation, and 2) CNS penetrance will provide a potential added 
benefit of modulating innate immunity mediated by [CONTACT_21400].  
The ability of SAR442168  to reduce the formation of acute  brain lesions in MS was assessed in 
a Phase 2 b dose-finding trial in participants  with relapsing MS (RMS ) (DRI15928). Patients  with 
progressive forms of MS may also present with acute focal infla mmatory activity in the CNS. 
This activity manifests  on MRI as T1 hyperintense Gd + lesions and new or enlarg ing T2 lesions. 
SAR442168  has proven to be effective in reducing both types of CNS lesions. The SAR4421 68 
Phase 2b results showed that SAR442168  reduced the number of new T1 hyperintense Gd+ 
lesions by 85% and the number of new or enlarged T2 lesions by 89% in the 60 mg group 
(the dose to be used in the Phase 3 program ) compared to placebo . 
Reduction in num ber of T1 -hyperintense (gadolinium -enhanced) lesions has been established as 
a highly reliable predictive biomarker for clinical efficacy in pi[INVESTIGATOR_21324]  3 RMS studies ( 3). While there is no comparable radiographic biomarker to predict clinical 
efficacy on disability progression, the assumption has been that doses effective at preventing 
relapses can be us ed to assess disabil ity progression in PPMS or SPMS (2, 4, 5, 6, 7). SAR442168  
was shown to achieve pharmacologically relevant concentra tions in cerebrospi[INVESTIGATOR_872] (CSF ) 
after a single oral administration, with the potential to inhibit microglia and infiltrating bone -
marrow -derived macrophages that are believed to drive neuroinflammatio n linked to disease 
progression.  
The goal of this Phase 3 clinical trial is to demonstrate the efficacy and safety of SAR442168  
compared to placebo in participants  with nonrelapsing secondary progressive multiple sclerosis 
(NRSPMS ). The primary endpoint is time to onset of 6-month CDP assessed via the Expanded 
Disability Status Scale (EDSS) score.  
The EDSS is widely used to measure neurological disability in clinical trials and routine settings 
(8). It will  be used to  assess  6-month CDP, as is standard practice in many clinical trials and as is 
recommended by [CONTACT_21401] ( 2, 4) and considered  as more stable than 3 -month CDP . Electronic 
EDSS score collection will be employed to ensure completeness and consistency of measurement. 
Magnetic resonance imaging outcomes will include change in brain volume, which is considered 
as a marker of the CNS degenerative process and therefore  recommended for use in progressive 
MS trials  (9). 
Together with additional evaluation of secondary and exploratory endpoints, this study will  
provide a comprehensive evaluation of the efficacy and safety of SAR442168  in people with 
NRSPMS . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 13 Objectives and endpoints  
Objectives  Endpoints  
Primary  
• To determine the efficacy of SAR442168  
compared to placebo in delaying disability 
progression in NRSPMS  • Time to onset of 6 -month CDP defined as follows:  
- Increase of ≥1.0 point from the baseline EDSS score 
when the baseline score is ≤5.0, OR  
- Increase of ≥0.5 point when the baseline EDSS score 
is >5.0 
Secondary  
• To evaluate efficacy of SAR442168  compared to 
placebo on clinical endpoints, MRI lesions, 
cognitive performance, physical function, and 
quality of life  • Time to onset of sustained 20% increase in the [ADDRESS_20224] 3 months  
• Time to onset of sustained 20% increase in the T25 -FW for 
at least 3 months  
• Time to onset of 3 -month CDP as assessed by [CONTACT_21402]  
• Total number of new and/or enlarging T2 -hyperintense 
lesions as detected by [CONTACT_9268], defined as the sum of the 
individual number of n ew and/or enlarging T2 lesions at all 
scheduled visits starting after baseline up to and including 
the EOS visit  
• Time to onset of CDI defined as a ≥1.[ADDRESS_20225] 
6 months  
• Percent change in brain volume  loss (BVL)  as detected by 
[CONTACT_21403] 6  
• Change in cognitive function at the EOS compared to 
baseline as assessed by [CONTACT_21404]  
• Change in cognitive function at the EOS compared to 
baseline as assessed by [CONTACT_21405] -II, where available  
• Change in MSQoL -54 questionnaire score from baseline 
through the EOS  
• To evaluate safety and tolerability of 
SAR442168  • Adverse events (AEs), serious AEs, AEs leading to 
permanent study intervention discontinuation, AEs of special 
interest, and potentially clinically significant abnormalities in 
laboratory tests, safety scales, ECG, and vital signs during 
the study period  
• To evaluate population pharmacokinetics of 
SAR442168  and relevant metabolite(s) in 
NRSPMS  and its relationship to efficacy and 
safety  • Plasma concentration of SAR442168  and relevant 
metabolite(s) (population PK assessment) at Months 6, 9, 
and 12  
• To evaluate pharmacodynamics (PD) of 
SAR442168  • Change in plasma NfL levels at the EOS compared to 
baseline  
• Change in lymphocyte phenotype subsets in whole blood at 
the EOS compared to baseline  in a subset of participants  
• Change in serum immunoglobulin level at baseline 
compared to the EOS  
• Change in serum Chi3L1 levels at baseline compared to the 
EOS  
Abbreviations: [ADDRESS_20226]; AE, adverse event; AESI, adverse event of special interest; CDI, confirmed disability improvement; CDP, 
confirmed disability progression; Chi3L1, chitinase -3-like protein 1; ECG, electrocardiogram; EDSS, Expanded Disa bility Status Scale; EOS, end 
of study; MRI, magnetic resonance imaging; MSQoL -54, Multiple Sclerosis Quality of Life -54 Questionnaire; NfL, neurofilament light chain; PD, 
pharmacodynamic; PK, pharmacokinetic; nrSPMS, non-relapsing secondary  progressive mu ltiple sclerosis; T25 -FW, timed 25 -foot walk . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 14 Overall design:  
This is a Phase 3, randomized, double -blind, 2 -arm, placebo -controlled, parallel group, 
multicenter , event -driven  (6-month CDP) trial with a variable treatment duration ranging from 
approximate ly 24 to 48  months  in participants  with NRSPMS . 
Disclosure Statement : This is a parallel treatment study with 2 arms that is blinded/masked for 
participants , the Investigator, any Investigator site staff, and the Sponsor.  
Number of participants : 
Approximately 1700 people will be screened to achieve up to 1290 participants  randomly 
assigned to study intervention.  
Enrolled participants  will be  randomly assigned at a ratio of 2:1 to  60 mg  (established fr om 
dose-finding Study DRI15928) of oral, daily SAR442168  or daily matching placebo. 
Randomization will be stratified by [CONTACT_21406] (>40 versus ≤40 years) and geographic 
region (US versus non -US). 
Note : “Enrolled ” means a participant ’s, or their legally acceptable representative’s, agreement to 
participate in a clinical study following completion of the informed consent process. Potential 
participants  who are screened for the purpose of determining eligibility for the study, but do not  
participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760].  
Intervention  groups and duration:  
Study intervention(s)  
Investigational medicinal product(s)  
• Formulation : SAR442168  film coated tablet  
• Route(s) of administ ration: oral  
• Dose regimen: [ADDRESS_20227](s)  
• Formulation: placebo to match SAR442168  film coated tablet  
• Route(s) of administration: oral  
• Dose regimen: once daily  
Noninvestigational medicinal product(s)  
• Formulation: MRI contrast -enhancing preparations  
• Route(s) of administration: intravenous ( IV) 
• Dose regimen: per respective label  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 15 Temporary  investigational medicinal produc t (IMP) interruption due to surgery  
If surgery is needed during the study, consider the benefit -risk of withholding the IMP for at least 
[ADDRESS_20228] -surgery and the risk of bl eeding . 
Devices  
Not applicable.  
Long -term safety study   
After the end of this study, participants  who complete the trial and are taking the IMP treatment  
until the end of the trial  (double -blind or open -label SAR442168  if meeting 6 -month CDP)  may 
be offered the op tion to participate in a long-term safety (LTS) study for an additional [ADDRESS_20229]. Details of the 
LTS study will be described in a separate protocol.  
Duration of study (per participant)  
The duration of treatment will vary for individual participants , depending on the time of 
recruitment . Considering the  recruitment  period of approximately  24 months  and a n assumed 
event rate (discussed below), the duration of the study should be approximately [ADDRESS_20230] been observed before the study end.  
Statistical considerations:  
• Primary endpoint : 
The primary estimand will be the treatment difference between SAR442168  and placebo in time 
to onset of 6 month -CDP regardless of completion of the treatment period. This estimand 
corresponds to a “treatment policy strategy”. This estimand will be considered primary for 
supporting regulatory decision making.  
The time to onset  of 6-month CDP will be analyzed by a Cox proportional hazards model with 
terms for treatment, age at screening (>40, ≤40 years) , geographic region (US, non -US), baseline 
EDSS score , and baseline Gd -enhancing T1 lesions (0, ≥1) . A log -rank test stratified by [CONTACT_21407] (>40, ≤40 years) and geographic region (US, non -US) to compare SAR442168  to 
placebo will also be examined.  
In this primary intent -to-treat ( ITT) analysis:  
• For participants  who complete  the study without an initial disability progression, the 
participant’s event time will be censored at the date of last EDSS assessment .  
• For participants who have an initial onset of disability progression but complete the study 
at the common study end da te without [ADDRESS_20231] EDSS assessment . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 16 • For participants who prematurely discontinue the study before [ADDRESS_20232] EDSS assessment . 
• For participants  who meet 3 -month CDP but complete the study at the common study end 
date without 6 -month confirmation , the event status of the participant will be determined 
by [CONTACT_21408] 3 -month 
confirmation to partic ipant’s end of study also meet the criteria for disability progression . 
Since in this setting, the partial missing data can reasonably be assumed to be missing at 
random, this approach leverages the partial information and follows the ITT principle. 
A logistic model with terms for age at screening (>40, ≤40 years) , geographic region (US, 
non-US), baseline EDSS score , and baseline Gd -enhancing T1 lesions (0, ≥1)  will be used 
to determine the event status as the imputation model within each treatment. A multi ple 
imputation approach will be used to summarize the results.  
Only EDSS assessments measured more than 90 days after the onset of an adjudicated relapse  will 
be used to determine onset of disability progression. In addition , for the purpose of confirmati on, 
only EDSS scores measured more than 90 days after the onset of a n adjudicated  relapse will be 
used. In case of such MS relapse, the next quarterly EDSS assessment >[ADDRESS_20233] 
also be maintained for any non -confirmatory (ie, intervening) EDSS assessment(s) between the 
initial (onset) and confirmation EDSS scores.  
• Main  secondary endpoints:  
For other time -to-event endpoints ( time to onset of sustained 20% increase in the 9 -HPT, of 
sustained 20% increase in the T25 -FW, of 3 -month CDP, and of CDI ), similar analysis as for the 
primary analysis of the primary efficacy endpoint will be performed in the ITT population , but 
without imputation .  
Conti nuous endpoints (percent change in brain volume loss, change in cognitive function, change 
in physical function, and change in MSQoL -54 at EOS) will be analyzed using a mixed -effect 
model with repeated measures (MMRM) approach. The model will include chang e/percent 
change values for the respective endpoint at each scheduled visit as response variables, and 
treatment,  age at screening (>40, ≤40 years) , geographic region (US, non -US), visit, treatment 
by-visit interaction, baseline value for the endpoint bein g assessed and baseline value -by-visit 
interaction as covariates.   
Categorical efficacy endpoints with count data (new and/or enlarging T2 hyperintense over the 
study period after baseline) will be analyzed using a negative binomial regression model. The 
model will include the tota l lesion count across all post -randomization MRI scans  during the study  
period as the response variable, with treatment group, age at screening (>40, ≤40 years) , 
geographic region (US, non-US), baseline EDSS score , and baseline T2 lesions  as covariates. 
Log-transformed observation duration  from screening MRI to last available MRI will be the offset 
variable.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 17 Analysis of safety data:  
All safety summaries will be descriptive; no statistical significance tests will be performed on 
safety data. This includes treatment -emergent adverse events (TEAEs) and other safety 
information (eg, clinical laboratory evaluations, electrocardiograms [ ECG s], and vital signs). 
TEAEs are defined as adverse events ( AEs) that developed or worsened or became serious during 
the treatment period. These analyses will be based on the safety population, defined as all 
participants  randomly assigned and exposed to study intervention, regardless of the amount of 
exposure, analyzed according to the treatment actually received.  
Data Monitoring Committee: Yes 
Scientific Advisory Committee: Yes  
Eligibility  Adjudication Committee: Yes  
Relapse Adjudication Committee: Yes  
Independent Hepatology Assessment Committee: Yes  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 18 1.2 SCHEMA   
Figure  1 - Graphical study design   
 
 
Abbreviations: CDP, confirmed disability progression; EOS, end of study; MRI, magnetic resonance imaging; R, randomization.  
“Month -1 (D-28 - D-1)” refers to screening period as “Day-28 to Day -1”; “Month 0 (D1) ” refers to randomization on Day 1.  
Screening 
PeriodTreatment Period : 24 to 48 months
All patients continue in the study until the 288 events of 6 -month CDP are observed before the study end
0 12 24 15 18MonthsPlacebo
Oral
1:2 randomization ratio SAR442168
60 mg Oral
2:1 randomization ratio 
3 6 9  21 -11 Tablet Daily (SAR442168)
MRI Scan:Disability
assessments:
End of Study and start of Long -term Safety Study
1 Tablet Daily (matched placebo)
[ADDRESS_20234] an option to receive 
open -label SAR442168 treatment
Quarterly
Yearly MRIR
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 19 1.3 SCHEDULE OF ACTIVITIES (SOA)   
 
Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Informed consent  X                       
Demography  X                       
Inclusion/exclusion 
criteria  X X                      
Medical/surgical 
history  X                       
Prior/concomitant 
medicationsg =========== ======== =========== ======== ============================= ===== ==== ============================================================= ===➔ 
Randomization   X                      
IRT contact  X X      X  X  X  X X X X X X X X X X 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 20 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Study treatment 
administration                        
IMP dispensation   X      X  X  X  X X X X X X X    
IMP Compliance         X  X  X  X X X X X X X Xe X  
Paper diary 
dispensation/collection   X      X  X  X  X X X X X X X X X  
Safetyy                        
Physical examinationh 
and vital signs  X X      X  X  X  X X X X X X X X X X 
Height  X                       
Body weight  X X      X  X    X  X  X  X X X X 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 21 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Serology tests for 
hepatitis B and C  X                       
HIV and other 
infectious diseases, if 
required locally  X                       
TB/QuantiFERON® TB 
Gold test or 
equivalenti X                       
Body temperature  X X      X  X  X  X X X X X X X X X X 
12-lead ECGj X       X  X  X  X    X  yearly  X X  
Hematology, 
biochemistryk X Xz  X  X  X X X  X  X X X X X X X X X X 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 22 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Liver function testsl   X  X  X    X  X           
Iron panel (serum): 
iron, ferritin, transferrin 
saturation,TIBC; to be 
repeated during the 
study if needed  X                       
Coagulation: PT/INR, 
aPTT (to be repeated 
during the study, if 
needed)  X                       
Urinalysis  X       X      X  X  X  X X X  
Pregnancy test (if 
applicable)m X X      X  X  X  X X X X X X X X X X 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 23 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Serum FSHn X                       
Suicidality 
assessment by 
C-SSRS  X X      X  X  X  X X X X X X X X X X 
Adverse event 
collection  ========= ======== =============================== ==== ====================================================================================== ➔ 
Efficacy                         
EDSS  X X      X  X  X  X X X X X X X X X  
Timed [ADDRESS_20235]   X      X  X  X  X X X X X X X X X  
SDMT and CVLT -II, 
where availableo  X      X  X  X  X X X X X X X X X  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 24 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Basic or expanded 
MRIp Xq         X    X  X  X  yearly  X X  
Actigraphy (optional 
for subset of 
participants)r  X 
Clinical outcome assessmentss 
MSQoL -54  X        X    X  X  X  X X X  
EQ-5D-5L  X        X    X  X  X  X X X  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 25 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Pharmacokinetics  
SAR442168  and 
relevant metabolite(s) 
pharmacokinetic 
plasma samplest          Xu  Xu  Xu       Xe   
Pharmacogenetics  
DNA sample 
(optional)w  X                      
Pharmacodynamics/biomarkers                      
Blood sample for 
archivingx X                       
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 26 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Immunophenotypi[INVESTIGATOR_007]/  
RNA sequencing 
(ToleDYNAMIC/ optiona
l substudy at selected 
sites)aa  X      X      X          
Lymphocyte 
phenotypi[INVESTIGATOR_21325] (s ubset of 
participants)bb   X                   X X  
Plasma samples (NfL), 
serum samples 
(Chi3L1)v  X      X  X    X    X  yearly  X X  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 27 Procedure  
Screeninga 
Randomization/ start of IMP  
To Year 2 (M24)b 
From M27 to EOSb 
Only for participants who 
prematurely discontinue IMP  
For all participants  
Only for participants who 
completed treatment EOS but 
do not enter LTSc 
Visit (a window of 
±7 days is allowed for 
all visits after D1)  
D-28 to D -1 
D1 
M0.5 (W2)  
M0.75 (W3)  
M1(W4)d M1.25 
(W5)  
M1.5 (W6)  
M1.75 
(W7) 
M2 (W8)d 
M2.25 (W9)  
 M2.5 (W10)  
M2.75 (W11)  M3 M4, 
M5d M6 M7 
M8 M9 M10 
M11  
M12 
M15 
M18 
M21 
M24 Quarterly 
visits  
(M27, M30, 
M33, M36, 
M39, M42, 
M45, 
M48…)  Semi -
annual 
visits  
(M30, M36, 
M42, 
M48…)  pEOTe EOS  
“Common  
study end 
date” visitf Follow -up 
visit 
(4 weeks)  
Visit Number  V1 V2  V3  V4  V5 V6, 
V7 V8  V9  V10 V11 V12 V13 V14 V15, V16, 
V17, V18, 
V19, V20, 
V21, V22  V16, V18, 
V20, V22  pEOTe EOS  FUV 
Serum samples (Ig 
levels)v  X        X    X    X  yearly  X X  
aPTT , activated partial thromboplastin time; β -HCG , β-human chorionic gonadotropin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Chi3L1 , chitinase -3-like protein 1; 
C-SSRS , Columbia Suicide Severity Rating Scale; D , day; DNA , deoxyribonucleic acid; ECG , electrocardiogram; EDSS , Expanded Disabili ty Status Scale; EOS , end of study; EOT , end of treatment; EQ -5D-5L, 
EuroQol 5 -dimension 5 -level instrument; FSH, follicle stimulation hormone; FUV, follow -up visit; ICF , informed consent form; Ig, immunoglobulin; IRT, interactive response technology; HIV, human immunodeficiency 
virus; IMP , investigational medicinal product; INR , international normalized ratio; LT S, long term safety study ; M, month; MCV , mean corpuscular volume; MCH , mean corpuscular hemoglobin; MRI:  magnetic 
resonance imaging; MS: multiple sclerosis; SDMT, Symbol Digit Modalities Test; CVLT -II, [LOCATION_004] Verbal Learning Test -II; MSQoL -54: Multiple Sclerosis Quality of Life -54; NfL: neurofilament light chain; pEOT: 
premature end of treatment; PK: pharma cokinetic; PT:  prothrombin time; RBC , red blood cell; SWI , susceptibility wei ghted imaging;  TB, tuberculosis ; TIBC: total iron -binding capacity; V: visit; WBC , white blood cell . 
Note: All assessments should be done as designated in this SoA unless not permitted according to local regulations.  All visit assessments should be performed during the visit window unless otherwise specified in this 
protocol.  
a Screening period can range from D -28 to D -1; Randomization visit can be performed only once IMPs are av ailable at site. The interval between screening and randomization visits can range from 11 days 
(minimum) to 28 days (maximum) . However, if required, the randomization visit can be performed earlier than 11 days upon IMP receipt at the site, assuming th e participant  is eligible for randomization.  In case of 
any delay to screening (MRI rescheduling, lab retests, etc ), an additional period of up to 2 weeks is allowed .  
b From D1 to EOS, unscheduled visits may be performed at any time by [CONTACT_737] (eg, for evaluation of an adverse event). Assessments may be done on as needed basis to evaluate the participant  in 
accordance with the Investigator’s best judg ement and in -line with the study protocol. At a minimum, a physical exam ination sho uld be performed , and body temperature and vital signs should be measured . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20236] completed treatment with IMP (double blind or open label if meeting CDP) may be offered participation in LTS study. Follow -up visit assessment only performed for those 
participants  who completed treatment and are not willing to take part in the LT S study.  For other situations where a follow -up visit is needed, please see Section  7.1 and the Study Manual.  
d These visits may be done as home health visits (where applicable) or onsite visits  (it is preferable that tests are performed at the central laboratory). In any situations where this is not possible (to be documented in 
source documents), the tests for these visits may be performed at a local laboratory . 
e If a participant  prematurely permanently discontinues treatment with IMP, the participant will undergo pEOT visit as soon as possible. A PK sample should also be collected if the pEOT visit can be scheduled 
within a maximum [ADDRESS_20237] IMP dose. Participants  will then be asked to continue with the study visits as scheduled until the common  EOS Visit is reached. During these vi sits, all study 
procedures/assessments will be performed except IMP administration and blood sampling for PK and biomarkers (NfL, Chi3L1, and  Ig levels). MRI scans for these participants  will only be performed annually 
(using the next annual visit as the s tarting point) . Additional information is provided in the Study Manual.  
f For participants  continuing in the study, the c ommon EOS visit will be done when  the prespecified number of events for 6 -month CDP is expected to be reached.  The timing and window of this visit will be 
communicated to sites.   
g Any disease -modifying therapy for MS taken at any time prior to signing the informed consent need s to be reported in the eCRF; other prior medications will be reported for the period of 6  months prior to signing 
the ICF.   
h Complete physical examination due at screening, baseline, yearly (M12, M24, M36, M48) and at EOS; brief physical examination is sufficient for the rest of the visits  (complete and brief  physical examinations will 
include neurological examination and collection of the following vital signs: arterial  blood pressure, heart rate, temperature).  
i To be performed at screening for all participants . Tuberculosis examination will be repeated based on clinical judgment, borderline results , or clinical suspi[INVESTIGATOR_21326].  For further details , refer to E 01. 
Screening tests for TB are described in Appendix  2 (Section  10.2). 
j ECG  and 30 second rhythm strips  will be obtained locally.  
k Hematology (platelet count, RBC count, hemoglobin, hematocrit, MCV, MCH, reticulocytes, WBC count with differential: neutroph ils, lymphocytes, monocytes, eosinophils, basophils) .  
Biochemistry (blood urea nitrogen [BUN ], creatinine, glucose, sodium, potassium, bicarbonate, calcium, liver function tests [AST, ALT, ALP, albumin, total and direct bilirubin ], total protein; creatine phosphokinase . 
Lipase will be tested at the Screening Visit, then quarterly . Monthly visits (M1, M2, M4, and M5) will include hematology and full liver panel only.  Additional safety assessments can be performed if required by [CONTACT_13125]. Su ch testing shall be performed at local laboratories . 
Note: a one -time retest at screening may be performed if laboratory test abnormality is considered temporary.  Additional safety assessments can be performed if required by [CONTACT_427]; such testing shall be 
performed locally whenever possible.  Additional visits may be added if required by [CONTACT_427].  
l At intermediate timepoints (W2, W3, W5, W6, W7, W9, W10, W11, M7, M8, M10, and M11),  only l iver function tests  will be collected ( AST, ALT, albumin, alkaline phosphatase, total and direct bilirubin, total 
protein ) and creatine phosphokinase ); these can be performed at central laboratory (preferred, as o n-site visits or home nursing as applicable for the site) or at local laboratory ; a window of ±[ADDRESS_20238] ( LFT) timepoints and ±[ADDRESS_20239] dose of IMP . Additional serum or urine pregnancy tests may be performed, as determined necessary by [CONTACT_21409], to 
establish the absence of pregnancy at any time during  the participant’s  participation in the study.  Communication by [CONTACT_21410] a pregnancy test performed at home to the site is allowed. See also 
Appendix 4 ( Section  10.4).  
n Only in female participants , if needed to establish menopausal status.  
o The SDMT and CVLT -II will be performed in all participants . If for some reason,  CVLT -II is not available at a given site due to reasons such as lack of translation, local certification, etc., then only the SDMT will be 
assessed for that participant.  
p A subset of sites that have 3T MRI capacity will perform additional sequences (eg, SW I). Further details will be defined in a central MRI manual.  
q A visit window of ±21 days is acceptable for MRIs performed after D1. For systemic corticosteroids and adrenocorticotropic hormone, 1 -month wash -out required prior to the MRI scan s. The screenin g MRI scan 
should be performed as close as possible before the start of IMP. As much as possible, the MRI scan should be performed durin g the screening period only after it has been established that the participant meets 
all inclusion and no exclusion crit eria. 
r A noninvasive activity monitor (actigraphy) may be optionally implemented by [CONTACT_21411] a subset of participants  during the course of the study if results from pi[INVESTIGATOR_21327].  
s When available, c linical outcome assessments are to be completed by [CONTACT_21412] n or other study related procedures  where 
available per local regulations . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] Group - strictly confidential  Page 29 t On days of PK sampling, the IMP needs to be taken at the study site after a “regular meal ”. In case a participant forgot IMP at home or took IMP prior to arriving at the site on the day of visits with PK sampling, 
he/she will be asked to have a repeat assessment within 3 days of the missed PK sampling. A PK assessment shall be done as so on as possible after an overdose or if otherwise specified per protocol 
(eg, investigation of a bnormal laboratory test values).  
u M6 and M12: Two samples: one sample between 30 to 90 minutes and one sample between 2.5 to 5 hours after IMP administration. M9: one sample 30 -90 minutes after IMP . 
v Pharmacodynamics and biomarkers samples will be collected  only if permitted per local regulations.  
w DNA testing will be allowed at any time after signature [CONTACT_21525] (in case it could not be done for some reason at D ay 1). Participation is optional. Participants  who do not wish to participate in the genetic research 
may still participate in the study.  A separate consent is required for the genetic analysis component of the study.  
x This sample will be collected and stored for use if any unexpected safety issue occ urs to ensure that a pre -dose baseline value is available for previously not assessed parameters (eg, serology)  and for 
biomarkers research, if agreed . 
y Additional safety assessments can be performed if required by [CONTACT_427]; such testing shall be p erformed locally whenever possible. Additional visits may be added if required by [CONTACT_427].  
z Samples for hematology and biochemistry tests on Day 1 (randomization) must be collected prior to administration of the first  IMP dose . 
aa Samples must be shipped within 24 hours. For detailed instructions see Appendix 11 ( Section  10.11 ) and the Study Manual . 
bb Blood sample collection for lymphocyte phenotypi[INVESTIGATOR_21328] a subset of randomized participants . Participants  who did not have a baseline sample collected, will no longer have this 
test performed; participants  who had a baseli ne sample collected will have a seco nd sample collected at EOT/pEOT . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 30 2 INTRODUCTION   
SAR442168 , a brain penetrant inhibitor of Bruton’s tyrosine kinase ( BTK ), is being developed for 
the indication of treatment of patients  with MS. This study is desi gned to collect evidence of 
SAR442168  efficacy and safety in the nonrelapsing SPMS ( NRSPMS ) population.  
2.1 STUDY RATIONALE   
The goal of this Phase 3 clinical trial is to demonstrate the efficacy and safety of SAR442168  
compared to placebo in participants  with NRSPMS . SAR442168  is a small molecule administered 
as a once daily oral treatment that is an irreversible, covalent inhibitor of BTK. SAR442168  is 
a brain -penetrant compound that modulates the pro -inflammatory activity of B cells in the 
periphery and in the CNS as a result of the BTK inhibition. The proposed mechanism of action for 
SAR442168  is to inhibit the coupling of the B cell receptor to downstre am signaling in B cells, 
thereby [CONTACT_21413] B cells without depleting them. Additionally, it is also known that activated 
B cells are key players in the pathogenesis of MS, specifically in the progressive form o f the 
disease.  
The immune complex receptor Fc γRII, found in macrophages and microglial cells and that also 
signals through BTK, will similarly be modulated. The Sponsor hypothesize s that this action will 
result in a decrease of inflammatory activity in the CNS, diminishing brain lesions as detected b y 
MRI as well as reducing the accumulation of disability progression.  
The advent of disease -modifying therapi[INVESTIGATOR_21329]. However, chronic 
disability accumulation remains a significant unmet need for people living with MS. Individuals 
with progressive disease, including SPMS, need therapi[INVESTIGATOR_21330]. With several drugs approved for active secondary prog ressive disease, there is still no 
treatment available for NRSPMS . 
Data from the recent  pi[INVESTIGATOR_21331], a S1P receptor modulator, in SPMS patients 
demonstrated reduc ed risk of 3 -month confirmed  disability progression (HR=0.79) (1). Data from 
ORATORIO, the pi[INVESTIGATOR_9205] 3 trial of ocrelizumab in a PPMS population, demonstrated that 
this anti -CD20 monoclonal antibody t hat depletes B lymphocytes could provide a small but 
statistically significant benefit (HR=0.76) in reducing the risk of disability progression (2).  
Furthermore, abundant evidence suggests that innate immunity, and specifically CNS -resident 
microglial cell activity, is a significant driver of disability accumulation in all forms of MS. The 
dual working hypothesis driving development of SAR44216 8 is based on the following: 
1) modulating B cells inert to antigenic stimulation will have an effect similar to B -cell depletion 
on progressive MS disability accumulation, and 2) CNS penetrance will provide a potential added 
benefit of modulating innate i mmunity mediated by [CONTACT_21400].  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 31 The ability of SAR442168  to reduce the formation of acute brain lesions in MS was assessed in 
a Phase 2 b dose-finding trial in participants  with RMS (DRI15928). Patients  with progressive 
forms of MS may also present with acute focal inflammatory activity in the CNS. This activity 
manifests  on MRI a s T1 hyperintense Gd+ lesions and new or enlarg ing T2 lesions. SAR442168  
has proven to be  effective in reducing both types of CNS lesions. The SAR442168  Phase 2b 
results showed that SAR442168  reduced the number of new T1 hyperintense Gd+ lesions by 85% 
and the number of new or enlarged T2 lesions by 89% in  the 60 mg group (the dose to be used in 
the Phase  3 program ) compared to placebo.  These data also support the use of this compound in 
progressive forms of MS.  
Reduction in number of T1 -hyperintense ( Gd-enhanced) lesions has been established as a highly 
reliable predictive biomarker for clinical efficacy in pi[INVESTIGATOR_21332]  3 RMS 
studies ( 3). While there is no comparable radiographic biomarker to predict clinical efficacy on 
disability progression, the assumption has been that doses effective at preventing relapses can be 
used to assess disability progression in PPMS or SPMS ( 2, 4, 5, 6, 7, 10, 11). SAR442168  was 
shown to achieve pharmacologically relevant concentra tions in CSF after a single oral 
administration, with the potential to inhibit microglia and infiltrating bone -marrow -derived 
macrophages that are believed to drive neuroinflammation  linked to disease progression.  
The primary endpoint is time to onset of 6-month CDP assessed via EDSS score. The EDSS is 
widely used to measure neurological disability in clinical trials and routine settings ( 8). Six-month 
CDP is standard practice in many clinical trials and is recommended by [CONTACT_21401] ( 2, 4) and  
considered clinically more meaningful than [ADDRESS_20240] 6 months measured by [CONTACT_21414] a secondary endpoint 
due to its clinical importance.  
Magnetic resonance imaging outcomes will include change in brain volume, which is considered 
as a marker of the CNS degenerative process  and therefore recommended for use in progressive 
MS trials ( 9). 
Population pharmacokinetics (PK ) will be performed in order to obtain a larger and more diverse 
population to evaluate the PK of SAR442168  in the NRSPMS  population, to assess sources of PK 
variability (ethnicity, special populations), and to establish exposure correlation to clinical 
efficacy, biomarkers, and safety endpoints. Soft lock of the population PK data may be performed 
as soon as all participant s have finished the Month 12 visit (a separate unblinded team will be 
used to preserve blinding integrity).  
This study will employ other secondary outcome measures to collect additional data in an effort to 
assess the benefit of SAR442168  for people with NRSPMS .  
Although no enrolled participants  are expected to have MS relapses, their occurrence cannot be 
ruled out completely. Relapse data will be carefully collected  and adjudicated,  and their impact on 
the primary endpoint will be assessed (see also stati stical considerations).  
Exploratory assessments are expected to provide additional evidence for SAR442168  activity on 
neuroinflammation and neurodegeneration.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20241] 
demonstrated efficacy of agents that target B lymphocytes, especially B -cell-depleting agents like 
ocrelizumab ( -CD20). Targeting B cells is a departure from the prevailing dogma b ased on 
animal models that demonstrated therapeutic benefits from modulating T -cell activity. Thus, 
B cells have become the cellular focus of current MS drug development ( 12). However, the 
importance of immune cells residing in the CNS is also well known ( 13) and needs to be 
considered in MS pathogenesis.  
Evidence of inflammation and presence of activated T and B cells in the brain have also been 
confirmed in PPMS and SPMS, especially in the early stages  (14). Inflammatory activity in RMS 
has been attenuated to different degrees with a variety of immunomodulatory therapi[INVESTIGATOR_014]; however , 
historically these therapi[INVESTIGATOR_21333]. This may relate to conditions in 
the CNS, especially the integrity of the blood brain barrier (BB B), but also to the potency and 
mechanism of action of the agents.  
There is still a significant unmet need for therapi[INVESTIGATOR_21334] 
a goal of halting long -term disability and neurodegeneration in all diagnostic categories  of MS 
(ie, RMS as well as progressive forms of the disease, PPMS and SPMS) ( 15). Even the most 
recent high -efficacy disease -modifying therap ies act mainly on adaptive immunity in the 
periphery with only modest or temporary ability to slow neuroinflammatory and 
neurodegenerative processes and stop disease progression ( 2, 3). Therefore, development of MS 
treatments with new modes of action is  of interest. This is particularly true for individuals with 
progressive disease, including SPMS, occurring in more than 50% of patients  with relapsing -
remitting multiple sclerosis (RRMS ) within 15 to 20  years.  
The disease progression for patients  with PMS is not driven by [CONTACT_21415]. During this time , MRI signs 
associated with  smoldering neuroinflammation and neurodegeneration mediated by [CONTACT_21416] (maladaptive microglia) have become more prominent. In this context, brain 
tissue loss (atrophy), slowly evolving lesions (SEL ) and paramagnetic  rim lesions, are important 
features in progressive form s of MS  (16, 17). 
SAR2442168 is thought to have the potential to address “outside -in” and “inside -out” MS 
pathological mechanisms. In the periphery, SAR442168  inhibits antigen -induced B cell 
activation, while, due to its property of brain penetrance, SAR442168  modulates mal adaptive 
microglial cells  in the CNS . Microglial cells express Fc -gamma receptors that couple  to BTK 
signaling pathways which result in the secretion of pro -inflammatory cytokines in the CNS. This 
pro-inflammatory activity , which is continuous, gradual , and chronic, is believed to drive 
neuroinflammation linked to progressive tissue damage in the brain and spi[INVESTIGATOR_21335] -enhancing lesions. This smoldering 
neuroinflammation has, as pathophysiological co nsequences, axonal loss, lack of remyelination, 
and myelin damage, all believed  to be closely related to clinical disability progression. In other 
words, a brain -penetrant compound that crosses the blood -brain barrier,  acts directly on 
maladaptive reactive  microglial cells, and modulates smoldering inflammatory activity may result 
in less tissue damage, resulting in less disability progression over  time.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 33 2.3 BENEFIT/RISK ASSESSMENT   
SAR442168  is a covalent, irreversible inhibitor of BTK that has a dual mode of action. In 
peripheral adaptive immunity, it inhibits signaling between the B -cell receptor and downstream 
signaling events associated with cellular proliferation, maturation, and production of secreted 
immunoglobulins. BTK is also a key signaling pathway in macrophage/microglial phagocytic 
cells of innate immunity. By [CONTACT_21417], SAR442168  has the 
potential to reduce lymphocyte -mediated acute infla mmation peripherally and neuroinflammation 
mediated by [CONTACT_21418].  
Benefit assessment:  
SAR442168  is expected to reduce MS relapse rate, disability progression, and underlying CNS 
damage through its dual action on adaptive immunity in the periphery and innate immunity and 
the inflammation process in the CNS.  
The results from the Phase 2b trial (DRI159 28) demonstrated a dose –response relationship for 
SAR442168  as evidenced by a reduction in the number of new Gd -enhancing T1 -hyperintense 
brain lesions detected by [CONTACT_21419] 12 weeks of treatment. There was an 85% relative 
reduction in lesions at 12 weeks in the 60 mg dose group as compared with placebo. This was 
obtained from the negative binomial regression model adjusted for baseline Gd -enhancing 
T1-hyperintense lesion activity.  
The potential benefits  of SAR442168  are as follows:  
Potential benefits  
• Decrease of annual ized relapse rate (ARR).  
• Reduction in the risk of loss of mobility.  
• Reduction in the accumulation of confirmed disability progression  (as expressed by 
[CONTACT_21420] [EDSS] score).  
• Reduction of disease activity as assessed by [CONTACT_9268] (Gd -enhancing lesions and 
new/enlarging T2 lesions).  
• Trend toward normalization of brain volume loss.  
• Reduction in neuroinflammation, as assessed by [CONTACT_21421] 
(slowly evolving lesions, paramagn etic rim lesions ) observed by [CONTACT_9268].  
Risk Assessment  
SAR442168  has been studied in healthy participants  and participants  with RMS. In the completed 
Phase 1 clinical trials in healthy participants , oral administration of SAR442168  was generally 
safe and well  tolerated.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 34 The results from the Phase 2b trial (DRI15928) suggest that SAR442168  is generally safe and 
well tolerated in patients  with RMS. No new risks were identified in this trial. The key results are 
summarized as follows:  
• There was no death or trea tment -emergent adverse event (TEAE) leading to permanent 
treatment discontinuation during the study. One treatment -emergent serious adverse event 
(SAE ) (MS relapse) was reported in a participant treated with 60  mg SAR442168 ; the 
remainder of the reported TEAEs were of mild or moderate intensity.  
• There was no direct correlation between the doses of SAR442168  administered and 
number or intensity of TEAEs.  The most common events reported in participants  in the 
SAR442168  treatment arms were headache, upper respi[INVESTIGATOR_1092], and 
nasopharyngitis.  
• Two participants had treatment -emergent transient alanine aminotransferase (ALT) 
increase >3 x upper li mit of normal (ULN ), 1 during the 30 mg SAR442168  treatment 
period (at Week 8, 105  U/L [normal range 6 to 34  U/L]) that returned to normal range 
within 4 days and 1  during the 60 mg SAR442168  treatment period (at Week 4, 107 U/L 
[normal range 6  to 34 U/L ]). The participant in the 60 mg group had slightly elevated ALT 
at screening (48  U/L) and at baseline (50 U/L); ALT levels returned to the normal range in 
8 weeks. Both participants  continued study treatment during this period. All other liver 
enzyme levels  for both participants  were within normal ranges during the treatment period ; 
one event was assessed as related and one as unrelated to the study drug by [CONTACT_21422] . Both participants  completed the DRI15928 study and successfully rolled 
over to the LTS follow -up study.  
• One event of mild petechia in a female participant (at Week 8 in the SAR442168  30 mg 
group) and 2  events of mild microscopic hematuria in 2 male participants  (1 event at 
Week  16 in the SAR442168  30 mg group and 1 event on Day 1 in the SAR442168  60 mg 
group, with occult blood noted in urine) were reported during the treatment period in the 
SAR442168  Phase 2b trial. The hematology results were clinically insignificant for all 
3 participants  from the  onset of the events. The participant with mild petechia had benign 
pi[INVESTIGATOR_21336], and the event was assessed as related to the 
study drug by [CONTACT_737]. The 2 events of mild microscopic hematuria were assessed 
as unrelate d to the study drug. All 3 events resolved spontaneously.  
• No severe infections occurred. The most frequently reported (≥3 events total) in the 
SAR442168  treatment period were upper respi[INVESTIGATOR_1092], nasopharyngitis, 
gastroenteritis, and respi[INVESTIGATOR_19625].  
• No clinically significant cytopenia, including thrombocytopenia and neutropenia, were 
reported or detected based on hematologic laboratory  results, and no clinically significant 
cardiac arrhythmia was observed via ECG monitoring durin g the study.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 35 Based on SAR442168  nonclinical safety data, Phase  1 results from healthy participants , Phase 2b 
results in participants  with RMS, and the published data of other marketed or investigational BTK 
inhibitors for various indications, the potentia l risks of SAR442168  are as follows:  
• Bleeding (hemorrhage) . 
• Infections . 
• Cytopenia including thrombocytopenia . 
• Atrial arrhythmias (atrial fibrillation and atrial flutter) . 
In the ongoing Phase 3 and LTS studies, tolebrutinib has been generally well tolerat ed to date. 
An identified risk for tolebrutinib has been identified as follows:  
• Treatment -emergent SAEs of drug -induced liver injury (DILI ), including severe DILI (risk 
of liver transplantation or death) as an identified risk, were reported in the ongoing Phase 3 
trials; cases occurred in Months 1 to 3, with  potential confounders identified for some of 
the cases.  
Assessment of COVID -19 in trial participants : 
Antiviral responses are likely to be driven mainly by T cells, in particular CD8+ cytotoxic 
T lymphocytes, and natural killer cells, and less so, at least initially, by B cells ( 18, 19). In vitro 
and cell -based assays indicate that SAR442168  does not deplete B lymphocytes and does not 
exhibit significant cellular off -target activity in human T  lymphocytes. In the completed Phase 2b 
study in participants  with RMS (DRI15928), the mean counts of CD19+ B cells, CD4 and CD8 
T cells, CD16+56 natural killer cells, and the levels of IgG and IgM remained stable at the end of 
12 weeks of treatment with SAR442168 .  
Infections are an important potential risk for SAR442168 , and severe infections are being 
monitored as an AESI in all on going and future clinical trials. In the completed Phase 2b trial in 
130 participant s with RMS, 23.8% of participants  reported only mild or moderate infections at the 
end of [ADDRESS_20242] clinical research showed that the 
administration of acalabrutinib, a highly specific covalent inhibitor of BTK, was associated with 
reduced inflammation and improved clinical outcome in 19 patients  hosp italized with severe 
coronavirus disease 2019 (COVID -19), without discernable toxicity, over a 10 - to 14 -day 
treatment course ( 20). Randomized studies with acalabrutinib and ibrutinib in COVID -19 are 
ongoing (21, 22, 23, 24). At present, it is unknown if people with MS are at increased risk for 
SARS -CoV -2 infection, acquiring COVID -19 or developi[INVESTIGATOR_21337] -19 (18). 
The risk of COVID -19 in participants  who receive SAR442168  is unknown based on currently 
available data. Out of precaution, the current trial  excludes people with known risk factors for 
severe COVID -19 including advanced age and comorbidities that may put patients  at higher risk 
for serious illness such as chronic  cardiovascular disease, liver disease, kidney disease, respi[INVESTIGATOR_21338], and malignancies. Concomitant use of immunosuppressive or 
chemotherapeutic medications is excluded.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20243], and the favorable ben efit-risk profile observed in the completed Phase 2b study 
in participants with RMS, the Sponsor maintains that  the trial can be initiated and conducted as 
planned .  
Overall benefit: risk conclusion  
No safety or tolerability concerns have been identified in the completed Phase  1 studies in healthy 
participants  or the Phase 2b trial (DRI15928) in participants  with RMS. In addition, the positive 
Phase  2b primary endpoint results support the potential fo r clinical efficacy.  
Drug -induced liv er injury , including severe DILI (risk of liver transplantation or death) as 
an identified risk,  has been identified in the ongoing Phase [ADDRESS_20244]. T he overall benefit /risk balance is 
acceptable  for further clinical development of SAR442168 . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 37 3 OBJECTIVES AND ENDPOINTS   
Table  1 - Objectives and endpoints   
Objectives  Endpoints  
Primary  
• To determine the efficacy of SAR442168  compared 
to placebo in delaying disability progression in 
NRSPMS  • Time to onset of 6 -month CDP defined as follows:  
- Increase of ≥1.0 point from the baseline EDSS 
score when the baseline score is ≤5.0, OR 
- Increase of ≥0.5 point when the baseline EDSS 
score is  >5.0 
Secondary  
• To evaluate efficacy of SAR442168  compared to 
placebo on clinical endpoints, MRI lesions, 
cognitive performance, physical function, and 
quality of life  • Time to onset of sustained 20% increase  in the 
9-HPT for at least 3 months  
• Time to onset of sustained 20% increase  in the 
T25-FW for at least 3 months  
• Time to onset of 3 -month CDP as assessed by [CONTACT_21423]  
• Total  number of new and/or enlarging 
T2-hyperintense lesions as detected by [CONTACT_9268] , defined  
as the sum of the individual number of new and/or  
enlarging T2 lesions at all scheduled visits starting 
after baseline up to and including the EOS visit  
• Time to onset of CDI defined as a ≥1.[ADDRESS_20245] 6  months  
• Percent change in BVL as detected by [CONTACT_21424] 6  
• Change in cognitive function at the EOS compared 
to baseline as assessed by [CONTACT_21404]  
• Change in cognitive function at the EOS compared 
to baseline as assessed by [CONTACT_21405] -II, where available  
• Change in MSQoL -54 questionnaire score from 
baseline through the EOS  
• To evaluate safety and tolerability of SAR442168  • Adverse events (AEs), serious AEs, AEs leading to 
permanent study intervention discontinuation, AEs 
of special i nterest, and potentially clinically 
significant abnormalities in laboratory tests, safety 
scales, ECG, and vital signs during the study period  
• To evaluate population pharmacokinetics of 
SAR442168  and relevant metabolite(s) in NRSPMS  
and its relationship to efficacy and safety  • Plasma concentration of SAR442168  and relevant 
metabolite(s) (population PK assessment)  at 
Months  6, 9, and 12  
• To evaluate pharmacodynamics (PD) of 
SAR442168  • Change in plasma NfL levels at the EOS compared 
to baseline  
• Change in l ymphocyte phenotype subset s in whole 
blood at the EOS compared to baseline  in a subset 
of participants  
• Change in serum immunoglobulin level at baseline 
compared to the EOS  
• Change in serum Chi3L1 levels at baseline 
compared to the EOS  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 38 Objectives  Endpoints  
Tertiary/exploratory  
• To evaluate efficacy of SAR442168  on disease 
progression and activity in NRSPMS , assessed by 
[CONTACT_21425] -
reported assessment  • Time to onset of sustained 20% increase in the 
9-HPT for at least 6 month s 
• Time to onset of sustained 20% increase in the 
T25-FW for at least 6 months  
• Time to onset of a [ADDRESS_20246] 3 and 6 months  
• The proportion of participants  with CDI confirmed 
over at least 6 months  
• The proportion of participants  with CDI confirmed 
over at least 6 months and maintained until the EOS  
• Change from baseline to Months 12, 18, and [ADDRESS_20247], 9 -HPT, 
SDMT , and C VLT-II 
• Change from baseline to Months 12, 18, and [ADDRESS_20248], 9 -HPT, and SDMT  
• Proportion of participants  with NEDA -3 at 
Months  18, 24, 30, 36, and the EOS  
• The annualized adjudicated relapse rate (ARR)  
• Actigraphic analysis of activity counts and indices of 
change from baseline to the EOS summarized over 
time (in a subset of participants ) 
• Change  from baseline of total volume of 
T2-hyperintense lesions as detec ted by [CONTACT_21426] 18, 24, and the EOS  
• Total number of new Gd -enhancing T 1-hyperintense 
lesions as detected by [CONTACT_9268], defined as the sum of 
the individual number of new Gd -enhancing 
T1-hyperintense lesions at all scheduled visits 
starting after basel ine up to and including the EOS 
visit  
• Change  from baseline by [CONTACT_21427] 
T1-hypointense lesions  and cumulative number of 
new T1  hypointense lesions  
• MTR recovery at EOS in new MTR lesions detected 
at months 6 and 12  
• Change in number of phase ri m lesions in SWI MRI 
from baseline through the EOS (subset of centers 
with capacity of 3T  MRI)  
• Number and volume  of slowly  evolving  lesions 
(SELs)  
• Normalized T1 (nT1) i ntensity evolution in SELs  
• To evaluate the treatment effect of SAR442168  via 
changes in participants’  health -related quality of life 
(HRQoL), and working capacity  • Change in EQ -5D-5L from baseline by [CONTACT_21428]: [ADDRESS_20249]; AE, adverse event; AESI, adverse event of special interest; ARR, annualized adjudicated relapse rate; BVL, brain volume 
loss; CDI, confirmed disability improvement; CDP, confirmed disability progression; Chi3L1, Chitinase -3 like protein -1; ECG, electrocardiogram; EDSS, Expanded 
Disability Status Scale; EQ -5D-5L, EuroQol 5 -dimension 5 -level instrument; EOS, end of study; Gd, gadolinium; HRQoL, health related quality of life; MRI, 
magnetic resonance imaging; MTR, magnetization transfer ratio; MSFC -3, Multiple Sclerosis Functional Composite 3; MSQoL -54, Multiple Sclerosis Quality of Life -
54 Questionnaire; NEDA -3, no evidence of disease activity -3; NfL, neurofilament light chain; NRSPMS, non -relapsing secondary progr essive multiple sclerosis; 
PD, pharmacodynamic; PK, pharmacokinetic; SAE, serious adverse event; SDMT, Symbol Digit Modalities Test; SEL, slowly evolving le sions; SWI, susceptibility 
weighted imaging; T25 -W, timed 25 -foot wal k 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 39 3.1 APPROPRIATENESS OF MEASUREMEN TS  
Nonrelapsing  SPMS is defined as an MS phenotype with progressive disability in the absence of 
relapse, after an initial variable period of a relapsing -remitting course . Hence,  delaying the 
progression of disability is a clinically relevant outcome and is an aim of any disease -modifying 
treatment in NRSPMS . Measurement of delay of disability progression is an important clinical 
endpoint and is endorsed by [CONTACT_21429] ( 9). The EDSS is widely used to measure 
neurological disability in clinical trials and routine settings (8). Due to known fluctuation in EDSS 
scores, CDP confirmed after 3 - or 6 months is used as an endpoint in clinical trials of progressive 
MS ( 1, 2). Confirmed disability progression lasting for at least [ADDRESS_20250] 6 months as measured by [CONTACT_21430] 
a secondary endpoint due to its clinical importance. Magnetic resonance imaging measurements 
will include change in brain volume, which is considered to be a marker of the CNS degenerative 
process and is therefore recommended in progressive MS (9). Magnetic resonance imaging at 
Month [ADDRESS_20251] of transient changes in brain volume associated with resolution of 
inflammation after introduction of treatment (so -called pseudoatrophy) (25). The MRI markers of 
inflammatory activity in the brain observed in previous clinical trials of progressive MS ( 1, 2) will 
also be measured. The number of active T2 -hyperintense lesions and change in their volume at the 
EOS are selected as secondary endpoints, as they reliably reflect accumulating MS lesion load 
over time.  
In addition, MRI measurements will include analysis of brain volume loss over time . Several MS 
drugs are known for their capacity to slow down brain volume loss, which will be assessed in 
search of a possible signal.  
Clinical outcome assessments are consid ered important for understanding the impact of treatment 
on function and well -being (26). In both progressive and relapsing MS, the increasin g limitation 
and loss of physical function are prevalent and among the most debilitating signs and symptoms 
of the disease (5). Physical func tion limitations are associated with decrements in quality of life 
due to diminishing productivity and ability to perform daily activities, maintain employment, and 
maintain social roles and emotional wellbeing. Reduction of disease impact on patient -repor ted 
physical function is therefore important to assess in addition to the clinician assessment and 
constitutes a direct measure of treatment effectiveness, ie, whether a treatment influences how 
a participant feels or functions (27). MS relapses may occur infrequently in a small part of the 
study population ( 1, 2). Relapse data will be carefully collected  and adjudicated,  and their  impact 
on the primary endpoint will be assessed.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 40 4 STUDY DESIGN   
4.1 OVERALL DESIGN   
This is a Phase 3, randomized, double -blind, 2 -arm, placebo -controlled, parallel -group, 
multicenter , event -driven (6-month CDP) trial with a variable treatment duration ranging from 
approxi mately [ADDRESS_20252] of the following study periods:  
Screening period: Day -28 to Day -1. 
Randomization /start of IMP: Eligible participants  will be randomly assigned at a 2:1 ratio to 
receiv e oral SAR442168  (60 mg) daily or matching placebo daily.  
Intervention period: Double -blind treatment period for assessment of efficacy and safety up to the 
EOS , as described in  Section  4.4. 
A month is defined as a period of 28  days by [CONTACT_559].  
Safety f ollow -up period /EOS : [ADDRESS_20253] dose of study treatment (for participants  
completing IMP treatment [double blind or open -label , if initiated  after 6-month CDP ] and not 
entering the LTS study ) to collect safety data .  
EOS: A participant is considered to have completed the study if he/she has completed all periods 
of the study including the EOS Visit, whether remaining on IMP  or not . 
Participants  with 6 -month CDP are eligible for open -label active treatment  (SAR442168 ) 
(Section  6.6.1 ). 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN   
This is a Phase  3 study for which a double -blind, randomized, placebo -controlled design has been 
selected to minimize possible biases in the study outcome.  
4.2.1  Justification for participant’s age and study duration   
Male and female participants  with a diagn osis of NRSPMS  between 18 and 60 years inclusive 
will be selected for this study. The age range is limited to participants  who are ≤60 years to reduce 
confounding neurological conditions prevalent in older individuals (eg, degenerative pathology of 
the spi[INVESTIGATOR_050], vascular disorders, other neurodegenerative processes). Besides, since the SPMS 
phenotype is more prevalent in an older population, it was considered appropriate to set the upper 
age limit to 60 years.  
The duration of the treatment period will vary for individual participants , depending on the time 
of recruitment and study end as described below. All recruited participants  will be followed in the 
study until approximately 288 events of 6 -month CDP are observed. Considering the  recruitment 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 41 period of a pproximately 24 months and an assumed event rate (see  Section  9.2), the duration of 
the study should be approximate ly 48  months, with estimated mean treatment duration of 33 to 
36 months.  
Participants will be encouraged to remain in the study and comply with all study visits until the 
EOS in the case that they discontinue the study intervention early.  
To minimize  possi ble biases in the study outcome, the study is double blinded. The blind of 
initial treatment will be kept from participants , any Investigator site staff, and the Sponsor until 
the study end.  
4.2.2  Justification for the use of placebo   
This study will explore the efficacy and safety of SAR442168  in participants  that are not routinely 
included in MS clinical trials: NRSPMS patients . This study will allow for a proper controlled 
data driven approach in a subset of MS patients  who do not have approved therapeutic options.   
Data obtained in recent MS clinical trials also support the use of placebo as a comparator in this 
target population. The results from the Phas e 3 EXPAND study (4), that explored the efficacy and 
safety of siponimod in SPMS participants , did not show a significant impact of this comp ound on 
disability progression in the sub -population of participants  without relapses. For this reason, EMA 
approved siponimod only for active SPMS, characterized by [CONTACT_21431].   In 
addition, ocrelizumab, the only DMT approved for prima ry progressive MS, has not been studied 
in NRSPMS  (2, 28). Despi[INVESTIGATOR_21339] -label use of other DMTs for NRSPMS patients , clinic al 
experience has confirmed a relative lack of efficacy for patients  with low or absent clinical or 
MRI activity.  
With the current study design, participants  will be allocated 2:1, SAR442168  to placebo, in order 
to minimize the exposure to placebo and maxi mize the chance of receiving active therapy. The 
participants  who enroll in the study and achieve disease progression (6 -month CDP) will be 
offered treatment with open -label SAR442168  or the possibility to switch to another DMT, if 
available  for NRSPMS in their country. All participant s who successfully complete the study will 
additionally be offered  the possibility to enroll in a long -term safety study where open label 
SAR442168  will be provided.  
4.2.[ADDRESS_20254] to study design is anticipated . 
4.3 JUSTIFICATION FOR DOSE   
The choice of the dose  of 60 mg SAR442168  taken wi th a meal is based on the results of the 
Phase 2b dose -finding trial for SAR442168  in participants  with RMS (DRI15928).  
In this study, doses of 5, 15, 30, and 60 mg SAR442168  were tested in a 12 -week double -blind 
treatment period with the number of new Gd-enhancing T1 -hyperintense lesions at the end of the 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 42 12 weeks of SAR442168  treatment as the primary endpoint. The results demonstrated 
a dose-response relationship for SAR442168  as evidenced by a reduction in the number of new 
Gd-enhancing T1 -hyperintens e brain lesions detected by [CONTACT_21419] 12 weeks of treatment. 
There was an 85% relative reduction in lesions at [ADDRESS_20255] common events (preferred terms) observed in participants  in the SAR442168  
treatment arms were headache, upper respi[INVESTIGATOR_1092], and nasopharyngitis. There were 
low numbers of AESIs and PCSA s observed. Overall, no new risks were identified in this trial.  
The Phase 2b trial tested efficacy and safety in a population that comprised people with RMS. 
One final consideration reg arding dose selection is whether doses that were effective in an RMS 
population would also be optimal for treating progressive disease. This question has been 
confronted by [CONTACT_21432]. Without exception, those 
trials have tested the same dose as that approved to treat relapsing forms of MS, including Avonex 
(IMPACT), Betaseron (North American Study Group on Interferon beta -1b in Secondary 
Progressive MS), Copaxone (PROMiSe), Rebif (SPECTRIMS), Tysabri (ASCEND), Gi lenya 
(INFORMS), Ocrevus (ORATORIO), and Mayzent (EXPAND). The main issue with dose 
selection for progressive forms of disease is that there is no clear predictive biomarker to explore 
doses in Phase 2b trials. The data from the Phase 2b trial support [ADDRESS_20256] completed the study if he/she has completed all periods of the 
study including EOS visit , whether remaining on IMP or not . 
This study will end when  approximately [ADDRESS_20257] been 
observed  which is expected to provide sufficient follow  up for safety and secondary efficacy 
endpoint evaluation . Considering the  recruitment  period of approximately 24 months and 
an assumed event rate as discussed in Section  9.2, the duration of the study should be 
approximately 48  months.  
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 43 5 STUDY POPULATION   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 INCLUSION CRITERIA   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
I 01. Participant must be [ADDRESS_20258] a previous diagnosis of RRMS in accordance with the 
2017  revised McDonald criteria (5). 
I 03. The participant must have a current diagnosis of SPMS in accordance with the clinical 
course criteria (11) revised in 2013 ( 10) and endorsed by [CONTACT_21433].   
I 04. The participant must have documented evidence of disability progression observed during 
the 12 months before s creening.  Eligibility will be analyzed by [CONTACT_21433]  
(to evaluate source data for disability confirmation; details see Section  [IP_ADDRESS] ).  
I 05. Absence of clinical relapses for at least [ADDRESS_20259] icable.  
Sex 
I 09. Male and/or female  
Contraceptive use should be consistent with local r egulations r egarding the methods of 
contraception for those participating in clinical studies.  
A) Male participants  
Not applicable.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 44 B) Female participants  
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least one of the following conditions applies:  
- Is not a wom an of childbearing potential ( WOCBP ).  
OR 
- Is a WOCBP and agrees to use an acceptable contraceptive method as d escribed in 
Appendix  4 (Section  10.4) during the intervention period. WOCBP must use reliable 
means of contracepti on as described in Appendix 4 ( Section  10.4) at a minimum. If 
local requirements are more stringent  than what is described in Appendix 4 
(Section  10.4), they should be followed.  
- A WOCBP must ha ve a negative highly  sensitive pregnancy test (urine or serum as 
required by [CONTACT_427]) (Appendix  2 [Section  10.2]) at screening and before the 
first dose of study intervention.  
- If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, t he participant must be excluded from 
participation if the serum pregnancy result is positive . 
- Requirements for pregnancy testing during and after study intervention are located in 
the SoA (Section  1.3). 
• Additional r equirements for pregnancy testing during and after study intervention are 
located in Appendix 2 (Section  10.2). 
• The Investigator is responsible for review of medical history, menstrual history, and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy , if allowed by [CONTACT_427] . 
Informed  consent  
I 10. The participant is capable of giving signed informed consent as described in Appendix 1 of 
the protocol which includes compliance with the requirements and restrictions listed in the 
informed consent form (ICF ) and in this protocol. In countries where the legal age of 
majority is above [ADDRESS_20260] also be signed by [CONTACT_2299]’s le gally 
authorized representative  (Appendix 1, Section  10.1.3 ). 
5.2 EXCLUSION CRITERIA   
Participants are excluded from the study if any of the following criteria apply:  
Medical cond itions  
E 01.  The participant has a history of infection or may be at risk for infection:  
• A history of T -lymphocyte or T -lymphocyte -receptor vaccination, transplantation 
(including solid organ, stem cell, and bone marrow transplantation) and/or antirejection 
therapy. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 45 • The participant has received any live (attenuated) vaccine (including but not limited to 
varicella zoster, oral polio, and nasal influenza) within [ADDRESS_20261] treatment 
visit.  
• The participant has a lymphocyte count less than the lower li mit of normal (LLN) at the 
Screening Visit.  
• A history of diagnosis of progressive multifocal leukoencephalopathy (PML ) or evidence 
of findings suggestive of PML on the screening  MRI. 
• A history of infection with human immunodeficiency virus (HIV) . 
• A history of active or latent tuberculosis (TB ); TB testing should be performed at 
screening and again during the study, if clinically indicated and maybe repeated based on 
clinical judgment, borderline results, or clinical suspi[INVESTIGATOR_21326] . In case of 
confirmed active or latent TB the patient can be re -screened after full completion of 
anti-tuberculosis treatment. Further details are described in the Study Manual  (see 
Section  10.2). 
NOTE: The Investigator may consult with an infectious disease expert if required, eg, test 
results are unclear or there is a suspi[INVESTIGATOR_21340] -positive test results. If the infectious disease 
expert considers the test results as false -positive and not clinically relevant and confirms that 
the part icipant can be enrolled in the trial, the Investigator must document this in the source 
data and may then randomize the participant.  
• Persistent chronic or active or recurring system infection that may adversely affect 
participation or IMP administration in  this study, as judged by [CONTACT_737].  
• Fever within 4 weeks of the Screening Visit (≥38°C; however, if due to brief and mild ear, 
nose, throat viral infection participant  may be included based on the Investigator’s 
judgment ). 
• Participants at risk of d evelopi[INVESTIGATOR_21341]: results at screening 
for serological markers for hepatitis B  and C indicating acute or chronic infection . See the 
Study Manual for further details . 
E 02.  The presence of psychiatric disturbance or substance abuse as evidenced by:  
• A history of any psychiatric disease, behavioral condition, or depression requiring 
hospi[INVESTIGATOR_21342] 2 years prior to the Screening Visit . 
• A documented history of attempted suicide or suicidal ideation of category [ADDRESS_20262] ing to the Columbia Suicide Severity Rating Scale (C -SSRS) baseline/screening 
version over the 6  months prior to  the Screening Visit , OR if in the Investigator's 
judgment, the participant is at risk for a suicide attempt.  
• Active alcohol use disorder or a  history of alcohol or drug abuse within 1 year prior to the 
Screening Visit . 
• Current alcohol intake >2 drinks per day for men and >1 drink per day for women 
(1 drink  = approximately 14 grams of alcohol = 350 mL beer = 140 mL wine = 40 mL of 
spi[INVESTIGATOR_2120]).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 46 E 03.  The following findings obtained during the Screening Visit considered in the Investigator’s 
judgment to be clinically significant  in the context of this trial : 
• Any screening laboratory values outside normal limits .  
• Abnormal ECG .  
E 04.  Conditions that  may predispose the participant  to excessive bleeding:  
• A bleeding disorder or known platelet dysfunction at any time prior to the Screening Visit . 
• A platelet count <150 000/μL at the Screening Visit . 
• The participant has had major surgery within [ADDRESS_20263] the participant’s safety or affect immune response (as judged by [CONTACT_3786]) or has planned any elective major surgery during the study.  
• A history of significant bleeding event within 6 months prior to sc reening, according to the 
Investigator’s judgment such as, but not limited to cerebral or gastrointestinal bleeding.  
E 05.  Conditions that would adversely affect participation in the study or make the primary 
efficacy endpoint non -evaluable:  
• A short life expectancy due to pre -existing health condition(s) as determined by [CONTACT_21434].  
• A history or presence of significant other concomitant illness according to the 
Investigator’s judgment such as, but not limited to cardiovascular ( including Stage  III or 
IV cardiac failure according to [LOCATION_001] Heart Association [NYHA] classification), or 
renal (ie,  undergoing dialysis), neurological, endocrine, gastrointestinal,  metabolic, 
pulmonary, or lymphatic disease that would adversely affect participation in this study.  
• Acute liver disease, cirrhosis, chronic liver disease (unless considered stable for 
>6 months).  
• Confirmed screening ALT >1.5 × ULN  OR aspartate aminotransferase ( AST ) >1.5 × ULN  
OR alkaline phosphatase (ALP ) >2 × ULN (unless caused by [CONTACT_105] -liver-related disorder or 
explained by a stable chronic liver disorde r) OR total bilirubin >1.5 × ULN (unless due to 
Gilbert syndrome or non -liver-related disorder).  
• At screening, elevated transferrin saturation (>50% in males and >40% in females) and/or 
with elevated ferritin levels >500 μg/L.  
• Any malignancy within 5 years prior to the Screening Visit (except for effectively treated  
carcinoma in situ of the cervix or adequately treated non -metastatic squamous or basal cell 
carcinoma of the skin) will also be exclusionary.  
• Any other medical condi tion(s) or concomitant disease(s) making them nonevaluable for 
the primary efficacy endpoint or that would adversely affect participation in this study, as 
judged by [CONTACT_12244] r. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 47 Prior/concomitant therapy  
E 06.  A requirement for concomitant treatment that could bias the primary evaluation, such as 
any of the  following medications/treatments within the specified time frame before any 
randomization  assessment (no wash out is required for dimethyl fumarate, interferon beta 
or glatiramer acetate treatments  although use is not permitted on or after D ay 1): 
 
Medication  Wash -out period duration  
Systemic corticosteroids, adrenocorticotropic hormone  1 month prior to screening MRI scan  
Siponimod, ponesimod  1 week before randomization with MRI and clinical 
assessment for PML prior to randomization  
Plasma exchange  1 month prior to randomization  
IV immunoglobulin  2 months prior to randomization  
Fingolimod , ozanimod  6 weeks before randomization with MRI and clinical 
assessment for PML  
Teriflunomidea mildly to moderately 
immunosuppressive/chemotherapeutic medications such 
azathioprine, mycophenolate mofetil , and methotrexate  3 months prior to randomization  
Natalizumab  2 months before rand omization with MRI and clinical 
assessments for PML  
B-cell depleting therapi[INVESTIGATOR_21343]  6 months prior to randomization  
Ofatumumab  4 months   
Highly immunosuppressive/chemotherapeutic medications: 
mitoxantrone up to 120 mg/m2 body surface area, cyclophosphamide, 
cladribine, cyclosporine  2 years prior to randomization  
Alemtuzumab  4 years prior to randomization  
Other MS -disease -modifying therapi[INVESTIGATOR_014]  5 half -lives or until end of pharmacodynamics 
activity, whichever is longer  
Lymphoid irradiation, bone marrow transplantation, mitoxantrone (with 
evidence of cardiotoxicity following treatment, or cumulative lifetime 
dose >120 mg/m2), other strongly immunosuppressive treatments 
with very long -lasting effects  No patient who has received any of these treatments 
at any time is eligible.  
IV: intravenous, MRI: magnetic resonance imaging, MS: multiple sclerosis, PML: progressive multifocal leukoencephalopathy  
a No time restriction if accelerated elimination procedure is done.  
Prior/concurrent clinical study experience  
E 07.  The participant is receiving potent and moderate inducers of CYP3A or potent inhibitors of 
CYP2C8 hepatic enzymes as listed in Appendix 9 ( Section  10.9). 
E 08.  The participant is receiving anticoagulant/antiplatelet therapi[INVESTIGATOR_014] ; those that  are not 
permitted to be taken concomitantly with the IMP , includ e the following : 
• Acetylsalicylic acid (aspi[INVESTIGATOR_248])  >81 mg/day . 
• Antiplatelet drugs (eg, clopi[INVESTIGATOR_7745]) . 
• Warfarin (vitamin K antagonist) . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 48 • Heparin, including low molecular weight heparin (antithrombin agents) . 
• Dabigatran (direct thrombin inhibitor) . 
• Api[INVESTIGATOR_3822], edoxaban, rivaroxaban (direct factor Xa inhibitors) . 
Note: All the above -mentioned drugs must be stopped at least [ADDRESS_20264] 8 days before.  These 
washout periods are only applicable in the case that the Investi gator deems it clinically 
appropriate to discontinue the listed medications or there is a recent history of use of these 
medications (as in the case when short -term treatment with anticoagulants is clinically 
recommended for certain thrombotic events), and  therefore these washout periods will 
need to be followed prior to randomization . 
If however the participant has a chronic underlying medical condition (stroke, coronary or 
carotid artery disease, valvular heart disease etc) requiring continued use of thes e 
medications, the participant cannot be enrolled in the study.  
E 09.  The participant has sensitivity to any of the study interventions, or components thereof, or 
has a drug or other allergy that, in the opi[INVESTIGATOR_689], contraindicates 
participation  in the study.  
E 10.  The participant was previously exposed to any BTK inhibitor, including SAR442168 . 
E 11.  The participant has taken other investigational drugs within 3 months or 5 half -lives, 
whichever is longer, before the Screening Visit . 
Diagnostic assessments  
E 12.  The participant has a contraindication for MRI, ie, presence of pacemaker, metallic 
implants in high risk areas (ie, artificial heart valves, aneurysm/vessel clips), presence of 
metallic material (eg, shrapnel) in high risk areas, known history of allergy to any contrast 
medium, or history of claustrophobia that would prevent completion of all protocol 
scheduled MRI . 
Note: People with a contraindication to Gd can be enrolled into the study but cannot 
receive Gd contrast dyes during their MRI scan.  
Other exc lusions  
E 13.  Individuals accommodated in an institution because of regulatory or legal order; prisoners 
or participants who are legally institutionalized . 
E 14.  Any country -related specific regulation that would prevent the participant from entering 
the study . See Ap pendix  8 (Section  10.8) (country -specific requirements) . 
E 15.  The participant is not suitable for participation, whatever the reason, as judged by [CONTACT_3786], including medical or clinical conditions, or participants potentially at risk of 
noncompliance to study procedures or not able to follow the schedule of protocol 
assessments due to other reasons . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20265] of the study, or immediate family members of such individuals  (in 
conjunction with S ection 1.61 of the International Council for Harmonisation [ ICH] - 
Good Clinical Practice [ GCP ] Ordinance E6) . 
E 17.  Any other  situation during study impl ementation/course that may r aise ethics 
considerations . 
Note: a one -time retest at screening may be performed if an abnormal laboratory test value 
is considered temporary.  
5.3 LIFESTYLE CONSIDERATIONS   
5.3.1  Meals and dietary restrictions   
SAR442168  shall  be taken with a regular meal. When possible, the meal with which SAR442168  
is taken (eg, breakfast, lunch , or dinner ) should be consistent  throughout the study. The typi[INVESTIGATOR_21344].  In case the mealtime needs to be 
changed  for IMP administration , a gap of a minimum of 12 hours between 2 doses should be 
mainta ined.  
5.3.2  Caffeine, alcohol, and tobacco   
For each visit with PK/PD assessment (refer to Section  1.3), participants will abstain from 
ingesting caffeine - or xanthine -containing products (eg, coffee, tea, cola drinks, and chocolate) for 
2 hours before the start of treatm ent until after collection of the final PK and/or PD sample later 
that day.  
For each visit with PK/PD assessment (refer to Section  1.3), participants will abstain from alcohol 
for 24 hours before the start of treatment until after collection of the final PK and/or PD sample 
later that day.  
During the entire study, participants  should be warned not to consume substant ial quantities of 
alcohol, defined as >14 gr ams ([ADDRESS_20266] drink) per day in female participants or >28 grams  
([ADDRESS_20267] drinks) per day in male participants on a regular basis . 
5.3.3  Activity   
No special restrictions.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 50 5.4 SCREEN FAILURES   
Screen failures are defined as participants  who consent to  participate in the clinical study but are 
not subsequently randomly assigned to study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards o f Reporting Trials (CONSORT) publishing requirements and to respond 
to queries from regulatory authorities. Minimal information includes demography, screen failure 
reasons, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for par ticipation in this study (screen failure) may be 
rescreened up to 2 times. Rescreened participants  should be assigned a different participant 
number. More information on rescreening procedures is provided in the Study Manual.  
5.5 CRITERIA FOR TEMPORARILY DELAY ING ADMINISTRATION OF STUDY 
INTERVENTION   
During a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency measures proposed in  
Appendix  10 (see Section  10.10 ) should be considered for screening, enrollme nt, randomization, 
and administration of study intervention.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 51 6 STUDY INTERVENTION   
Study intervention is defined as any investigational intervention(s), marketed product(s), or 
placebo intended to be administered to a study participant according to the study protocol.  
6.1 CRITERIA FOR TEMPORARILY DELAYING ENROLLMENT AND ADMINISTRATION 
OF STU DY INTERVENTION   
During a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency me asures proposed in 
Appendix  10 (Section  10.10 ) should be considered for screening, enrollment, randomization, and 
administration of  the study intervention.  
6.2 STUDY INTERVENTION (S) ADMINISTERED   
Table  2 - Overview of study intervention s administered   
ARM name  [CONTACT_13108]442168  Placebo  
Intervention name  [CONTACT_13108]442168  Placebo  
Type  Drug  Drug  
Dose formulation  Film coated t ablet  Film coated tablet  
Unit dose strength(s)  60 mg 0 mg 
Dosage level(s)  Once daily  Once daily  
Route of administration  Oral Oral 
Use Experimental  Placebo  
IMP and NIMP  IMP IMP 
Packaging and l abeling  Study intervention will be provided in 
wallet blister  packaging . Each wallet 
blister packaging will be labeled as per 
country requirements.  Study intervention will be provided in 
wallet blister  packaging . Each wallet 
blister packaging will be labeled as per 
country requirements.  
Current  name  [CONTACT_13108]442168  Not applicable  
IMP: investigational medicinal product; NIMP: noninvestigational medicinal product . 
Between the protocol -scheduled on -site visits, interim visits may be required for IMP dispensing. 
As an alternative to these visits  or to replace on -site IMP dispensation, if needed , SAR442168  
may be supplied from the site to the participant via a  Sponsor -approved courier company 
(direct -to-patient  [DTP ]) where allowed by [CONTACT_21435].  
6.2.[ADDRESS_20268] -enhancing preparations  
• Route(s) of administration: IV  
• Dose regimen: as per respective label  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 52 6.3 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY   
1. The Investigator  or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study interve ntion received and any discrepancies are 
reported and resolved before use of the study intervention.  In case of DTP shipment, 
temperature monitoring is under vendor responsibility.  
2. Only participants  enrolled in the study may receive study intervention and only authorized 
site staff may supply or administer study intervention. All study interventions must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area 
in accordance with the labeled storage conditions with access l imited to the Investigator  
and authorized site staff.  
3. The Investigator , institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance 
(ie, receipt, reconc iliation, and final disposition records).  
Any quality issue noticed with the receipt or use of an IMP  (deficiency in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_320], etc) must be promptly notified to the Sponsor . 
Some deficiencie s may be recorded through a complaint procedure (see Section  8.3.10 ). 
A potential defect in the quality of IMP may be subject to initiation of a recall procedure by [CONTACT_429] . In this case, the Investigator  will be responsible for promptly addressing any request 
made by [CONTACT_1034] , in order to recall the IMP and eliminate potential hazards.  
Under no circumstances will the Investigator  supply IMP to a third party (except for DTP  
shipment, for which a courier company has been approved by [CONTACT_1034] ), allow the IMP to be 
used other than as directed by [CONTACT_13129], or dispose of  IMP in any other manner.  
6.4 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING   
All participants  will be centrally assigned to randomized study intervention using an interactive 
response technology (IRT ). Randomization will be stratified by [CONTACT_21406] (>40, ≤40 years) 
and geographic region (US versus non -US). A participant cannot be randomized more than once 
in the study. A participant assigned to a specific arm at randomization may be allocated, by [CONTACT_21436], to several (varying) intervention numbers (and corresponding intervention kit numbers) for 
multiple visits despi[INVESTIGATOR_21345]. That is, 
in these cases, the intervention/kit number varies but the arm assignment at randomization does 
not change. Before the study is initiated,  the log in information and instructions for the Interactive 
Web Response System ( IWRS ) will be provided to each site.  
Study intervention will be dispensed at the study visits summarized in the SoA  (Section  1.3). 
Returned study intervention should not be re -dispensed to the participants . 
The Treating Investigator, Examining Investigator /rater , clinical site staff, and Sponsor’s clinical 
trial team members will not have access to the randomization (treatment) codes. The IRT will be 
programmed with blind -breaking instructions. In case of an emergency, the Investigator  has the 
sole responsibility for determining if unblinding of a participant’s treatment assignment is 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 53 warranted (eg, in case of available antidote). Participant safety must always be the 
first consideration in making such a determination. If a participant’ s treatment assignment is 
unblinded, the Sponsor must be notified within [ADDRESS_20269] be recorded in the source documentation and electronic 
case report form  (eCRF ), as applicable.  If unblinded, information pertaining to the treatment 
allocation should not be shared with other members of the study team or Sponsor.  
Methods of blinding  
This study is blinded for assignment of SAR442168  and placebo. Tablets of SAR442168  and 
placebo will appear identical.  
In order to maintain the study blind and ensure participant safety, each site will have 2 types of 
Investigator s: A Treating Investigator and an Examining Investigator /rater  (blinded). The study 
site personnel designated to conduct efficacy assessments (Examining Investigators /raters  or other 
qualified site staff ) must be different than physicians  responsible for participants’  medical 
management (Treating In vestigators) in order to protect against possible unblinding of the treatment  
assignment during regular clinical care of participants . In view of the extended duration of this 
study, each site will identify primary and back -up Treating and Examining Invest igators /raters . 
A Treating Investigator cannot change roles to Examining Investigator /rater  during the study.  
The Treating Investigator is the physician responsible for participant ’s care and should be 
a neurologist experienced in the care of MS patients . The Treating Investigator will not have 
access to efficacy data including EDSS scores other than the score at screening but will receive 
alerts on [ADDRESS_20270] access t o the participant’s other 
collected data and will follow the participant, collect safety events, and make treatment decisions 
based on the participant’s clinical response and laboratory findings. Once the participant has been 
randomly assigned to treatment , the Treating Investigator will use  a local laboratory if needed for 
additional safety assessments . 
The Examining Investigator /rater  should be trained and certified in administering the EDSS and 
other efficacy tests. Details for certification and re -certification requirements for administering the 
EDSS will be provided in the  Study Manual . The Examining Investigator /rater  will be responsible 
for assessment of the EDSS including the screening EDSS score assessment and other clinical 
efficacy tests and will have access only to data needed for these assessments. The Examining 
Investigator/rater can delegate assessment of T25 -FW, 9 -HPT, SDMT and CVLT -II to qualified 
study staff. The Examining Investigator /rater  will not have access to scores and prior EDSS  
assessments. Whenever possible, the same individual should perform the examinations for the full 
study duration. All efforts should be made to keep the Examining Investigator /rater  blinded to 
a participant’s treatment assignment, treatment dates, and consequen tly to AE data, 
non-neurological  symptoms, laboratory data, concomitant and prior medications, and any other 
information not related to the EDSS and other efficacy assessments. Participants  will be instructed 
not to discuss any symptoms related to the IMP with the Examining Investigator /rater ; the 
Examining Investigator /rater  will remind the participant of this at the start of the examination and 
will not ask any questions that are not related to the neurological examination. Participants  will be 
asked not to communicate any co -medication used or symptoms unless requested by [CONTACT_21437] /rater  for efficacy evaluation.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20271] access to unblinded data.  
6.5 STUDY INTERVENTION  COMPLIANCE   
• Methods used by [CONTACT_21438]/her delegate to ensure that the IMP was 
administered may include mouth inspection (eg, for on -site visits).  
• Measures taken to ensure study intervention accountability include  the following : 
- Intervention units are ret urned by [CONTACT_21439]. In case of direct -to-
patient  process, the intervention units can be returned by [CONTACT_21440] (if defined in the 
contract) . 
- The Treating Investigator or his/her delegate counts the number of tablets remaining in 
the re turned packs and fills in the Intervention Log Form . 
- The Treating Investigator or his/her delegate records the dosing information on the 
appropriate page(s) of the eCRF . 
- The monitor in charge of the study then checks the eCRF data by [CONTACT_21441]/she has retrieved and Intervention Log Form . 
A paper diary, to capture the details of the use of study medication, timing of meals, change in 
mealtime for IMP administration, missed doses, and overdoses, will be provided to each study 
partic ipant after they have received training on how to use the diary. Participants should bring the 
diary to each site visit for review by [CONTACT_11219]/or study staff and monitoring of 
compliance and exposure data. A new paper diary should be provided t o the study participant at 
each visit when study medication will be dispensed . In case of DTP  shipment, the new paper diary 
will be dispensed along with IMP, and the participant will return the previous completed paper 
diary to the study site via the carri er. 
Participant compliance with study intervention will be assessed at each study site visit. 
Compliance will be assessed by [CONTACT_21442]. Deviation(s) from the prescribed 
dosage regimen should be recorded in the eCRF.  
When participants  self-administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by [CONTACT_21443] . Deviation(s) 
from the prescribed dosage r egimen should be recorded in the eCR F. 
A record of the number of SAR442168  tablets dispensed to and taken by [CONTACT_21444]. Intervention start a nd 
stop dates, including dates for intervention delays and/or dose reductions will also be recorded in 
the eCRF.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 55 6.6 CONCOMITANT THERAPY   
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements)  that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:  
• Reason for use . 
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency . 
Any live (attenuated) vaccine within [ADDRESS_20272] treatment visit and during the 
intervention period is prohibited.  
Therapi[INVESTIGATOR_21346] E 06 are not permitted after randomization 
while the participant  is on study treatment.  Short -term use (3 to 5 days) of glucocorticoids (eg, for 
MS relapse treatment o r an acute illness) and local corticosteroids (eg, topi[INVESTIGATOR_2855], nasal, ocular, otic, 
intra-articular) are allowed.  
The Medical Monitor should be contact[CONTACT_21445] r egarding concomitant or 
prior therapy.  
Participants must abstain from taking prescription or nonprescription drugs (including vitamins 
and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever is longer) before the start of study inter vention until 
completion of the follow -up visit, unless, in the opi[INVESTIGATOR_16176], the 
medication will not interfere with the study.  
Medications for treatment of MS symptoms (eg,  walking impairment, fatigue, spasticity, 
incontinence, pain) should be maintained at a stable dose prior to screening and for the duration of 
the treatment period, if clinically feasible.  
Anticoagulant/antiplatelet  therapi[INVESTIGATOR_21347], 
including  the following : 
• Acetylsalicylic acid (aspi[INVESTIGATOR_248])  >81 mg/day .  
• Antiplatelet drugs (eg, clopi[INVESTIGATOR_7745]) . 
• Warfarin (vitamin K antagonist) . 
• Heparin, including low molecular weight heparin (antithrombin agents) . 
• Dabigatran (direct thrombin inhibitor) . 
• Api[INVESTIGATOR_3822], edoxaban,  rivaroxaban (direct factor Xa inhibitors) . 
Paracetamol/acetaminophen , at doses of ≤3 grams/day, is permitted for use at any time during 
the study. Short courses (up to 5 days) of nonsteroidal anti -inflammatory drugs ( NSAIDs ) (other 
than acetylsalicylic acid) , preferably selective cyclooxygenase -[ADDRESS_20273] the use of NSAIDs (and any other 
comedication) in the eCRF.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 56 CYP Inhibitors and Inducers:  
Potent and moderate inducers of CYP3A or potent  inhibitors of  CYP2C8 hepatic enzymes are not 
permitted throughout the study  (Appendix 9 [ Section  10.9]). 
Based on nonclinical drug metabolism studies, SAR442168  is a s ubstrate of the CYP3A and 
CYP2C8 isoenzymes.  In healthy participants , potent CYP3A4 inhibitor (itraconazole 200 mg 
once daily for 4  days) increased  SAR442168  area under the curve AUC exposure 1.8 -fold 
(Study  INT16385) and potent CYP2C8 inhibitor (gemfibroz il 600 mg twice daily for 6 days) 
increased SAR442168  AUC exposure 8.4 -fold ( Study  INT16726). Based on a satisfactory safety 
and tolerability profile and on the observed exposure in healthy participants  who received 
SAR442168  at a dose of up to 240 mg SAR4 [ZIP_CODE]  once daily for 14  days under fed conditions 
(Study  TDR16862), drugs that strongly inhibit CYP3A4 are allowed and drugs that strongly 
inhibit CYP2C8 are not permitted. In healthy participants , potent CYP3A4 and moderate CYP2C8 
induction by [CONTACT_21446][INVESTIGATOR_2513] (600 mg once daily for 8 days) decreased SAR442168  exposu re 6-fold 
(Study  INT16726). Therefore, potent and also moderate (based on prediction) CYP3A inducers 
are not permitted due to their potential to decrease SAR442168  exposure and efficacy.  
See Appendix 9 ( Section  10.9) for the list of drugs to be avoided . 
The Sponsor  should be contact[CONTACT_10964].  
6.6.1  Open -label treatment   
If a participant achieves the primary  endpoint ( 6-month CDP), they may, in conjunction with the 
Treating Investigator, choose to receive one of the following :  
1. To switch to open -label SAR442168  treatment ; OR 
2. To switch to a non -study treatment approved  for NRSPMS  in their respective country.  In 
this case, t he participant will permanently discontinue the IMP and  will be encouraged to 
remain in the study for planned  clinical visits (see  Section  7.1.1 ) until common study end . 
In case the participant switch es to open -label SAR442168  treatment, he/she will need to be 
monitored for liver function tests after the first open -label dose at Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 
11, and 12, and then monthly for the next 9 months. After that, the schedule visits timepoints per 
SoA will be resumed (ie, every 3 months), until the common study end. Whenever a timepoint 
will coincide with a scheduled visit a s per SoA ( Section  1.3), the full scheduled visit assessments 
will be performed instead of the liver monitoring testing alone.   
For participants achieving [ADDRESS_20274] ensure that the participant does not 
meet any of the following criteria prior to the switch to open -label SAR442168 treatment:  
• Current alcohol intake >2 drinks per day for men and >1 drink per day for women 
(1 drink  = approximately 14 grams of alcohol = 350 mL beer = 140 mL wine = 40 mL of 
spi[INVESTIGATOR_2120]).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 57 • Acute liver disease, cirrhosis, chronic liver disease (unless considered stable for 
>6 months).  
• Confirmed ALT >1.5 ×  ULN OR AST >1.5 × ULN OR ALP  >2 × ULN (unless caused by 
[CONTACT_105]-liver-related disorder or explained by a stable chronic liver disorder) OR total 
bilirubin >1.5 × ULN (unless due to Gilbert syndrome or non -liver-related disorder).  
Liver function tests will be per formed for all participants prior to the start of open -label treatment.  
Should  the participant and Investigator opt for the provision of open -label  medicine , they will 
remain blinded to the original treatment assignment . 
All individual blinded data will be reviewed and all queries resolved , if possible,  before the switch 
to the open -label treatment  to ensure data integrity for primary assessment.  Prior to initiation of 
open -label  treatment , the Investigator shall confirm that there has been no adjudi cated relapse 
within 90 days prior to the onset or confirmation of 6 -month CDP.  Based on individual symptoms 
and assessed risk of further progression, the Investigator and participant may choose for the 
participant to remain on the initial double -blind tre atment after achieving 6 -month CDP.  
The initial treatment assignment will be kept  blinded  from participants , any Investigator site staff, 
and the Sponsor until the study end.   
The supply of SAR442168  as open -label medication will be specified at the countr y level.  
Multiple sclerosis relapses are not frequent in the NRSPMS  population, but their occurrence 
during the study cannot be ruled out completely. In the case of MS relapse, treatments are allowed 
as per local routine practice (eg, high dose IV methylp rednisolone for 3 to 5 days). The date and 
time of relapse treatment administration as well as the name [CONTACT_21526].  
6.7 DOSE MODIFICATION   
Dose modification is not foreseen in this study. Treatment might need to be interrupted or 
permanently discontinued if deemed necessary due to an AE  (Section  7 and Section  8.3). 
6.8 INTERVENTION  AFTER THE END OF THE STUDY   
After the end of this study, participants  who complete the IMP treatment  (double -blind or 
open -label SAR442168  if meeting 6 -month CDP ) may be offered  the option to participate in 
an LTS study for an additional [ADDRESS_20275].  Details of the LTS study w ill be described in a separate protocol.   
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 58 7 DISCONTINUATION  OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/ WITHDRAWAL   
7.1 DISCONTINUATION OF STUDY INTERVENTION   
7.1.1  Definitive  discontinuation   
The study intervention should be continued whenever possible.  
Permanent intervention discontinuation is any treatment discontinuation associated with the 
definitive decision by [CONTACT_21447] -expose the participant to the 
study intervention at any time.  
In rare instances, it may be necessary for a participant to permanently discontinue the study 
intervention. If study intervention is permanently discontinued, the participant will be asked to 
remain in the study to be evaluated until the EOS visit. For thi s set of participants  (participants  
who discontinued the IMP and/or switch ed to other DMT s), no PK or biomarker samples will be 
collected after  the pEOT visit , and MRI assessments will be performed only annually using the 
next annual visit as the starting point.   
This will be important to co ntinue to evaluate for safety  and efficacy . See the SoA ( Section  1.3) 
for data to be collected at the time of discontinuation of the study intervention.  In the case that the 
study intervention is permanently discontinued, the participant should be treated for MS 
according to local clinical practice and the best judgment of the Investigator.  
The following may be justifiable reasons for the Investigator or Sponsor to discontinue 
a participant from treatment:  
• Adverse events that endanger the safety of the participant, or if discontinuation of study 
intervention is desired or considered necessary by [CONTACT_11219]/or participant . 
• If IMP discontinuation criteria are met as per  the guidance for the follow up of laboratory 
abnormalities (Appendix 2 [Section  10.2]). 
• The participant is no longer deriving a therapeutic/clinical benefit in the opi[INVESTIGATOR_684].  
• If a female participant becomes pregnant or wishes to become pregnant during the study . 
• At participant’s request, ie, withdrawal of the consent for treatment.  
• Any serious opportunistic infections (eg, PML [ see Appendix 6 {Section  10.6}], HIV)  
• Continued need for/chronic use of prohibited a concomitant medication  (see Appendix 9 
[Section  10.9]). 
• Use of open -label SAR442168  or non -study disease modifying therapy approved for 
NRSPMS  in their respective countries (eg, after 6-month CDP) .  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 59 Discontinuation of study intervention for abnormal liver function is required  by [CONTACT_21448] a participant meets one of the conditions outlined in the algorithm (Appendix  6 
[Section  10.6]) or if the Investigator believes that it is in best interest of the participant.  
Any clinically significant abnormal l aboratory value or ECG parameter will be rechecked for 
confirmation after 24 hours before making a decision of definitive discontinuation of the IMP for 
the concerned participant.  
If a clinically significant finding is identified in the ECG (including, but  not limited to changes 
from baseline in QT interval corrected using Fridericia’s formula [QTcF]) after enrollment, the 
Investigator or qualified designee will determine if the participant can continue in the study and if 
any change in participant manageme nt is needed. Review of ECG findings by a cardiologist may 
be considered  for a decision of a definitive discontinuation of study intervention because of ECG 
changes. This review of the ECG printed at the time of collection must be documented. Any new 
clinically relevant finding should be reported as an AE.  
See the SoA ( Section  1.3) for data to be collected at the time of intervention discontinuation and 
follow -up and for any further evaluations that need to be completed.  
Handling of participants  after definitive interve ntion  discontinuation  
Participants  will be followed according to the study procedures specified in this protocol:  
• Up to the scheduled date of study completion, or ,  
• Up to recovery or stabilization of any AE to be followed as specified in this protocol, 
whichever comes last.  
The participant should be treated for MS according to local clinical practice and the best 
judgement of the Treating Investigator.  
If possible, and after the definitive discontinuation of study drug, the participants  will be assessed 
using the procedures planned for the pEOT visit, including collection of a PK sample if the pEOT 
visit can be scheduled within a maximum of [ADDRESS_20276] IMP dose . Participants  will be 
asked to continue in the study, attending all scheduled visits  per SoA ( Section  1.3), if possible 
until the end of the study. If the participant does not agree to the full visit schedule after a decision 
for permanent end of treatment, a reduced visit schedule may be agreed with the participant. 
Every effort should be made to collect endpoint information and vital status at least once a year 
and at the end of study.   
For participants  with definitive discontinuation of study drug who do not agree to remain in the 
study after the premature end of treatment visit, if the premature end of treatment visit is less than 
[ADDRESS_20277] dose of the study drug, an additional  visit shoul d be performed with 
assessments normally planned for the follow -up visit.  
Participants  who are treated with open label IMP who decide to prematurely and permanently 
discontinue the open label IMP prior to the common study end date should be assessed as so on as 
possible using the procedures normally planned for the premature end of treatment visit.  
Participants  who prematurely and permanently discontinue open label IMP who do not agree to 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20278] be recorded by [CONTACT_21449].  
7.1.2  Temporary discontinuation   
Temporary intervention discontinuation, because of suspected AEs  or disruption of the clinical 
trial due to a regional or national emergency declar ed by a governmental agency (Appendix 10 
[Section  10.10 ]: Contingency measures for a regional or national emergency that is declared by 
a governmental agency)  may be considered by [CONTACT_21450]. For all temporary 
intervention discontin uations, duration should be recorded by [CONTACT_21451].  
If surgery is needed during the study, the benefit -risk of withholding the IMP for at least [ADDRESS_20279] -surgery  and the risk of bleeding  should be considered .  
The following shall  lead to temporary treatment discontinuation:  
• Cytopenias: algorithm for neutropenia and thrombocytopenia as per Appendix 6 
(Section  10.6) should be followed . 
• Serum creatinine, creatine phosphokinase ( CPK ) and liver enzyme increase: follow 
corresponding algorithms as per Appendix 6 ( Section  10.6). 
• Cardiac arrhythmia (Atri al fibrillation): Any Grade 3 event (symptomatic, urgent 
intervention indicated; device [eg, pacemaker]; ablation; new onset) . 
• Suicidal risk as per C -SSRS: if a participant scores “yes” on items 4 or 5 of the Suicidal 
Ideation Section, or “yes” on any item  of the Suicidal Behavior Section . 
If needed, temporary treatment discontinuation can be considered by [CONTACT_21452], including due to any safety concerns because of disruption of the 
clinical trial due to a re gional or national emergency declared by a governmental agency such as 
COVID -19 (Appendix 1 0 [Section  10.10 ]) or another illness or if there is a need for a prohibited 
concomitant medication. Treatment can be resumed later when it is considered safe and 
appropriate.  
[IP_ADDRESS]  Rechallenge   
Reinitiation of intervention with the IMP will be done under close and appropriate clinical  and/or 
laboratory monitoring once the Investigator will have considered , according to his/her best 
medical  judgment , that the responsibility of the IMP(s) in the occurrence of the concerned event 
was unlikely, there are no safety concerns and if the criteria for permanent treatment 
discontinuation have not been met (refer to  Section  5). 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 61 For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 10 (see Section  10.10 ). 
7.2 PARTICIPANT DISCONTINUATION/ WITHDRAWAL FROM THE STUDY   
• A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator  for safety, behavioral, 
compliance, or administrative reasons.  This is expected to be uncommon.  
• At the time o f discontinuing from the study, if possible, a premature EOT  visit should be 
conducted, as shown in the SoA. See SoA  (Section  1.3) for data to be collected at the time 
of study discontinuation and follow -up and for any further evaluations that need to be 
completed.  
• The participant will be permanently discontinued both from the study intervention and 
from the study at that time.  
• If the participant withdraws consent for disclosure of future information, the Sponsor  may 
retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destructi on of any samples 
taken and not tested, and the Investigator  must document this in the site study records.  
If participants  no longer wish to take the IMP, they will be encouraged to remain in the study  until 
the EOS Visit. 
The Investigators should discuss with them key visits to attend. The value of all their study data 
collected during their continued involvement will be emphasized as important to the public health 
value of the study.  
Participants who withdraw from the study intervention should be explicit ly asked about the 
contribution of possible AEs to their decision, and any AE information elicited must be 
documented.  
All study withdrawals should be recorded by [CONTACT_21453]’s medical reco rds. In the medical record, at least the date of the 
withdrawal and the reason should be documented.  
In addition, a participant may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention should be distinguished from withdrawal of consent for 
follow -up visits and from withdrawal of consent for non -participant contact [CONTACT_21454], 
eg, medical record checks. The site should document any case of withdrawal of consent.  
Participants  who have withdrawn from the study cann ot be rerandomized (treated) in the study. 
Their inclusion and intervention numbers must not be reused.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20280] be taken if a participant fails to return to the clinic for a required study 
visit: 
• The site must attempt to contact [CONTACT_21455]/or should continue in 
the study.  
• Before a participant is deemed lost to follow up, the Investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, [ADDRESS_20281] can be made with 3 telephone ca lls, a certified letter to the participant’s last 
known mailing address or local equivalent methods). Participants  who are unable to be 
reached should be recontact[CONTACT_21456] e. These contact [CONTACT_21457]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.   
Discontinuation of specific sites or of the study as a whole  are handled as part of Appendix  1 
(Section  10.1). 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 63 8 STUDY ASSESSMENTS AND PROCEDURES   
• Study procedures and their timing are summarized in the SoA  (Section  1.3). Protocol 
waivers or exemptions are not allowed.  
• Adherence to the study design requirements, including those specified in the SoA  
(Section  1.3), is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigato r will maintain a screening log to 
record details of all participants  screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, blood 
coun t) and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the SoA. Such assessments will be recorded on the 
designated field in the eCRF.  
• Blood sampling details including volume for all laboratory assessments will be provided in 
the laboratory manual, and the informed consent form. Repeat or unscheduled samples 
may be taken for safety reasons or for technical issues with the samples.  
• In exce ptional cases, under regional or national emergencies (eg, natural disaster, epi[INVESTIGATOR_21348], terrorist attack), onsite visits may be replaced with telephone/ remote  visits.  For 
example, participant  interviews for medical history/prior medications could be  performed 
by [CONTACT_648], local safety labs and some efficacy assessments could be performed off -site/at 
the participant ’s home (eg, home nursing) if agreed by [CONTACT_21458].  In such circumstances, the visit window may be  expanded, if needed 
(eg, ±14 days for quarterly visits).  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Section  10.10 , Appendix 10: Contingency measures for a regional or national 
emergency that is declared by a governmental agency.  
8.1 EFFICACY ASSESSMENTS   
Planned time points for all efficacy asses sments are provided in the SoA ( Section  1.3). 
Key efficacy assessments will be scored by a blinded Examining Invest igator /rater  or blinded 
imaging raters who are not otherwise involved in the management of participants  in this study.  
Key assessments of disability (EDSS score) will be performed by a blinded Examining 
Investigator /rater  who will have no access to laboratory and AE reports. Magnetic resonance 
imaging scans for efficacy analyses will be analyzed by a blinded, independent, central MRI -
reading unit.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 64 8.1.1  Expanded disability status scale   
The Examining Investigator /rater  will perform the EDSS assessment (8). All Examining 
Investigators /raters  will be trained and certified to perform the EDSS assessment in a consistent 
manner.  
The EDSS score will be captured using an electronic EDSS tool. Quality control measures will be 
put in place to ensure scoring error detection and thus minimize the impac t of any scoring and 
calculation errors.  
The Examining Investigator /rater  will rate functional systems in the context of a standard 
neurological examination and will report these ratings as per the EDSS reporting instructions 
together with information on t he participant’s mobility, gait, and use of assistive devices. Standard 
EDSS assessments of 7 functional domains (Visual, Brainstem, Pyramidal [motor], Cerebellar 
[coordination], Sensory, Cerebral , and Bowel/bladder) scoring will be performed by [CONTACT_21459]. Ambulation scoring will be done to conclude 
evaluation. The fatigue evaluation may be optionally recorded, but it will not contribute to 
assignment of the EDSS score. The total EDSS score will be assigned acc ording to EDSS scoring 
rules. The Examining Investigator /rater  will not be aware of which visit a participant is 
completing, will not have access to previous EDSS scores, and will be blinded to all data that 
could unblind the participant’s treatment assign ment (see Section  6.4). 
A screening EDSS assessment must be completed to confirm eligibility , and it must be repeated at 
the randomization  visit.  
EDSS scores, except for screening EDSS scores, will not be communic ated to any study staff 
including the Treating Investigator. The Treating Investigator will be notified if the participant 
meets the EDSS criteria for 6 -month CDP . Participants  will not be informed of their EDSS scores. 
They will be informed of 6 -month CDP  by [CONTACT_21460]  6.6.1 . 
[IP_ADDRESS]  Confirmed disability progressio n  
Three - and 6 -month CDPs are defined as an increase in EDSS score (defined as an increase of 
≥1.0 point from the baseline EDSS score when the baseline score is ≤5.0 or an increa se of 
≥0.5 points from the baseline EDSS score when the baseline score is >5.0) confirmed after 
a minimum of 3 - and 6 -month interval, respectively.  
EDSS scores used for potential onset of disability progression may be observed by [CONTACT_21461] /rater  during routine quarterly visits or unscheduled visits. However, confirmation of 
CDP (at least 3 or 6 months later) must be at a routine quart erly visit.  Results of all EDSS 
assessments obtained during routine or unscheduled visits throughout the minimum 3 - or 6-month 
period (for the primary endpoint) will serve as the basis for conclusion. Once confirmation is 
achieved, the potential onset beco mes the actual onset for time to onset of CDP.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20282] also be mai ntained 
for any non -confirmatory (ie, intervening) EDSS assessment(s) between the initial (onset) and 
confirmation EDSS scores.  
Confirmed disability improvement is defined as a ≥[ADDRESS_20283] 6 months.  
[IP_ADDRESS]  Confirmed disability improvement   
Confirmed disability improvement is defined as a ≥[ADDRESS_20284] 6 months.  
8.1.2  Magnetic resonance im aging   
Cranial (brain) MRI before  and after administering the Gd contrast agent will be performed.  
• The basic MRI will be performed at all sites and will consist of the following sequences: 
T2- and T1 -weighted sequences before and after administering a Gd contrast  agent  (if 
there is no contraindication).  
• An e xpanded MRI protocol will be conducted using additional MRI sequences such as 
magnetization transfer ratio (MTR ) (all centers) and susceptibility -weighted imaging  
(SWI ), (subset of centers with capacity of 3T MRI) .  
• Basic MRI sequences will be used to evaluate MRI -related endpoints of change in 
T2-hyperintense lesion volume , new and enlarging T2 -hyperint ense lesion count, number 
and volume of T1 -hypoinense lesion, brain volume  loss rate , volume, number and 
intensity (T1) of SEL, and Gd -enhancing T1 -hyperintense lesion count (see  Section  3). 
The expanded MRI protocol will be used to evaluate Gd enhancement recovery (MTR) 
and phase rim lesions (SWI). Due to a potential safety risk related to deposition of certain 
IV Gd co ntrast agents in the brain, these agents should be used in accordance with local 
recommendations/regulations (29).  
A central MRI manual, containing instructions for brain MRI standard image acquisition 
requirements, MRI acquisition validation, data transfer to the central review center, archiving a nd 
shippi[INVESTIGATOR_007], and image approval process, will be provided to all participating sites. Study site 
personnel will undergo training regarding MRI acquisition and data handling procedures. Training 
will be documented, and adherence to the central MRI manual will be monitored throughout the 
study with retraining performed as necessary.   
Unless specified otherwise, the screening brain MRI scan will be used as the reference to assess 
all MRI -derived endpoints. Standardized endpoint evaluation is assured by [CONTACT_21462]. A blinded MRI central review will be performed for all MRI -derived endpoints. All 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20285] e sclerosis relapse assessment   
[IP_ADDRESS]  Definition of multiple sclerosis relapse   
For the purposes of this stu dy, MS relapse is defined as monophasic, acute  or subacute onset of , 
new neurological symptoms or worsening of previous neurological symptoms with 
an objective change on neurological examination.  Symptoms must:  
1. Be attributable to MS,  
2. Last for ≥24 hours, with or without recovery,  
3. Be present at normal body temperature (ie, no infection, excessive exercise, or excessively 
high ambient temperature), and  
4. Be preceded by ≥30 days of clinical stability (including no previous MS relapse).  
Note: An exacerbation or recurrence of symptoms and signs in a participant with MS that can be 
reasonably attributed to transient impairment of conduction in previously demy elinated pathways 
due to drugs (such as rarely occurs a few hours after injections of interferon beta), or raised core 
body temperature (the Uhthoff phenomenon), will not be considered a relapse.  
Confirmation of MS relapse will be done by [CONTACT_21463] ( 8) (provided by [CONTACT_21464] /rater ), based on the 
following definition:  
• A confirmed MS relapse is one accompanied by a clinically relevant change in the EDSS 
score performed by [CONTACT_21464] /rater , ie, an increase of at least 0.5 points 
in the EDSS score, an increase of 1 point on 2 functional scores, or an increa se of 2 points 
on 1 functional score, excluding changes involving bowel/bladder and cerebral functional 
score compared to the previously available rating (the last EDSS rating that did not occur 
during a relapse).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 67 Confirmation of MS relapse for analysis an d study report purposes is detailed in Section  9.4.2 .  
Refer to Section  8.3.7  for details regarding MS relapse reporting and Appendix  1 
(Section  [IP_ADDRESS] ) for details regarding the Relapse Adjudication Committee.  
[IP_ADDRESS]  Unscheduled assessment visits   
Participants  must be instructed to immediately report new neurological symptoms and recurring or 
worsening of previous symptoms to the Investigator. Any reported symptoms will b e collected. 
If a participant reports symptoms that may be consistent with relapse, an unscheduled assessment 
visit to the Treating Investigator and the Examining Investigator /rater  (blinded) must be scheduled 
as soon as possible (whenever possible within 7 days of onset of the symptoms). The assessment, 
management, and reporting of MS relapse is made by [CONTACT_21450].  
Diagnosing MS relapses during the study: The Treating  Investigator will assess whether the 
reported epi[INVESTIGATOR_21349]. If it is consistent with the 
definition of MS relapse or if there is any doubt and possibility of relapse cannot be ruled out, the 
standard neurological  examination (for the EDSS score) will be performed by [CONTACT_21461] /rater . If the participant is not referred for EDSS assessment, this will be documented 
with an explanation of the reason. Whenever possible, the Examining Investigator /rater  should 
perform the EDSS rating the same day the examination is performed by [CONTACT_21450]. 
Subsequent EDSS assessments can still be utilized for confirmation of MS relapses but should be 
avoided to reduce the risk of changes in participant stat us in between the assessments by [CONTACT_21465] /raters . 
All MS relapses must be reported on the MS relapse eCRF page. Multiple sclerosis relapse should 
not be reported as an AE unless, in the judgment of the Investigator, it is un usually severe or 
medically unexpected, or matches definition of an SAE.  
Safety laboratory tests are optional for this unscheduled assessment visit if no intercurrent disease 
is suspected. If any intercurrent disease is diagnosed, it will be reported as an  AE as per the safety 
reporting rules.  
The participant will be actively asked about possible relapse symptoms at each study visit . If 
relapse is suspected, the above decision -making and reporting rules will apply.  
8.1.[ADDRESS_20286] will be used to assess a participant’s walking ability. The participant is directed 
to one end of a clearly marked 25 -foot course and is instructed to walk 25 feet as quickly as sa fely 
possible with several repetitions (30). The mean walk time will be used for assessment of the 
participant’s walking ability. An increase of >20% from the baseline in the T25 -FW test is 
considered meaningful worsening  (31). The Examining Investigator/rater or qualified study staff 
will perform this test.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20287]   
Time to complete the 9 -HPT will be used to assess a participant’s manual dexterity and fine motor 
skills. A participant will be asked to place the pegs into the holes and remove them with the 
dominant and nondominant hand f or several repetitions  (32). The mean time to test completion 
will serve for assessment of the participant’s hand dexterity. An increase of >2 0% from the 
baseline in the 9 -HPT is considered meaningful worsening (31). The Examining Investigator/rater 
or qualified study staff will perf orm this test.  
8.1.[ADDRESS_20288] for cognitive function by [CONTACT_21466] (33) involves a simple substitution tas k using a reference key. The number of correct 
pairings made in 90 seconds is recorded. A decrease of 4 points from baseline on the SDMT is 
considered meaningful worsening (34). The Examining Investigator/rater or qualified study staff 
will perform this test.  
The CVLT -II (35) measures verbal learning and memory by [CONTACT_2329] a [ADDRESS_20289] and report as many of the items as possible. 
Five successive trials are scored.  The Examining Investigator/rater or qualifie d study staff will 
perform this test.  
8.1.7  Composite analyses   
Data from the clinical assessments described above will be utilized in various composite analyses 
and endpoints to assess  effects of SAR442168  on a range of clinical measures. The following 
sections provide additional details on these composite scales and related criteria for analyses.  
[IP_ADDRESS]  Modified Multiple Sclerosis Functional Composite -3  
The modified Multiple Sclerosis Functional Composite -3 (MSFC -3) tool is the composite of the 
T25-FW test, 9 -HPT, and SDMT ( 32, 36). The MSFC -3 score wi ll be calculated from these 
component tests.  
[IP_ADDRESS]  Assessment of no evidence of disease activity   
No evidence of disease activity -3 (NEDA -3) is defined as absence of all of the following (37): 
• 6-month CDP . 
• Active MRI lesions (both new or enlarged T2-hyperintense lesions and Gd -enhancing 
T1-hyperintense lesions) . 
• Adjudicated MS relapse . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20290] 
clinical outcome assessments at the clinic prior to any s tudy procedures or discussion of 
health -related issues to ensure the objectivity of their responses. This device replaces the paper 
questionnaires that are normally used. Although the software is not approved as a medical device, 
appropriate validation of the device to ensure accurate and consistent functioning has been 
performed.  
• Multiple Sclerosis Quality of Life -54: The MSQoL -54 (38, 39) is a standardized 
instrument comprising generic and MS -specific item s. It includes the SF -36 which has 
been used in many MS clinical trials, especially of disease -modifying therapi[INVESTIGATOR_014] 
(eg, teriflunomide). This 54 -item instrument generates 12 subscales and 2 single -item 
measures. The 12 subscales are  as follows : physical hea lth (10 items), emotional 
well-being (5 items), cognitive function (4 items), role limitation physical (4 items), 
energy (5  items), health distress (4 items), overall quality of life (2 items), health 
perceptions (5  items), role limitations emotional (3 it ems), sexual function (4 items), pain 
(3 items), and social function (3 items) covering all aspects of MS. The single -item 
measures are satisfaction with sexual function (1 item) and change in health (1 item). 
A linguistically validated MSQoL -54 is availab le in multiple languages.   
• EuroQoL 5 -Dimension 5 -Level Instrument: The EQ -5D-5L is a generic quality of life 
instrument used for measuring utility ( 40) and some of the regulatory bodies’ 
requirements. It consists of 2 parts: a descriptive part (5 questions) and a visual assessment 
scale. It is used in the majority of MS ( 41), (eg, daclizumab [STUDY_ID_REMOVED]) and non -MS 
clinical studies routinely. The EQ -5D-5L is available in multiple languages.  
All clinical outcome  assessments are quantitative tools; they do not collect tolerability data. No 
information that could be a potential safety signal is expected, so clinical outcome assessments 
data will be analyzed at the end of the study.  
8.2 SAFETY ASSESSMENTS   
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). 
8.2.1  Physical examinations   
A physical examination will be performed at the time points specified in the SoA ( Section  1.3). 
• A complete physical examination will include, at a minimum, assessments of the general 
appearance, head  and neck, abdomen, lymph nodes, skin, cardiovascular system, 
respi[INVESTIGATOR_2133], musculoskeletal system, and neurological examination by [CONTACT_21467].  Height (at screening) and weight will also be measured and recorded.  Further 
details will b e provided in the Study Manual.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 70 • A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system,  neurological examination,  and abdomen (liver and spleen).  
• Investigator s should pay special attention to clinical signs related to previous serious 
illnesses.  
• Any clinically significant new finding or worsening of previous finding should be reported 
as an AE, per Investigator’s judgement . 
The extent of the physical examination can be broadened at the discreti on of the Treating 
Investigator in order to evaluate AEs or abnormal clinical laboratory test values . 
8.2.2  Vital signs   
• Body  temperature , heart rate, and blood pressure will be assesse d. 
• Blood pressure and pulse measurements will be assessed with the participant in a supi[INVESTIGATOR_21350] a completely automated device. Manual techniques  will be used only 
if an automated device is not available.  
• Blood pressure and pulse measure ments should be preceded by [CONTACT_2669] [ADDRESS_20291] 
for the participant in a quiet setting without distractions (eg, television, cell phones).  
• Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 heart 
rate and 3 bloo d pressure measurements ([ADDRESS_20292] 1  minute).  
8.2.3  Electrocardiograms   
• 12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF 
intervals. Refer to Section  7 for QTcF withdrawal  criteria . In case the ECG machine does 
not automatically calculate QTcF, manual calculation using nomogram or automatic 
website calculator (eg, https://reference.medscape.com/calculator/48/ecg -corrected -qt) is 
accepta ble 
• ECG  and 30 second rhythm strips  will be obtained locally.  Further details will be included 
in the Study  Manual.  
8.2.4  Clinical safety laboratory assessments   
• See Appendix 2 ( Section  10.2) for the list of clinical laboratory tests to be performed. Per 
the SoA, serology tests for hepatitis B and C will be performed during screening; testing 
for other infectious disease should b e performed during screening if required locally.  
• The Treating Investigator may solicit emergency local laboratory data in case of emergent 
safety events to allow for appropriate treatment decisions. All clinically relevant solicited 
emergency local labor atory data will be recorded in the eCRF.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 71 • The Treating Investigator must review the laboratory report, document this review, and 
record any clinically relevant changes occurring during the study in the AE section of the 
eCRF. The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by [CONTACT_21468]’s condition.  
• All labo ratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_20293] dose of study intervention should 
be repeated until the values return to normal or baseline or are no longer considered  
clinically significant by [CONTACT_737].  
- If abnormal laboratory values do not return to normal/baseline within a period of time 
judged reasonable by [CONTACT_737], the etiology should be identified and the 
Sponsor notified.  
• All protocol -required lab oratory assessments, as defined in Appendix 2 ( Section  10.2), 
must be conducted in accordance with the laboratory m anual and the SoA.  In the event the 
laboratory assessments in Appendix 6  (Section  10.6) indicate discontinuation of IMP, 
temporary discontinuation should be considered unless otherwise specified.  
- If laboratory values from non -protocol specified laboratory assessments performed at 
the institution’s local laboratory require a change in partici pant management or are 
considered clinically significant by [CONTACT_737] (eg, SAE or AE or dose 
modification), then the results must be recorded in the eCRF.   
8.2.[ADDRESS_20294] be interrupted if a participant scores “yes” on items 4 or 5 of the 
Suicidal Ideation Section of the C -SSRS, or “yes” on any item of the Suicidal Behavior Section. 
A psychiatrist will be consulted and decide whether the study drug can be restarted and if any 
additional risk mitigation strategies are required (eg, increased  monitoring, antidepressant 
administration).  
8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS   
The definitions of an AE or SAE  can be found in Appendix 3 (Section  10.3).  
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a car egiver, surrogate, or the 
partic ipant ’s legally authorized representative).  
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the study intervention  (see Section  7).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 72 8.3.1  Time period and frequency for collecting  AE and SAE information   
All SAEs will be collected from the signing of the  ICF until the follow -up visit /EOS visit  at the 
time points specified in the SoA ( Section  1.3). 
All AE will be collected from the signing of the ICF  at the time points specified in the SoA  
(Section  1.3). 
All SAEs and AESI will be recorded and reported to the Sponsor  or designee  immediately and 
under no circumsta nce should this exceed  24 hours, as indicated in  Appendix  3 (Section  10.3). 
The Investigator  will submit any updated SAE data to the Sponsor  within 24  hours of it being 
available.  
Investigator s are not obligated to actively seek AE or SAE after conclusion of the stu dy 
participation . However, if the Investigator  learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study intervention or study participatio n, the Investigator  must promptly notify the 
Sponsor . 
8.3.2  Method of detecting AEs and SAEs   
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3). 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurren ces.  
8.3.3  Follow -up of AEs and SAEs   
After the initial AE/ AESI/ SAE report, the Investigator  is required to proactively follow each 
participant at subsequent visits/ contacts. At the  pre-specified study end -date, a ll SAEs,  and AE SIs 
(as defined in Section  8.3.9), will  be followed until resolution, stabilization, the event is otherwise 
explained, or the participant is lost to follow  up (as defined in Section  7.3). Further information on 
follow -up procedures is provided in Appendix  3 (Section  10.3). 
8.3.4  Regulatory reporting requirements for SAEs   
• Prompt notification b y the Investigator  to the Sponsor  of an SAE is essential so that l egal 
obligations  and ethical responsibilities towards the safety of participants  and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor  has a l egal responsibility to notify both the local r egulatory authority and 
other r egulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor  will comply with country -specific r egulatory requirements 
relating to safety repor ting to the r egulatory authority, Institutional Review Boards 
(IRB )/Independent Ethics Committees (IEC ), and Investigator s. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 73 • Reportin g of s uspected unexpected serious adverse reactions (S[LOCATION_003]Rs ) will be in 
accordance with Directive 2001/20/EC or as per national regulatory requirements in 
participating countr ies. S[LOCATION_003]Rs are reported to regulatory authorities, Investigators, and 
IRBs/IECs as follows:  
- For S[LOCATION_003]Rs that are life -threatening or result in death, reporting is no later than  
[ADDRESS_20295] knowledge by [CONTACT_1034] . 
• Adverse events that are considered expected will be  specified in the reference safety 
information (see the Investigator’s brochure [IB]) .  
• An Investigator who receives an Investigator safety report describing a n SAE, S[LOCATION_003]R or 
any other specific safety information ( eg, summary or listing of SAEs) from the Sponsor 
will review and then file it along with the IB and will notify the IRB/IEC, if appropriate 
according to local requirements.  It is the responsibility of t he Sponsor to assess whether 
an event meets the criteria for a S[LOCATION_003]R, and therefore, is expedited to regulatory 
authorities.  
8.3.5  Pregnancy   
Details of all pregnancies in female partic ipants  and female partners of male participants  will be 
collected after the start of study intervention and until the follow -up/EOS Visit (Note: A separate 
informed consent must be obtained for data collection from partners of male participants ). The 
participant will be followed to determine the outcome of the pregnancy and should be followed 
even after the end of the study (See Appendix 4 [ Section  10.4]). 
• If a pr egnancy is reported, the Investigator  should inform the Sponsor  within 24 hours of 
learning of the pr egnancy and should follow the procedures outlined in  Appendix  4 
(Sectio n 10.4). 
• A negative pregnancy test is required prior to starting a treatment course. In the event that 
a pregnancy is confirmed during a course of treatment, the IMP should be discontinued.  
• A pregna ncy will qualify as an SAE only if it fulfills at least 1 of the seriousness criteria 
(see Appendix  3 [Section  10.3]). 
• Abnormal pr egnancy outcomes ( eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pr egnancy) are considered SAEs.  
• AEs that occur to study participants  who become pregnant are to be reported according to 
the relevant portion of Appendix 3 ( Section  10.3). 
8.3.[ADDRESS_20296] safety reporting and safety 
oversight practices (including data review by [CONTACT_21469] ).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20297] SAE reporting rules. Every effort will be made to 
clarify the cause of death and to report the diagnosis of the fatal event as an SAE.  
8.3.7  Multiple sclerosis relapse reporting   
Multiple sclerosis relapses, determined from the evaluations described in Section  8.1.3 , as with all 
efficacy endpoints, will be exempt from being reported as AEs except when they meet the 
definition of an SAE  or are medically severe or medically unexpected . Hospi[INVESTIGATOR_21351], if done routinely at the site (eg, for high dose IV methylpred nisolone), will not be 
considered as a seriousness criterion for this study.  
Multiple sclerosis relapses will be collected on the eCRF and be analyzed as part of the efficacy 
analysis. Other worsening of neurological symptoms that do not meet the definitio n of MS relapse 
will be reported as AEs according to general safety reporting rules.  
8.3.8  Magnetic resonance imaging   
Magnetic resonance imaging scans need to be reviewed locally for a ny pathology. In case of 
clinically significant findings, relevant information needs to be provided to the Treating 
Investigator for appropriate safety reporting  and also to ensure the appropriate management of the 
participant’s identified safety finding . When available, a diagnosis of pathology at cause of such 
MRI findings or the findings themselves will be reported as an AE until the diagnosis is clear.  
Multiple sclerosis findings on MRI do not need to be reported unless they are deemed unusual and 
thus a distinct safety finding.  
8.3.[ADDRESS_20298]  
An AESI is an AE (serious or nonserious) of scientific and medical concern specific  to the 
Sponsor’s product or program, for which ongoing monitoring and immediate notification by [CONTACT_21470]. Such events may require further investigation in order to 
characterize and understand them. Adverse events of spec ial interest may be added, modified , or 
removed during a study by [CONTACT_12548].  
• Pregnancy of a female participant entered in a study as well as pregnancy occurring in 
a female partner of a male participant entered in a study with IMP/NIMP   
- It will be qualified as an SAE only if it fulfills one of the seriousness criteria 
(see Appendix 3 [ Section  10.3]), 
- In the event of pregnancy in a female participant, IMP should be discontinued ,  
- Follow -up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outcome has been determined (See Appendix 4 
[Section  10.4]). 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 75 • Symptomatic overdose (serious or nonserious) with IMP  
- An overdose (accidental or intentional) with the IMP is an eve nt suspected by [CONTACT_13148] (not based on systematic pi[INVESTIGATOR_12988]) and defined as at least twice the intended dose within the intended therapeutic 
interval  (eg, ≥2 tablets of the IMP within a 12 -hour interva l).  
• Increase in alanine transaminase (ALT)  >3 × ULN   
- ALT increase >3 × ULN  confirmed by [CONTACT_21471] [ADDRESS_20299] within 72 hour s. 
• Other project specific AESI(s)  
- ECG observation of atrial fibrillation  or atrial flutter , 
- Severe infection (NCI CTCAE Grade 3 or above) infection,  that may or may not meet 
seriousness criteria  (eg, a Grade 3 opportunistic infection ), 
- Moderate or severe hemorrhagic events  (NCI CTCAE Grade 2 or above) , including 
but not limited t o symptomatic bleeding , bleeding in a critical area or organ such as the 
CNS, or intraocular bleeding , 
- Thrombocytopenia, platelet count < 75 000/mm3 (see Appendix 6 [Section  10.6] for 
management flow chart) . 
8.3.[ADDRESS_20300] complaint form within required timelines.  
Appr opriate information ( eg, samples, labels or documents like pi[INVESTIGATOR_12989]) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigator  
will assess whether or not the quality issue has to be reporte d together with an AE or SAE.  
8.4 TREATMENT OF OVERDOSE   
The Sponsor  does not recommend specific treatment  for an overdose . 
In the event of an overdose, the Treating Investigator should do the following:  
1. Contact [CONTACT_21472].  
2. Closely monitor the participant for any AE/SAE and abnormal laboratory test values.  
3. Obtain a plasma sample for PK analysis within [ADDRESS_20301] documented IMP dose.  
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF.  
5. Decisions regarding dose interruptions will be made by [CONTACT_21473].  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 76 8.5 PHARMACOKINETICS   
• Blood samples of approximately 2 to 3 mL will be collected for measurement of plasma  
concentrations of SAR442168  and relevant metabolite(s) as specified in the SoA  
(Section  1.3). The 5 scheduled samples will be collected at selected timepoints during the 
study (for participants  who discontinued IMP, no PK samples are collected after pEOT 
visit).  If warranted and agreed upon between the Investigator and the Sponsor, additional 
PK samples may be collected (eg, for retesting, pEOT, or if clinically indicated). The PK 
sample collection/storage is strongly recommended for events of confirmed ALT increase 
>5 × ULN (recommended for ALT >3 × ULN) and thrombocytopenia (platelets 
<75 000/mm3), and is recommended for events of neutropenia (neutrophils <1500/mm3), 
serum creatinin e increase (confirmed increase >1.7 × ULN or decrease clearance >50%, 
cannot be rapi[INVESTIGATOR_21352]), and CPK increase (confirmed >10 × ULN)  (see Section  10.6 
for more details).  
• Instructions for the collection and handling of biological samples will be provided by [CONTACT_429] . The actual date and time (24 -hour clock time) of each sample will be recorded.  
• Each plasma  sample will be divided into 2 aliquots (1 each for [PK, other analyses, and 
a back -up]). Samples collected for analyses of SAR442168  and relevant metabolite(s) 
plasma concentration may also be used to evaluate safety or efficacy aspects related to 
concerns  arising during or after the study.  
• Population PK analysis will be performed using SAR442168  and relevant metabolite(s) 
concentration and will be reported in a standalone report.  
Drug concentration information that would unblind the study will not be repor ted to investigative 
sites or blinded personnel until the study has been unblinded.  
8.6 PHARMACODYNAMICS   
Blood samples for lymphocyte phenotypi[INVESTIGATOR_21353] a s detailed in the 
SoA (Section  1.3) for a subset of up to [ADDRESS_20302] perform ed; participants  who had a baseline 
sampl e collected  will have a second sample collected at EOT/pEOT. For additional PD 
evaluations (NfL levels and Chi3L1 and Ig levels), sample collections are no longer needed for 
participants  who discontinued IMP or switched to other DMTs.  For participants in China, 
see Appendix 7 (Section  10.7). 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20303] consented 
to participate in the genetic analysis component of the study. Participation is optional. Participants  
who do not wish to participate in the genetic research may still participate in the study.  DNA 
samples will be collected during the s tudy as detailed in the SoA ( Section  1.3). Samples will be 
stored, and analysis may be performed on genetic varian ts thought to play a rol e in MS including, 
but not limited to, specific candidate genes/genome a nalyse s to eva luate their association with 
observed clinical responses to SAR442168 . For participants in China, see Appendix  7 
(Section  10.7). 
In the event of DNA extraction failure, a replacement genetic blood sample may be requested 
from the par ticipant. Signed informed consent will be required to obtain a replacement sample 
unless it was included in the original consent.  
8.8 BIOMARKERS   
Blood samples for biomarkers research  will be collected from all participants  in this study as 
specified in the SoA ( Section  1.3). 
• Collection of plasma and serum samples for biomarker research is also part of this study.  
• Samples will be tested to evaluate biomarkers and their association with the observed 
clinical res ponses to SAR442168 . 
• In addition, samples will be stored , and analysis may be performed on biomarker variants 
thought to play a role in MS including, but not limited to, plasma or serum analytes  to 
evaluate their association with observed clinical response s to SAR442168 . 
Samples may be stored for a maximum of 2 years (or according to local regulations)  following the 
last participant’s last visit for the study at a facility selected by [CONTACT_21474]442168 . For participants in China, see Appendix 7  
(Section  10.7). 
8.9 IMMUNOGENICITY ASSESSMENTS   
Not applicable.  
8.10 MEDICAL RESOURCE UTILIZATION AND HEALTH ECONOMICS   
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 78 8.11 USE OF BIOLOGICAL SAMPLES AND DATA FOR FUTURE RESEARCH   
Future research may help further the understan ding of disease and the development of new 
medicines. Reuse of coded data and biological samples (leftover) will be limited to future 
scientific research conducted under a research plan for the purpose of diagnosing, preventing or 
treating diseases. The fu ture research projects will be conducted under the Sponsor’s and/or its 
affiliates’ and/or, if applicable, the partner of the Sponsor which has licensed the study drug to the 
Sponsor or which is co -developi[INVESTIGATOR_21354]’s control, acti ng alone or in 
collaboration with research partners such as universities, research institutions or industrial 
partners with whom the coded data may be shared.  
Data and biological samples will be stored and used for future research only when consented to b y 
participants (see Section  10.1.3 ) and, when applicable, further information on the future research 
has been provide d to the study participant, unless prohibited by [CONTACT_21475]/IECs (in such 
case, consent for future use of data/sample will not be included in the local ICF). The conditions 
for reuse will be adapted locally with the appropriate language in the ICF.   
In any case, a specific consent will be collected for the performance of genetic analyses on 
leftover samples.  
Data protection – Processing of coded clinical data  
The study participant will be provided will all mandatory details of the data processing in Part 2 
of the core ICF.   
The Sponsor adopts safeguards for protecting participant confidentiality and personal data 
(see Section  10.1.4 ). 
Use of leftover samples for future research  
Remaining leftover samples will be used only after the study ends, ie, end of study as defined in 
the study protocol.  
The study participant will be provided with all mandatory details of the use of the human 
biological samples (leftover) in Section 2 of the Core ICF.  
Study participant data will be stored for up to 25 years for regulatory purposes and future 
research. Bio logical samples for future use will be stored for up to 25 years after the end of the 
study. Any samples remaining at the end of retention period will be destroyed. If a participant 
requests destruction of his/her samples before the end of the retention pe riod, the Investigator 
must notify the Sponsor (or its contract organization) in writing. In such case, samples will be 
destroyed and related coded data will be anonymized unless otherwise required by [CONTACT_21476].  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 79 9 STATISTICAL CONSIDERATIONS   
9.1 STATISTICAL HYPOTHESES   
The null hypothesis for the primary efficacy endpoint of time to onset of 6-month CDP is that 
there is no treatment difference between SAR442168  and placebo, and the alternative  hypothesis  
is that there is a between -treatment difference.  
To strongly control the Type 1 error rate for the study, a hierarchical testing procedure will be 
applie d at a 2 -sided 5% significance level, ie, each hypothesis will be formally tested only if the 
preceding one is significant at the 5% level.  If SAR442168  is significant for the primary endpoint, 
a selective set of secondary endpoints will be tested followin g the hierarchical testing procedure. 
The complete list of the secondary endpoints that will be adjusted for multiplicity with their 
testing order will be detailed in the statistical analysis plan prior to database lock or any interim 
analysis, if applicab le. The study will be declared positive if the null hypothesis for the primary 
endpoint of 6 -month CDP for SAR442168  versus placebo is rejected.  
9.2 SAMPLE SIZE DETERMINATION   
Approxi mately 1700 participants  will be screened to achieve up to 1290  randomly assigned to 
study intervention (2:1 randomization ratio of SAR442168  to placebo) . This study is planned as 
an event -driven trial based on [ADDRESS_20304] occurred to provide 80% power to detect a 30% risk reduction in 
6-month CDP with SAR442168  compared to placebo (2 -sided α=0.05). The following 
assumptions were used for the calculations: 2 -year placebo e vent rate of 23.6%; annual 
discontinuation rate of 10%;  constant hazard rates using a log -rank test; estimated enrollment 
period of [ADDRESS_20305] randomized participant followed for 24 months.  
Actual recruitment and disability event rates may vary; t herefore, it is possible  to stop with 
a reduced sample size of around [ADDRESS_20306].  
Note : “Enrolled” means a participant's, or their legally acceptable representative’s, agreement to 
participate in a clinical study following completion of the informed consent process. Potenti al 
participants  who are screened for the purpose of determining eligibility for the study, but do not 
participate in the study, are not considered enrolled, unless otherwise specified by [CONTACT_760].  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 80 9.3 POPULATIONS FOR ANALYSES   
For purposes of analysis, t he following populations are defined  (Table  3): 
Table  3 - Populations for analysis   
Population  Description  
Enrolled  All participants  who sign the ICF  
Randomly Assigned to Study 
Intervention  All participants  with a treatment kit number allocated and recorded in the IRT 
database, regardless of whether the treatment kit was used or not.  
Participants  treated without being randomized will not be considered randomized 
and will not be included in any efficacy popul ation.  
ITT The primary efficacy population will be the ITT population, defined as all randomly 
assigned participants . All efficacy analyses will be conducted according to the 
treatment group allocated by [CONTACT_21477], irrespective of the 
treatment received.  
Safety  All participants  randomly assigned and exposed to study intervention, regardless of 
the amount of exposure, analyzed according to the treatment actually received.  
Randomized participants  for whom it is unclear whether they took the  study 
medication will be included in the safety population as randomized.  
The pharmacodynamic (PD) analyses will be performed on the safety population.  
Pharmacokinetics  All participants  in the safety population with at least one non - missing PK sample 
after first dose of the study intervention. Participants will be analyzed according to 
the treatment actually received.  
ICF: informed consent form; ITT: intent to treat; PK: pharmacokinetic(s) . 
9.[ADDRESS_20307] dose of IMP.  Unless otherwise indicated, al l statistical hypotheses for the primary and 
secondary endpoints and other treatment comparisons will be tested at the 5% significance level 
(α=0.05) against 2 -sided alternatives.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 81 9.4.2  Primary endpoint   
The primary estimand will be the treatment difference between SAR442168  and placebo in time 
to onset of 6 month -CDP regardless of completion of the treatment period. This estima nd 
corresponds to a “treatment policy strategy”. This estimand will be considered primary for 
supporting regulatory decision making.  
The time to onset of 6 -month CDP will be analyzed by a Cox proportional hazards model with 
terms for treatment, age at scr eening (>40, ≤40 years) , geographic region (US, non -US), baseline 
EDSS score , and baseline Gd -enhancing T1 lesions (0, ≥1) . A log -rank test stratified by [CONTACT_21407] (>40, ≤40 years) and geographic region (US, non -US) to compare SAR442168  to 
placebo w ill also be examined. Kaplan -Meier plots of the cumulative incidence rate will be 
provided by [CONTACT_21478][INVESTIGATOR_21355] 6 -month CDP over time. The 
proportion of participants  with events at given time points (eg, Month 24) will be cal culated using 
the KM estimates.  
In this primary ITT analysis:  
• For participants who complete the study without an initial disability progression, the 
participant’s event time will be censored at the date of last EDSS assessment . 
• For participants who have a n initial onset of disability progression but complete the study 
at the common study end date without [ADDRESS_20308] EDSS assessment . 
• For participants who prematurely discontinue the study before [ADDRESS_20309] EDSS assessment . 
• For participants  who meet 3 -month CDP but complete the study at the common study  end 
date without 6 -month confirmation , the event status of the participant will be determined 
by [CONTACT_21408] 3 -month 
confirmation to participant’s end of study also meet the criteria for disability progression . 
Since in this setting , the partial missing data can reasonably be assumed to be missing at 
random, this approach leverages the partial information and follows the ITT principle. 
A logistic model with terms for age at screening (>40, ≤40 years) , geographic region (US, 
non-US), baseline EDSS score , and baseline Gd -enhancing T1 lesions (0, ≥1)  will be used 
to determine the event status as the imputation model within each treatment. A multiple 
imputation approach will be used to summarize the resul ts. Details will be provided  in the 
SAP.  
Only EDSS assessments measured more than 90 days after the onset of an adjudicated relapse will 
be used to determine onset of disability progression. In addition, for the purpose of confirmation, 
only EDSS scores measured more than 90  days after the onset of an adjudicated relapse will be 
used. In case of such MS relapse, the next quarterly EDSS assessment >90 days after relapse onset 
will be used for CDP confirmation. In order to assess robustness of the primary analysis, 
sensitivity  analyses handling miss ing or incomplete data differently will be conducted. This will 
include an  analysis that treats missing or incomplete data as censored data.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20310]. The 
subgroup factors include geographic region (US, non -US; Eastern EU, Western EU, North 
America, Rest of the World ), age strata (ie , age at screening; >40, ≤40 ye ars), sex (male, female), 
baseline Gd-enhancing T1 lesion s (0, ≥1), baseline  EDSS score  ( ≤4.5 versus  >4.5 and  ≤5.5 versus  
>5.5), prior  disease modifying  therapy use ( 0, 1, ≥2 ), duration since RRMS symptom onset 
(≤5, >5 to ≤10, >10 years) and adjudicated relapse during the study. The detailed list of subgroups 
and additional details of  the subgroup analyses will be provided in the SAP.  
9.4.3  Secondary endpoint(s)   
For other time -to-event  endpoints (time to onset of sustained 20% increase in the 9 -HPT , of 
sustained 20% increase in the T25 -FW, of 3-month CDP , and of  CDI), similar analysis as for the 
primary analysis of the primary efficacy endpoint will be performed in the ITT population  but 
without imputation .  
Continuous endpoints (percent change in brain volume loss, change in cognitive function, change 
in physica l function, and change in MSQoL -54 at EOS) will be analyzed using a mixed -effect 
model with repeated measures (MMRM ) approach. The model will include change/percent 
change values for the resp ective endpoint at each scheduled visit as response variables, and 
treatment,  age at screening (>40, ≤40 years) , geographic region (US, non -US), visit, treatment by -
visit interaction, baseline value for the endpoint being assessed and baseline value -by-visit 
interaction as covariates. Difference in LS means, the corresponding 95% CI, and p -value will be 
provided for the comparison of SAR442168  versus placebo. For percent change in brain volume 
loss, log transformation will be applied in the MMRM model. In o rder to assess the impact of 
deviation from the normality assumption, a sensitivity analysis using rank ANCOVA with the 
same covariates as for the MMRM analysis except visit and related interaction terms, will be 
performed for these continuous endpoints to  provide the p -value for the comparison between the 
treatment groups . 
Categorical efficacy endpoints with count data (new and/or enlarging T2 hyperintense over the 
study period after baseline) will be analyzed using a negative binomial regression model. Th e 
model will include the total lesion count across all post -randomization MRI scans  during the study  
period as the response variable, with treatment group, age at screening (>40, ≤40 years) , 
geographic region (US, non-US), baseline EDSS score , and baseline T2 lesions  as covariates. 
Log-transformed observation duration from screening MRI to last available MRI will be the offset 
variable. In order to assess the impact of open -label  therapy, sensitivity analysis excluding the 
data after initiation  of open -label  therapy will be performed for the key secondary endpoints that 
will be pre -specified in the  SAP. Further details including details of missing data handling and 
subgroup analyses for secondary endpoints will also be detailed in the SAP.  
9.4.4  Terti ary/exploratory endpoint(s)   
Methods for analysis of tertiary/exploratory endpoints will be included in the SAP.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 83 9.4.5  Other safety analyses   
All safety analyses will be performed on the safety population.  
Safety summaries will be descriptive, ie, no statistical significance tests will be performed on 
safety data. The summary of safety results will be presented by [CONTACT_1570].  
Safety analyses will be based on the reported AEs and other safety information, such as clinical 
laboratory data, vital signs, and ECG.  
The observation period will be divided into 4 epochs:  
• The screening epoch is defined as the time fr om the signed informed consent date up to the 
first administration of the study intervention.  
• The treatment epoch is defined as the time from the first administration of the study 
intervention to : 
- The earlier of  last administration of the study intervention plus [ADDRESS_20311] administration of SAR442168  open -label treatment for participants  switching 
to open -label therapy . 
• The open -label  epoch, applic able only for participants  switching to SAR442168  open -
label treatment, is defined as the time from first administration of SAR442168  open -label 
treatment to the earlier of last administration of open -label  treatment plus [ADDRESS_20312] 
IMP in the LTS study . 
• If applicable, the post -treatment epoch is defined as the time from the end of treatment 
epoch (or end of open -label  epoch, if applicable) to the participant’s final study contact [CONTACT_568] .  
The safety analysis of AEs will focus on TEAEs, defined as AEs that developed, worsened,  or 
became serious during the treatment period. All AEs reported in this study will be coded using the 
Medical Dictionary for Regulatory Activities (MedDRA ) version in effect at the time of database 
lock.  
Table  [ADDRESS_20313] one incidence of potentially clinically 
significant abnormality at any time during the treatment -emergent period will be summarized by 
[CONTACT_1570].  
AE: adverse event; AESI: adverse event of special interest;  ECG: electrocardiography;  SAE: serious adverse event; TEAE: treatment -
emergent advers e event  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 84 9.4.6  Other analyses   
Pharmacokinetic, pharmacodynamic (PD ), and biomarker exploratory analyses that will be 
included in the study report will be described in the SAP. Biomarker research will not be part of 
statistical analysis in this study and will not be reported in the clinical study report (CSR ). 
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Section  10.10 , Appendix 10: Contingency measures for a regional or national 
emergency that is declared by a governmental agency.  
9.5 INTERIM ANALYSES   
An optional, non -binding interim futility analysis may be performed when approximately 50% of 
the primary endpoint events are observed. The futility interim analysis will be conducted by 
[CONTACT_21479]. Neither the Sponsor’s team nor the 
Investigator’s staff will have access to the treatment information at the individual participant level 
or group level before the study is formally unblinded after study completion or after the DMC 
recommendation /Sponsor agreement  for stoppi[INVESTIGATOR_21356].  
9.6 DATA MONITORING COMMITTEE (DMC)   
For details on the DMC , refer  to Appendix 1 ( Section  10.1.5 ). 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 85 10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS   
10.1 APPENDIX 1: R EGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS   
10.1.1  Regulatory and ethica l considerations   
• This study will be conducted in accordance with the protocol and with the following:  
- Consensus ethical principles derived from international guidelines including the 
Declaration  of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines , 
- Applicable ICH GCP Guidelines , 
- Applicable laws and regulations (eg, data protection law as General Data Protection 
Regulation - GDPR) . 
• The protocol, protocol amendments, ICF, I B, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_21480]/IEC before the study is initiated.  
• Any am endments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants .  
• The Investigator will be responsible for the following:  
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC. Determining whether an incidental finding should be 
returned to a  participant and, if it meets the appropriate criteria, to ensure the finding is 
returned (an  incidental finding is a previously undiagnosed medical condition that is 
discovered unintentionally and is unrelated to the aims of the study for which the tests 
are being performed). The following should be considered when determining the return 
of an  incidental finding:  
- The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so designated by [CONTACT_2299]) is consistent with all 
applicable national, state, or regional laws and regulations in the country where the 
study is being conducted, and , 
- The finding reveals a substantial risk of a serious health condition or has 
reproductive importance, AND has analytical  validity, AND has clinical validity ,  
- The participant in a clinical study has the right to opt out of being notified by [CONTACT_21481]. In the event that the participant has opted 
out of being notified and the finding has consequences for other individuals, eg, the 
finding relates to a communicable disease, Investigators should seek independent 
ethical advice before determining next steps.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20314] in the 
site medical files that she/he does not want to know about such findings.  
- Notifying  the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures , 
- Providing  oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulation ( CFR ), ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations . 
As appl icable, according to Directive 2001/20/EC , the Sponsor will be responsible for obtaining 
approval from the Competent Authorities of the EU Member States and /or Ethics Committees, as 
appropriate, for any amendments to the clinical trial that are deemed as “substantial” (ie , changes 
which are likely to have a significant impact on the safety or physical or mental integrity of the 
clinical trial participants  or on  the scientific value of the trial) prior to their implementation.  
10.1.2  Financial disclosure   
Investigator s and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate r egulatory authorities. Investigator s are 
responsible for providing infor mation on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3  Informed consent process   
• The Investigator or his/her representative wil l explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions regarding 
the study.  
• Participants  must be informed that their participation is voluntary. Participants  or their 
legally authorized r epresentative will be required to sign a statement of informed consent 
that meets the requirements of [ADDRESS_20315] (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent mu st also sign the ICF.  
• Participants  must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s legally 
authorized representative.  
• Participant who is rescreened is required to sign a new ICF.  
• The ICF contains a separate section that addresses the use for research of participants’ data 
and/or samples (remaining mandatory ones ). Future research is to be defined in Core 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 87 Study Informed Consent Form  (CSICF) Part 2 : consent for use of leftover samples and 
associated coded data for future research, and consent for performance of genetic analyses 
on biological samples . Each option is subject to an independent consent and must be 
confirmed by [CONTACT_13158] a checkbox in CSICF Part 3. The Investigator or authorized d esignee 
will explain to each participant the objectives of the exploratory research and why data and 
samples are important for future research. Participants will be told that they are free to 
refuse to participate and may withdraw their consent at any time  and for any reason during 
the storage period.  
For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix 10 (see Section  10.10 ). 
10.1.4  Data protection   
All personal data collected related to participants , Investigators, or any person involved in the 
study  will be handled in compliance with all applicable Privacy & Data Protection laws and 
regulations, including the General Data Protection Regulation ( GDPR ). The study Sponsor is the 
[COMPANY_011] company responsible for ensuring compliance with this matter, when p rocessing data from 
any individual who may be included in the [COMPANY_011] databases, including Investigators, nurses, 
experts, service providers, Ethics Committee members, etc.  
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor takes all appropriate measures to safeguard and prevent access to this 
data by [CONTACT_13159].  
• Data collected must be adequate, relevant , and not excessive in relation to the purposes for 
which they are collected. Each category of data must be properly justified and in line with 
the study objective.  
• Participant race and ethnicity will be collected in this study because these data are required 
by [CONTACT_17513] (eg, on Afro American popu lation for the FDA or on Chinese 
population for the China Food and Drug Administration in China)  (42, 43). Participant 
race and ethnicity will not be collected in the countries where this is prohibited by [CONTACT_21482].  
• Since a participant’s response to treatment may vary by [CONTACT_21483], subgroup analyses by [CONTACT_21484] a specific subgroup.  
• Participants  will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant 
names or any information which would make the participant identifiable will not be 
transferred to the Sponsor.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_9324]. The level of disclosure must also 
be explained to the participant as described in  the informed consent.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 88 • The participant must be informed that his/her medical records may be examined by 
[CONTACT_13162], by [CONTACT_6667]/IEC members, and by [CONTACT_21485].  
• When archiving or processing personal data pertaining to the Investigator and/or to the 
participants , the Sponsor will take all appropriate measures to safeguard and prevent 
access to this data by [CONTACT_13159].  
• Participa nts must be informed that their study -related data will be used for the whole “drug 
development program”, ie, for this trial as well as for the following steps necessary for the 
development of the investigational product, including to support negotiations with payers 
and publication of results.  
Protection of data related to professionals involved in the study  
• Personal data (eg, contact [CONTACT_8972], affiliation(s) details, job title and related professional 
information, role in the study, professional resume, t raining records) are necessary to 
allow [COMPANY_011] to manage involvement in the study and/or the related contractual or pre -
contractual relationship. They may be communicated to any company of the [COMPANY_011] group 
(“[COMPANY_011]”) or to [COMPANY_011] service providers, where n eeded.  
• Personal data can be processed for other studies and projects. At any time, objection to 
processing can be made by [CONTACT_13164] (link available at 
[COMPANY_011].com).  
• In case of refusal to the processing of personal data by  [CONTACT_13165], it will be 
impossible to involve the professionals in any [COMPANY_011] study. In case the professionals have 
already been involved in a [COMPANY_011] study, they will not be able to object to the processing of 
their personal data as long as the y are required to be processed by [CONTACT_5279]. 
The same rule applies in case the professionals are listed on a regulatory agencies 
disqualification list.  
• Personal data can be communicated to the following recipi[INVESTIGATOR_840]:  
- Personnel within [COMPANY_011] or partners or service providers involved in the study .  
- Judicial, administrative,  and regulatory authorities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the 
framework of judicial or administra tive procedures. Contact [CONTACT_21486] . 
• Personal data may be transferred towards entities located outside the Economic European 
Area, in countries where the  legislation does not necessarily offer the same level of data 
protection or in countries not recognized by [CONTACT_21487]. Those transfers are safeguarded by [CONTACT_21488], notably:  
- The standard contractual clauses of the European Commission for transfers towards 
our partners and service providers . 
- [COMPANY_011]’s Binding Corporate Rules for intra -group transfers.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 89 • Professionals have the possibility to lodge a complaint with [COMPANY_011] leading Supervisory 
Authority, the “Commission Nationale de l’Informatique et des Libertés” (CNIL) or with 
any competent local regulatory authority.  
• Personal data of professionals will be retained by [CONTACT_21489] 30 years unless  further 
retention is required by [CONTACT_5279].  
• In order to facilitate the maintenance of Investigators personal data, especially if they 
contribute to studies sponsored by [CONTACT_13170], [COMPANY_011] participates 
in the Shared Investigator Platform (SIP) and in the Trans Celerate Investigator Registry 
(IR) project ( https://transceleratebiopharmainc.com/initiatives/investigator -registry/ ). 
Therefore, personal data will be securely shared by [CONTACT_21490]. This sharing allows Investigators to keep 
their data up  to date once for all across pharmaceutical companies partici pating in the 
project, with the right to object to the transfer of the data to the Trans Celerate project.  
Professionals have the right to request the access to and the rectification of their personal data, as 
well as their erasure (where applicable) by [CONTACT_21491]: [COMPANY_011] 
DPO - 46 Avenue de la Grande Armée - [ZIP_CODE]  Paris - [LOCATION_009] (to contact [CONTACT_21492], visit 
https://www.sanofi.com/en/our -responsibility/sanofi -global -privacy -policy/contact ). 
10.1.5  Committee structure s  
[IP_ADDRESS]  Data Monitoring Committee   
A DMC , operating independently of the Sponsor and clinical Investigators, will be responsible for 
overseeing the safety of participants  throughout the study. This committee is composed of 
externally  based individuals with exp ertise in the disease under study, biostatistics, or clinical 
research. The primary responsibilities of the DMC  are to review and evaluate the safety data and 
to assess futility through an interim analysis during the trial and to make appropriate 
recommend ations to the Sponsor regarding the conduct of the clinical trial.  
Details describing the DMC  processes and procedures are outlined in the DMC  charter. To 
maintain continuous blinding and study integrity, the analysis will be conducted by 
[CONTACT_21493], and measures will be 
taken to ensure the validity of the data.  
[IP_ADDRESS]  Scientific Advisory Committee   
A Scientific Advisory Committee will provide advice to the Sponsor regarding scientific issues 
and operational conduct of the study. This committee will be composed of a Chairperson, selected 
by [CONTACT_1034], field experts, and Sponsor -based scientists with  clinical and methodological 
expertise. The Scientific Advisory Committee will also review any amendments and provide input 
regarding interpretation of study results. The members will remain blinded until completion of the 
study. Among its responsibilities , the Scientific Advisory Committee will receive blinded study 
status reports from the Sponsor and will review the recommendations from the DMC  throughout 
the study.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 90 The responsibilities of the Scientific Advisory Committee are provided in the Scientific A dvisory 
Committee charter.  
[IP_ADDRESS]  Eligibility Adjudication Committee   
Before randomization, an adjudication committee of MS experts will evaluate anonymized data of 
participants  to endor se the diagnosis of NRSPMS  and disability progression during the last 
12 months. Details of the workflow between the adjudication committee and Investigators will be 
provided in the Study Manual . 
Any increase in EDSS score is sufficient to confirm disabili ty progression. If an EDSS score is 
unavailable or disability progression is not confirmed by [CONTACT_21494], disability progression 
can be further explained by a functional systems assessment. In addition, objective neurologic 
findings can also be used t o support disability progression (a validated checklist for trial eligibility 
will be provided to the site).  
[IP_ADDRESS]  Relapse Adjudication Committee   
To ensure objectivity in the assessment of relapses, a Relapse Adjudication Committee will be 
convened to evaluate all relapses reported during the study. This committee will consist of 
independent neurologists with expertise in MS clinical research who be trained on study 
procedures.  Relapses, as adjudicated by [CONTACT_942], need to meet protocol criteria 
(Section  [IP_ADDRESS] ). 
Relapse Adjudication Committee assessments will be performed using blinded data. Details of the 
responsibilities of the Relapse Adjudication Committee and workflow will be described in 
a separate charter.  
[IP_ADDRESS]  Independent Hepatology Assessment Committee   
An expert committee of independent hepatologists will review all cases of potential DILI and will 
provide guidance on case evaluation and risk mitigation. The Hepatology Assessment Committee 
recommendations will be made available to the DMC. Details of the responsibilities of the 
Independent Hepatology Assessment Committee and its workflow will be described in a separate 
charter.  
10.1.6  Dissemination of clinical study data   
[COMPANY_011] shares information about clinical trials and results on publicly accessible websites, based 
on company commitments, international and local l egal and r egulatory requirements, and other 
clinical trial disclosure commitments established by [CONTACT_13174]. These 
websites include clinicaltrials.gov, EU clinicaltrialr egister (eu.ctr ), euclinicaltrials.eu, and 
sanofi.com, as well as some national r egistries.  
In addition, results from cl inical trials in patients  are required to be submitted to peer -reviewed 
journals following internal company review for accuracy, fair balance , and intellectual property. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20316] the privacy of 
participants  in their clinical trials. Details on data sharing criteria and process for requesting 
access can be f ound at this web address: vivli.org .  
Professionals involved in the study or in the drug development program   
[COMPANY_011] undertakes the legal obligation to disclose the full name [CONTACT_21527]/her 
affiliated institute/ hospi[INVESTIGATOR_307]’s name [CONTACT_21528] n on the China Trial Disclosure website as required 
by [CONTACT_21495] (NMPA) in its guidance “Implementation of 
Drug Clinical Trial Information Registration and Disclosure” (“Notification No. 28”), requesting 
name [CONTACT_21529] o f Chinese and foreign investigational sites and Investigators in any eligible 
clinical trial.  
[COMPANY_011] may publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, m ade to healthcare organizations and 
professionals and/or any direct or indirect advantages and/or any related information or document 
if required by [CONTACT_1289], by [CONTACT_13175] a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of  Value from Pharmaceutical Companies to Healthcare Professionals and 
Healthcare Organisations”.  
10.1.7  Data quality assurance   
All participant data relating to the study will be recorded  on printed or eCRF unless transmitted to 
the Sponsor  or designee electronically ( eg, laboratory data). The Investigator  is responsible for 
verifying that data entries are accurate and correct by [CONTACT_21496].  
The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
The Investig ator must permit study -related monitoring, audits, IRB/IEC review, and r egulatory 
agency inspections and provide direct access to source data documents.  
Monitoring details describing strat egy (eg, risk -based initiatives in operations and quality such as 
Risk Management and Mitigation Strat egies and Analytical Risk -Based Monitoring), methods, 
responsibilities , and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote, or on -site monitoring) are provided in separa te study documents.  
The Sponsor  or designee is responsible for the data management of this study including quality 
checking of the data.  
The Sponsor assumes accountability for actions del egated to other individuals ( eg, Contract 
Research Organizations) . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 92 Study monitors will perform ongoing source data verification to confirm that data entered into the 
eCRF by [CONTACT_1191], complete, and verifiable from source documents; 
that the safety and rights of participants  are being protected;  and that the study is being conducted 
in accordance with the currently approved protocol and any other study agreements, ICH GCP, 
and all applicable r egulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_14344] 25 years after the signature [CONTACT_21530] a longer retention period. No records may be destroyed 
during the retention period without the written approval of the Sponsor . No records may be 
transferred to another location or party without written notificati on to the Sponsor .  
10.1.8  Source documents   
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents  are filed at the Investigator ’s site.  
Data entered in the eCRF that are transcribed from source documents must be consistent with the 
source documents or the discrepancies must be explained. The Investigator  may need to request 
previous medical records or  transfer records, depending on the study. Also, current medical 
records must be available.  
Definition of what constitutes source data can be found in the Study Manual .  
10.1.[ADDRESS_20317] been collected and a study -site closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advan ce of the intended termination.  
Reasons for study termination by [CONTACT_1034], as well as reasons for the early closure of a study 
site by [CONTACT_21497] : 
• For study termination:  
- Information on th e product leads to doubt as to the benefit/risk ratio . 
- Discontinuation of further study intervention development . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 93 • For site termination:  
- Failure of the Investigator  to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, th e Sponsor ’s procedures, or GCP guidelines . 
- Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants  by [CONTACT_737] . 
- Total number of participants  included earlier than expected . 
If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The Investigator will promptly inform the participant and should assure 
appropriate participant therapy and/or follow  up. 
10.1.[ADDRESS_20318] editorial and ethical practice, the Sponsor  will generally support publication of 
multicenter studies onl y in their entirety and not as individual site data. In this case, a coordinating 
Investigator  [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_21498].  
10.2 APPENDIX 2: CLINICAL LABORATORY TESTS   
The tests detailed in Table  5 will be performed by [CONTACT_21499] .  
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either stu dy intervention administration and/or response evaluation. 
Additionally, if the local laboratory results are used to make either a study intervention decision or 
response evaluation, the result s must be entered into the eCRF.  
Protocol -specific requirements  for inclusion or exclusion of participants  are detailed in Section  5. 
Additional tests may be performed at any time d uring the study as determined necessary by [CONTACT_21500] r egulations.  Additional serum or urine pregnancy tests may be 
performed, as determined necessary by [CONTACT_21409], to 
establish the absence of pregnancy at any time during the participant’s participation in the study.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 94 Table  5 - Protocol -required laboratory assessments   
Laboratory assessments  Parameters  
Hematology   
 Platelet count  
 RBC count  
 Hemoglobin  
 Hematocrit  
 RBC indices : 
 MCV  
 MCH  
 %Reticulocytes  
 WBC count with differential : 
 Neutrophils  
 Lymphocytes  
 Monocytes  
 Eosinophils  
 Basophils  
Clinical chemistrya  
 BUN  
 Creatinine  
 Glucose  
 Potassium  
 Sodium  
 Calcium  
 Chloride  
 AST/SGOT  
 ALT/SGPT  
 Alkaline phosphatase  
 Total and direct bilirubin  
 Creatine phosphokinase  
 Albumin  
 Bicarbonate  
 Total protein  
 Lipase  
Routine urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte 
esterase  by [CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal  and for signs of infection ) 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 95 Laboratory assessments  Parameters  
Other screening tests  • Follicle -stimulating hormone ( if needed in female participants  to confirm 
postmenopausal stat us) 
• Highly sensitive serum or urine hCG pr egnancy test (as needed for women of 
childbearing potential)b 
• Serology test for hepatitis B (HBs Ag, anti -HBc IGM and total, anti - HBs) and C  
(anti HCV); in case these results are inconclusive (eg , anti-HBs negative and anti -
HBc positive or anti -HC IgG p ositive), HBV -DNA and/or HCV -RNA should be done, 
respectively, for confirmation . HIV and other infectious disease, if locally required  
• Coagulation: PT/international normalized ratio (INR), aPTT  
• Tuberculosis test: Blood testing (eg, QuantiFERON® TB Gold tes t) is preferred; skin 
testing (eg, tuberculin skin test) with ancillary testing  will be allowed if blood testing 
is not available  and T -SPOT can also be performed , if availablec  
• Iron panel (serum): iron, ferritin, transferrin saturation, TIBC.  
The results of each test must be entered into the eCRF.  
ALT: alanine aminotransferase; anti-HBc: antibody to hepatitis B cor e antigen; anti -HBs: hepatitis B surface antibody; AST:  aspartate 
aminotransferase; aPTT: activated partial thromboplastin time; BUN: blood urea nitrogen; eCRF: electronic case report form; hCG: human 
chorionic gonadotropin; HIV: human immunodeficiency vir us; IEC: independent ethics committee; INR: international normalized ratio; 
HBsAg : hepatitis B surface antigen; HBV : hepatitis B virus; HCV : hepatitis C virus; HIV : human immunodeficiency virus; Ig : immunoglobulin; 
IRB: institutional review board; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; PT: prothrombin time; RBC: red bl ood 
cell; SAE: serious adverse event; SGOT: serum glutamic -oxaloacetic transaminase; SGPT: serum glutamic -pyruvic transaminase; TB:  
tuberculosis;  TIBC: total iron -binding capacity; ULN: upper limit of normal; WBC: white blood cell . 
a Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments observations of ALT >3 × ULN are given in 
Appendix 6 ( Section  10.6). Clinical laboratory findings of ALT >3 × ULN and bilirubin ≥2 × ULN (>35% direct bilirubin) or ALT >3 × ULN and 
INR >1.5, if INR measured that may suggest severe liver injury and must be reported as an SAE .  
b Local urine testing will be standard for the protocol (except for the Screening Visit when serum pregnancy test is required) unless serum 
testing is required by [CONTACT_18039]/IEC . 
c Further details are given in E 01. 
Investigator s must document their review of each laboratory safety report.   
Laboratory/analyte results  that could unblind the study will not be reported to investigative sites 
or other blinded personnel until the study has been unblinded . This includes PK assessments and 
any post -baseline biomarker or PD assessments.  
10.3 APPENDIX 3: ADVERSE EVENTS: DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW -UP, AND REPORTING   
10.3.1  Definition of AE  
AE definition  
• An AE is any untoward medical occurrence in a patient  or clinical study participant, 
temporally associated with the use of study intervention , whether or not considered related 
to the study intervention . 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 96 Events meeting  the AE definition  
• Any abnormal laboratory test re sults (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment o f the Investigator ( ie, not related to progression of underlying 
disease), eg:  
- Symptomatic and/or  
- Requiring either corrective treatment or consultation, and/or  
- Leading to IMP discontinuation or modification of dosing, and/or  
- Fulfilling a seriousness criterion, and/or  
- Defined as an AESI . 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention  administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervention  or a concomitant medication.  
• “Lack of efficacy ” or “failure of expected pharmacological action ” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or cli nical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfil the definition of an AE or SAE.  
Events NOT meeting the AE definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments w hich are associated with the underlying disease, unless judged by [CONTACT_21501]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being  studied, unless more severe than expected for the participant’s 
condition.  
• Medical or surgical procedure ( eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur ( social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 97 10.3.2  Definition  of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
progression of disease).  
An SAE  is defined as any untoward medical occurrence that, at any dose:  
A) Results in death  
B) Is life -threatening  
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
C) Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment  that would not have been appropriate in the physi cian’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If 
a complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or  was necessary, the AE 
should be considered serious.  
Hospi[INVESTIGATOR_21358] a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
D) Results in persistent disability/incapacity  
- The term disability means a subst antial disruption of a person’s ability to conduct 
normal life functions.  
- This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( eg, sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
E) Is a congenital anomaly/birth defect  
F) Other situations:  
- Medical or scientific judgment should be exercised in deciding wh ether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_21359]. These events should usually be 
considered serious.  
- Examples of such events include invasive or malignant cancers, intensive treatment  in 
an emergency room or at home for allergic bronchospa sm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 98 10.3.3  Recording and follow  up of AE and/or SAE   
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all  
documentation ( eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator  will then record all relevant AE/SAE i nformation in the eCRF.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor representative in lieu of completion of the SAE eCRF page.  
• There may be instances when copi[INVESTIGATOR_21360] c ertain cases are requested by 
[CONTACT_1034]’s representative . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_12997]’s representative . 
• The Investigator  will attempt to establish a diagnosis of th e event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of severity  
The Investigator will assess the severity for each AE and SAE using the National Cancer Institute  
Common Terminology Criteria for Adverse Events (NCI CTCAE ) Version 5.0, published on 
[ADDRESS_20319] in NCI CTCAE to look 
for severity grade description for a particular AE. For AEs not listed in the NCI CTCAE, the 
Investigator will be required to assess the severity of the AE using general guideline:  
1. Grade  1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
2. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental Activity of Daily Living ( ADL )*. 
3. Grade 3 Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care 
ADL**.  
4. Grade 4 Life-threatening consequences; urgent intervention indicated.  
5. Grade 5 Death related to AE.  
Note: ADL  
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc.  
**Self -care ADL refer to bathing , dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20320] be reported as a n SAE. Any other AE event can be  defined 
as “serious ” if it meets at least 1 of the predefined outcomes as described in the definition of 
an SAE  in Section  10.3.2 . 
Assessment of causality  
• The Investigator  is obligated to assess the relationship between study intervention  and 
each occurrence of each AE/SAE.  
• A “reasonable possibility ” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a re lationship cannot be ruled out.  
• The Investigator  will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention  
administration will be considered and investigated.  
• The Investigator  will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.  
• For each AE/SAE, the Investigator  must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator  has minimal 
information to include in the initial report to  the Sponso r’s representative . However, it is 
very important that the Investigator  always make an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor’s 
representative . 
• The Investigator  may change his/her opi[INVESTIGATOR_1101] c ausality in light of follow -up information 
and send a n SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining r egulatory reporting 
requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_1034]’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, th e Investigator  will provide the Sponsor’s representative with a copy of any post -
mortem find ings including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The Investigator  will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 100 10.3.4  Reporting  of SAEs  
SAE reporting to the Sponsor’s representative via an electronic data collection tool  
• The primary mechanism for reporting an SAE to the Sponsor’s representative will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see Section  10.3.4 ) in order to report the event within 24 hours . 
• The site will enter the SAE data into the electronic system as soon as it becomes avail able.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updat ed data 
on a previously reported SAE after the electronic data collection tool has been taken  
off-line, then the site can report this information on a paper SAE form (see Section  10.3.4 ) 
or to the  Sponsor’s representative by [CONTACT_756].  
• Contacts for SAE reporting can be found in  the Study Manual . 
10.4 APPENDIX 4: CONTRACEPTIVE GUIDANCE AND COLLECTION OF PR EGNANCY 
INFORMATION   
DEFINITIONS : 
Woman of childbearing potential  (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (se e below).   
If fertility is unclear ( eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation shoul d be considered.  
Women in the following cat egories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with 1 of the following:  
- Documented hysterectomy , 
- Documented bilateral salpi[INVESTIGATOR_1656] , 
- Documented bilateral oophorectomy , 
For individuals with permanent infertility due to an alternate medical cause other than 
the above,  (eg, Mullerian agenesis, androgen insensitivity), Investigator discretion 
should be applied to determining study entry.  
Note: Documentation can come from the sit e personnel’s: review of the participant’s 
medical records, medical examination, or medical history interview.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 101 3. Postmenopausal female  
- A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
- A high follicle stimulat ing hormone (FSH ) level ( eg, >30 IU/L  or as per  the 
laboratory reference range ) in the postmenopausal range may be used to confirm 
a postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy (HRT ). However, in the absence of 12  months of amenorrhea, 
confirmation with more than one FSH measurement  is required ; 
- Females on HRT and whose men opausal status is in doubt will be required to use 
one of the non -estrogen hormonal acceptable  contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to 
allow confirmation of postmenopausal status be fore study enrollment.  
CONTRACEPTION GUIDANCE : 
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationb 
- Intrauterine device (IUD)  
- Intrauterine hormone -releasing system (IUS) c 
• Bilateral tubal occlusion  
Vasectomized partner  
(Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90  days.)  
Highly Effective Methodsb That Are User Dependent  
Failure rate of <1% per year when used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of ovulationc 
- oral 
- intravaginal  
- transdermal  
- injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
- oral 
- injectable  
Sexual abstinence  
(Sexual abstinence is considered  a highly effective method only if defined as refraining from heterosexual intercourse during 
the entire period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the participant.)  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 102 ACCEPTABLE METHODSd 
1. Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary mode of action  
2. Male or female condom with or without spermicidee 
3. Cervical cap, diaphragm, or sponge with spermicide  
4. A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double -barrier 
methods)c 
a Contraceptive use by [CONTACT_13188].  
b Failure rate of <1% per year when used consistently and correctly.  Typi[INVESTIGATOR_21361].  
c If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods  are limited to 
those which inhibit ovulation as the primary mode of action.  
d Considered effective, but not highly effective - failure rate of ≥1% per year. Periodic abstinence (calendar, symptothermal, post -ovulation 
methods), withdrawal (coitus interruptus) , spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of 
contraception.  
e Male condom s and female condom s should not be used together (due to risk of failure with friction).  
COLLECTION OF PR EGNANCY INFORMATION :  
Male participants  with partners who become pr egnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning  of the partner’s pregnancy.  
• The female partner will also be fol lowed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor.  
• Generally, the follow  up will be no longer than 6 to 8 weeks following the estimated 
delivery date. Any termination of the  pregnancy will be reported regardless of fetal status 
(presence or absence of anomalies) or indication for the procedure.  
Female participants  who become pr egnant  
• The Investigator will collect pregnancy information on any female participant who 
becomes p regnant while participating in this study. Information can be collected either 
during site visits or by [CONTACT_648] (in case a pregnancy test has been performed at home by [CONTACT_2416]) and it will be recorded on the appropriate form and submitted to the Sponsor 
within 24 hours of learning of a participant’s pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the participant and the neonate , and the 
information will be forwarded to the Sponsor. Generally, follow  up will not be required for 
longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or 
indicati on for the procedure.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 103 • Any pregnancy complication or elective termination of a pregnancy for medical reasons 
will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at 
>22 weeks gestationa l age) is always considered to be an SAE and will be reported as 
such.  
• Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by [CONTACT_21502]  8.3.4 . While the Investigator is not obligated to actively seek this information in 
former study participants , he or she may lear n of an SAE through spontaneous reporting.  
• The participant will be invited to remain in the study in any case. Pregnancy outcome and 
data of the newborn will be reported to the Sponsor as per usual pharmacovigilance 
reporting practice.  
10.5 APPENDIX 5: GENETIC S  
Use/Analysis of DNA  
• Genetic variation may impact a participant’s response to study intervention , susceptibility 
to, and severity and progression of disease. Variable response to study intervention may be 
due to genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology ; and/or molecular subtype of 
the disease being treated. Therefore, where local r egulations and IRB/IEC allow, a blood 
sample will be collected for DNA analysis from consenting participants . 
• DNA samples will be used for research related to SAR442168  or NRS PMS  and related 
diseases. They may also be used to develop tests/assays including diagnostic tests related 
to SAR442168  and NRSPMS . Genetic research may consist of the analysis of one or more 
candidate genes or the analysis of genetic markers throughout th e genome.  
• DNA samples will be analyzed for human leukocyte antigen genotypi[INVESTIGATOR_007]. Specific analysis 
of these samples will be determined at a later date once the blinded clinical data becomes 
available. These analyses may be conducted if it is hypothesized tha t this may help further 
understand the clinical data.   
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to SAR442168  or study intervention s of this class to understand 
study disease or related cond itions.  
• The results of genetic analyses may be reported in the CSR or in a separate study 
summary.  
• The Sponsor  will store the DNA samples for [ADDRESS_20321] confidentiality.  
• The samples will be retained  while research on SAR442168  for NRSPMS  or other period 
as per local requirements.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 104 10.6 APPENDIX 6: LIVER AND OTHER SAFETY:  ACTIONS AND FOLLOW -UP 
ASSESSMENTS   
These actions are required for ALT increase and thrombocytopenia  events  ONLY. For all other 
safety events described , these are suggested  per the Investigator’s medical judgement .  
 
Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Appendix 3 ( Section  10.3) is met.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 105  
Abbreviations: aPTT: activated partial thromboplastin time; EDTA: Ethylenediaminetetraacetic acid; INR: international normalized rati o; 
PK: pharmacokinetic; PT: prothrombin time  
Thrombocytopenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting AEs in Appendix 3 ( Section  10.3) is met.   
Platelets <75 000/mm3(rule out EDTA -induced 
pseudo -thrombocytopenia with sample using citrate
Repeat immediately locally the count (rule out EDTA 
anticoagulant in the sample using citrate)
Platelets <75 000/mm3
confirmed with bleedingPlatelets <75 000/mm3
confirmed with no bleeding
1.DISCONTINUE
Investigational Medicinal 
Product
2.HOSPI[INVESTIGATOR_21362] <50 000/mm31.DISCONTINUE
Investigational Medicinal 
Product
2.INVESTIGATE for 
bleeding
3.INFORM the local monitor
4.QUESTION about alcohol habits, any drug intake including (quinine), heparin 
administration, aspi[INVESTIGATOR_248], immunotherapy, etc.
5.PERFORM or collect the following investigations:
•Complete blood count, schizocytes , creatinine
•Locally: 
•Bleeding time and coagulation tests (INR, PT, aPTT , D-Dimers) 
•Infectious serologies to be performed according to clinical symptoms / medical history
6.COLLECT/STORE one sample following handling procedures described in PK sections 
(for studies with PK sampling)
7.DECISION for bone marrow aspi[INVESTIGATOR_21363]
8.MONITOR the platelet count every day for at least one week and then regularly until it 
returns to normalIn both situationsTHROMBOCYTOPENIA
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20322] MONITORING ADDITIONAL GUIDANCE:  
To allow timely review for these data, please enter the date of collection for the central lab and the 
date of collection and the results for the local lab in the eCRF within 24 hours of their 
availability.   
1. If 1 LFT monitoring timepoint is missed, the study site should:  
- Reach out to the study participant as soon as possible to schedule an alternative 
timepoint as soon as possible and prior to the next scheduled timepoint.  
- Retrain the study participant on the LFT monitoring rationale and requirements and 
inform the study participan t that IMP will need to be interrupted if LFTs cannot be 
monitored as required.  
2. If 2 consecutive LFTs timepoints are missed, the site should:  
- Call the participant immediately to reschedule the next LFTs timepoint as soon as 
possible and discuss with them  about the underlying reasons of missing the timepoints.  
- Instruct participant to hold IMP immediately if they decline to reschedule the 
timepoint or miss the rescheduled timepoint.   
- Inform the participant that IMP can resume only after LFTs monitoring co mpliance is 
achieved.  
- Inform the monitoring team of any underlying reason identified for participant non -
compliance and work with the monitoring team to resolve underlying issues to ensure 
compliance . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Proper ty of the [COMPANY_011] group - strictly confidential  Page 107  
 
*If unable to retest in 72 hours, use original laboratory results to decide on further reporting/monitoring/discontinuation.  
Note: “Baseline” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the baseline visit. The algorithm does not apply to the instance s of increase in ALT during 
screening. See  Section  8.3 for guidance on safety reporting. Normalization is defined as ≤  ULN or baseline value if baseline value is > ULN.  
ALT >3 X ULNIncrease in ALT Algorithm
Confirm ALT >[ADDRESS_20323] within 72 hours of initial sample*
Yes No
•COMPLETE the specific CRF forms for ALT increase and inform 
the monitoring team within 24 hours
•Consider alternative etiologies
•Complete mandatory testing if ALT >[ADDRESS_20324]
•ALT >[ADDRESS_20325], OR
•ALT >[ADDRESS_20326] for >2 weeks, OR
•ALT >[ADDRESS_20327] 
AND 
Total Bilirubin >[ADDRESS_20328] OR INR >1.5, OR
•ALT >[ADDRESS_20329] with appearance of 
fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, 
rash, and/or eosinophilia (>5%)Continue IMP 
administration
No •If clinically appropriate, IMP administration  
can be continued, as long as conditions for 
discontinuation per protocol are not met. 
•ALT, AST, and bilirubin must be monitored 
2-3 times weekly. ReassessInterrupt IMP administration and 
monitor every 2 -3 days until ALT 
down trending, then monitor 
weekly until ALT <1.5 X ULNYes
If abnormalities stabilize or IMP is 
discontinued and the participant is 
asymptomatic, the monitoring 
frequency can decrease to weekly or 
bi-weekly until ALT <1.[ADDRESS_20330]
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 108  
 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CMV, cytomegalovirus; CPK, creatine phosphokinase; CRF, case report form; 
EBV, Epstein -Barr virus; GGT, gamma glutamyl transferase; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatiti s C virus; HEV, hepatitis 
E virus; IgG, immunoglobulin G; IgM, immunoglobulin M;  IMP, investigational medicinal product; INR, international normalized ratio; LFT, liver 
function test; LKM, liver -kidney microsomal antibody; PT, prothrombin time; ULN, upper limit of normal.  
 
 In ANY CONFIRMED CASE of ALT >[ADDRESS_20331] or ALT >[ADDRESS_20332] with bilirubin >[ADDRESS_20333] , the following steps are 
REQUIRED (recommended for ALT >[ADDRESS_20334] but ALT <[ADDRESS_20335], as clinically indicated):   
• INFORM the Site Monitor, who will forward the information to the Study Manager.  
• INVESTIGATE specifically for malaise with or without loss of consciousness, dizziness, and/or hypotension and/or 
epi[INVESTIGATOR_21364], particularly in the previous 72 hours; rule out muscular injury.  
• PERFORM  the following tests /actions:  
-  LFTs: AST, ALT, alkaline phosphatase, GGT, total and conjugated bilirubin, and prothrombin time/INR (mandatory 
assessments for ALT >[ADDRESS_20336]);  
-  CPK, serum creatinine, complete blood count;  
- Anti-HAV IgM, anti -HBc IgM, (HBV -DNA if clinically indicated),  hepatitis B surface antigen (HBsAg),  anti-HCV and 
HCV RNA, anti -CMV IgM and anti -HEV IgM antibodies;  
-  Iron, ferritin , transferrin saturation;  
-  Auto-antibodies: serum IgG levels, antinuclear, anti -DNA, anti -smooth muscle, anti -LKM, anti -mitochondrial;  
-  Evaluate recent infection with EBV, herpes viruses. Depending on the clinical context, consider testing for 
toxoplasma;  
-  Collect and freeze serum sample (5  mL x 2);  
-  Collect and store one PK sample following the instructions in the central laboratory manual;  
-  Perform  hepatobiliary imaging ( ultrasonography or other imaging investigations is required ); 
-  Consider  DNA test for  Gilbert’s disease if clinically indicated;  
-  Recommend consulting a hepatologist (mandatory if ALT >[ADDRESS_20337] or is asso ciated with elevated bilirubin);  
o Discuss with the hepatologist  the clinical indication for potential liver biopsy (strongly recommended if the 
participant meets Hy’s law criteria or has ALT >[ADDRESS_20338]) and/or initiation of treatment with steroids ; 
-  Consider patient hospi[INVESTIGATOR_21365] >2 (or PT <50%) and/or central  nervous system disturbances suggesting 
hepatic encephalopathy.  
• MONITOR LFTs after discontinuation of IMP:  
-  Monitor closely (every 2 -3 days) until ALT is down -trending, then weekly until  <1.[ADDRESS_20339], and then at every 
scheduled visit;  
-  This frequent LFT monitoring may be done through central or local lab, o r via home visit (depending on the 
Investigator’s  assess ment and/or local regulatory requirements).  
• RECHALLENGE: Re-initiation of the study drug can only be considered after discussion with the Sponsor’s Medical 
Monitor once the ALT/AST decreases to <1.[ADDRESS_20340], and there is no clinical contraindication. Rechallenge is not 
permitted for the following participants unless a clear non -DILI etiology is identified:  
▪ ALT >[ADDRESS_20341]  
▪ ALT >[ADDRESS_20342] for greater than two weeks  
▪ ALT >[ADDRESS_20343] and total bilirubin >[ADDRESS_20344]  
-  In case it is agreed to re -start the study drug, it is recommended that ALT/AST be assessed per protocol schedule of 
assessments for the first 6 months of the treatment period.   
-  The occurrence of new elevation to >[ADDRESS_20345] for the ALT/AST values will lead to permanent discontinuation of the 
study drug.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 109  
ARF, acute renal failure; CPK, creatine phosphokinase; DIC, disseminated intravascular coagulation; ECG, electrocardiogram; 
PK, pharmacokinetic(s); ULN, upper limit of normal  
Increase in serum creatinine is to be recorded as an A E only if at least 1 of the criteria listed in the 
general guidelines for reporting AEs in Appendix 3 ( Section  10.3) is met.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 110  
CK-MB, creatine kinase -MB; CK -MM, creatine kinase -MM; ECG, electrocardiogram; PK, pharmacokinetic(s); ULN, upper limit of normal  
Increase in CPK is to be recorded as an AE only if at least 1 of the criteria in the general 
guidelines for reporting AEs in Appendix 3 ( Section  10.3) is met.  
  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 111 SUSPECTED PML  
If either the clinical presentation or MRI features of a participant are suggestive of PML, the 
following diagnostic and action algorithm is recommended.  
 
Abbreviatio ns: CSF, cerebrospi[INVESTIGATOR_872]; Gd, Gadolinium; IMP, investigational medicinal drug; JCV, John Cunningham virus; MRI, magnetic 
resonance imaging; PCR, polymerase chain reaction; PML, progressive multifocal leukoencephalopathy  
Clinical manifestations or MRI l esions features suspi[INVESTIGATOR_21366]  6 
(based on [44] and [45]). 
Table  6 - Clinical and MRI features suggestive of PML   
Clinical history   Subacute onset of weakness, sensory deficits , cognitive or behavioral abnormalities , gait dysfunction, 
speech/language difficulties or any other signs of cortical dysfunction, retrochiasmal visual defects or seizure . 
Brain MRI   ≥1 T2/FLAIR hyperintense and T1 hypointense lesions involving the subcortical and juxtacortical white matter, 
sparing the cortex, with no mass effect, with a continuous progression; new lesions with no enhancement (even 
when large) or with faint rim enhancement . 
In the event that PML is suspected based on imaging  results , the local radiologist will directly 
inform the Investigator and a central review of the MRI will not be required. The Investigator will 
obtain additional plasma, urine, and CSF samples for John C unningham virus (JCV) analysis. 
Samples will be analyzed upon receipt and the results will be provided directly to the 
investigational site and to the Sponsor. Further management will be deferred to the Treating 
Investigator. However , next steps will inclu de discontinuation of study treatment. Additional 
imaging will be at the discretion of the Investigator depending on  the diagnostic workup and 
treatment plan.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 112 • The detection of JCV DNA in the CSF of a participant  with clinical and MRI features 
suggestive of PML establishes the diagnosis of PML.  
• If JCV DNA is not detected in CSF and if clinical suspi[INVESTIGATOR_21367], another 
lumbar puncture should be performed.  
• If diagnosis remains uncertain and sus pi[INVESTIGATOR_21367], a brain biopsy may be 
considered to establish a definitive diagnosis.  
Clinical or MRI features suggestive of PML should be recorded as an AE/AESI/SAE following 
the definitions and procedures in Appendix 3 ( Section  10.3).  
10.7 APPENDIX 7: MEDICAL DEVICE ADVERSE EVENTS (AE S), ADVERSE DEVICE 
EFFECTS (ADE S), SERIOUS ADVERSE EVENTS (SAE S) AND DEVICE 
DEFICIENCIES : DEFINITION AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW -UP, AND REPORTING   
Not applicable.  
10.8  APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENTS   
10.8.1  Contraception requirements in [LOCATION_006], [LOCATION_013] , and Denmark   
For inclusion criterion I  09, the following apply:  
• For [LOCATION_006] and [LOCATION_013] Only: Acceptable forms of effective contraception include the 
following:  
- Established use of oral, injectable, or implantable progestogen -only hormonal 
contraception associated with inhibition of ovulation;  
- Placement of an intrauterine de vice (IUD ) or intrauterine hormone -releasing system 
(IUS ); 
- Bilateral tubal occlusion;  
- Male sterilization (provided that the partner is the sole sexual partner of the WOCBP 
study participant and that the sterilized partner has received medical assessment of the 
surgical success);  
- True abstinence: When this is in line with the preferred and usual lifestyle of the 
participant (Per iodic abstinence [eg, calendar, ovulation, symptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).  
• For Denmark Only: Acceptable methods of effective contraception include the following:  
- IUD;  
- Hormonal contraceptiv es (contraceptive pi[INVESTIGATOR_3353], implants, transdermal patches, hormonal 
vaginal devices, or injections with prolonged release).  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 113 10.8.2  Country -specific differences for China   
There will be no b iological sample exportation from China in this study, and the sites in China 
will not participate  in the following testing:  
• Pharmacodynamic: Assessment of NfL levels in plasma.  
• Genetics: A 6 mL blood sample will be collected for DNA isolation, then be sto red. 
Analysis may be performed on genetic variants thought to play a role in MS including, but 
not limited to, specific candidate genes/genome analyses to evaluate their association with 
observed clinical responses to SAR442168 . 
• Biomarkers: Samples may be stored for a maximum of 2 years (or according to local 
regulations) following the last participant’s last visit for the study at a facility selected by 
[CONTACT_21503]442168 . 
10.8.3  Country -specific provisions for [LOCATION_009]  and Japan   
Temporary IMP interruption will occur for all ALT >[ADDRESS_20346]. The remaining components of the ALT algorithm (Appendix 6, 
Section  10.6) apply for participants in [LOCATION_009]  and Japan . 
For participants starting IMP/ open -label  tolebrutinib , liver testing will occur at Weeks 1 and 3 in 
addition to the frequent liver monitoring outlined in the Schedule of Activities ( Section  1.3). 
It is strongly recommended to avoid initiating an d continuing use of hepatotoxic drugs and 
hepatotoxic herbs/supplements while receiving IMP, due to the risk of hepatotoxicity associated 
with the administration of tolebrutinib.  
Large, publicly available resources such as the DILIrank reference drug list (46, 47) can be 
a useful guide in identifying hepatotoxic medications. Examples of hepatotoxic 
herbals/supplements determined by [CONTACT_21504] ( Table  7, 48). Please note that the lists provided 
are not exhaustive and that the product information of drugs intended for concomitant use should 
be consulted.  
Table  7 - Examples of herbal and dietary supplements involved in hepatotoxicity   
Herbal and dietary supplements  Type of liver injury  
Herbal preparations  
Pyrrolizidine alkaloids, eg, Crotalaria,senecio, heliotrpi[INVESTIGATOR_1890], Symphytum 
officinale (comfrey)  Acute and chronic SOS  
Teucrium chamaedrys  (germander)  AHH, ACH, ALF, chronic hepatitis, cirrhosis, 
cholangitis  
Teucrium polium  AHH, ACH, ALF  
Atractylis gummifera  L. AHH, ACH,  ALF 
Callilepis laureola  L. AHH, ALF  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 114 Herbal and dietary supplements  Type of liver injury  
Mentha pulegium  AHH, ACH, ALF  
Hedeoma pulegioides  AHH, ACH, ALF  
Chelidonium majus  (greater celandine)  AHH, ACH, chronic hepatitis, cholangitis  
Pi[INVESTIGATOR_21368]  (kava -kava)  AHH, ACH, ALF, chronic hepatitis  
Camellia sinensis  (green tea extracts)  AHH, ACH, ALF  
Actaea racemosa  (black cohosh)  AHH, ACH  
Cimicifuga racemosa  AHH, ACH  
Morinda citrifolia  (Noni juice)  AHH, ACH, ALF  
Serenoa  ACH  
Azadirachta indica  Microvesicular steatosis  
Catha edulis  (khat)  AHH, ACH, ALF  
Borago officinalis  (borage)  AHH, ACH  
Cassia angustifolia  (senna)  AHH, ACH  
Larrea tridentata  (chaparral)  AHH, ACH, cholangitis, chronic hepatitis/cirrhosis  
Asian herbal medicine (Chinese, Japanese, ayurvedic medicines)  
Lycopodium serratum  (Jin Bu Huan)  AHH, ACH, ALF  
Ephedra  (Ma Huang)  AHH with autoimmunity  
Sho-Saiko -To (Xiao -Chai-Hu-Tang; complex preparation)  AHH/chronic hepatitis  
Dai-Saiko -To (complex preparation)  AHH with autoimmunity  
Chaso and Onshido  AHH, ACH, ALF  
Boh-Gol-Zhee/Bu Ku Zi  ACH  
Polygonum multiflorum  (Shou -Wu-Pi[CONTACT_1629])  AHH, ACH  
Ganoderma lucidum  (Linghzi)  AHH  
Brena officinalis  (Chi R Yun)  AHH  
Dysosma pleiantha  (Boh -Gol-Zhee)  AHH  
Dietary supplements  
Usnic acid with other ingredients:  
    LipoKinetix® AHH, ALF  
    UCP -1® AHH, ALF  
    Oxy ELITE® AHH, ALF  
Hydroxycut® AHH, ACH, ALF, AHH with autoimmunity  
Linoleic acid  AHH  
Plethoryl® (vitamin A, thyroid hormones)  AHH, ACH, chronic hepatitis, cirrhosis  
Illicit anabolic androgenic steroids  AHH, ACH, liver adenoma, HCC, SOS  
ACH, acute cholestatic hepatitis; AHH, acute hepatocellular hepatitis; ALF, acute liver failure; HCC, hepatocellular carcinom a; SOS, 
sinusoidal obstruction syndrome.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 115 10.8.4  Country -specific provisions for Japan   
Temporary IMP interruption will occur if ALT >3 × ULN and INR >1.3 or bilirubin >2  × ULN. 
Monitoring should then occur every 2  to 3 days until ALT and INR/bilirubin start downtrending , 
then monitoring can be decreased to weekly until ALT < 1.5 × ULN.  
The remaining components of the ALT algorithm ( Appendix 6, Section  10.6) and Appendix 8, 
Section  10.8.[ADDRESS_20347] monitori ng at Weeks 2, 3, 
4, 5, 6, 7, 8, 9, 10, 11, and 12  (M3) , and then monthly for the next 9 months  until M12 . After that, 
the schedule visit timepoints per SoA (Section  1.3) will be resumed (ie, every 3 months), until the 
study end. Whenever a timepoint will coincide with a scheduled visit as per SoA, the full 
scheduled visit assessments will be performed instead of the l iver monitoring testing alone.  
10.8.[ADDRESS_20348] of the trial (see  Appendix 9, Section  10.9). 
Participants must refrain from consumption of grapefruit or grapefruit juice  (due to inhibition of 
CYP3A4) from 5 days prior to intervention administration and throughout the treatment phase.  
If medications that are mild, moderate, or potent inhibitors of CYP3A or CYP2C8 are clinically 
indicated, alternative options for non -CYP3A or non -CYP2C8 inhibitors should be considered, as 
medically appropriate. For participants not eligible for alternative options, IMP should be 
temporarily discontinued for the durat ion of treatment on these medications.  
10.9 APPENDIX  9: EXAMPLE OF DRUGS WITH A POTENTIAL TO CHANGE SAR442168  
METABOLISM OR ABSORPTION   
The following drugs should not be taken during t he study concomitantly with IMP due to their 
potential to change SAR442168  kinetics due to interaction with P450 -mediated metabolism, being 
potent and moderate inducers of CYP3A  or potent inhibitors of  CYP2C8 liver enzymes  (Table  8). 
Additionally, participants in the US, Israel , and any other  sites following  FDA partial clinical hold 
conditions must not take medications that are mild, moderate,  or potent inhibitors of C YP3A or 
CYP2C8 ( Table  9).  
Please note that the lists provided in Table  [ADDRESS_20349] 
information of drugs intended for concomitant use should be  consulted.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 116 Table  8 - Potent and moderate CYP3A inducers and potent CYP2C8 inhibitors   
Potent CYP3A Inducers:  
Rifampin  Carbamazepi[INVESTIGATOR_21369]'s Wort extract  Phenobarbital  
Avasimibe  Lumacaftor  
Rifapentine   
Phenytoin   
Potent CYP2C8 Inhibitors:  
Gemfibrozil  Clopi[INVESTIGATOR_21370]3A Inducers:  
Semagacestat  Asunaprevir/beclabuvir/daclatasvir  
Cenobamate  Nafcillin  
Lesinurad  Telotristat ethyl  
Bosentan  Elagolix  
Thioridazine  Rifabutin  
Table  [ADDRESS_20350]. John's Wort  Elagolix  
Cenobamate  
Nafcillin  
Asunaprevir/beclabuvir/daclatasvir  
Lesinurad  
Bosentan  
Thioridazine   
Rifabutin    
CYP3A  inhibitors  Potent  Moderate  Mild 
 Clarithromycin  
Itraconazole  
Ketoconazole  
Nirmatrelvir and ritonavir  
Fluoxetine  
Grapefruit juice  Ciprofloxacin  
Diltiazem  
Erythromycin  
Fluconazole  
Verapamil  
Sertraline  Alprazolam  
Atorvastatin  
Amlodipi[INVESTIGATOR_21371]-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 117 10.10  APPENDIX  10: CONTINGENCY MEASURES FOR A REGIONAL OR NATIONAL 
EMERGENCY THAT IS DECLARED BY A GOVERNMENTAL AGENCY   
A regional or national emergency declared by a governmental agency (eg, public health 
emergency, natural disaster, pandemic, terrorist attack) may prevent access to the clinical trial 
site. 
Contingency procedures are suggested below for an emergency that prevents access to the study 
site, to ensure the safety of the patients , to consider continuity of the clinical study conduct, 
protect trial integri ty, and assist in maintaining compliance with Good Clinical Practice in 
Conduct of Clinical Trials Guidance. Sponsor agreement MUST be obtained prior to the 
implementation of these procedures for the duration of the emergency; this agreement must be 
provid ed in writing by [CONTACT_21505].  
Monitoring details describing strategy (eg , risk-based initiatives in operations and quality such as 
Risk Management and Mitigation Strategies and Analytical Risk -Based Monitoring), me thods, 
responsibilities , and requirements, including handling of noncompliance issues and monitoring 
techniques (central, remote , or onsite monitoring) are provided in separate study documents.  
During the emergency, if the site will be unable to adequately  follow protocol mandated 
procedures, screening and enrollment may be temporarily delayed/halted . 
Attempts should be made to perform all assessments in accordance with the approved protocol to 
the extent possible. In case this is not possible due to a temp orary disruption caused by 
[CONTACT_13193], focus should be given to assessments necessary to ensure the safety of patients  and 
those important to preserving the main scientific value of the study.  
10.10.1  Informed consent   
For a regional or national emergency declared by a governmental agency, contingency procedures 
may be implemented for the duration of the emergency. The participant or their legally authorized 
representative should be verbally informed prior to initiating any changes that are to be 
implemented for the duration of the emergency (eg, study visit delays/treatment extension, use of 
local labs), and the verbal information given to the participant  should be documented in the 
subject’s medical record.  
10.10.2  Study proce dures   
Procedures to be considered in the event of a regional or national emergency declared by 
a governmental agency:  
1. New screenings during a regional or national emergency declared by a governmental 
agency can be performed only if allowed by [CONTACT_21506]’s agreement is obtained. Rescreening will be permitted when the situation 
normalizes and only if allowed by [CONTACT_21507]’s 
agreement is obtained.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 118 2. If onsite visits or alternative location (out of subject’s home) are not possible, all visits 
from Week 1 (including those planned to be done onsite) will be per formed at home by 
a trained healthcare professional and if allowed by [CONTACT_21508]:  
- Treatment administration  
- Blood sampling for safety (at least hematology, hepatic function panel, coagulation 
panel) and other safety assessment s (at lea st serum creatinine), and pregnancy test (if 
applicable)  
- Measuring vital signs  
- Monitoring of injection site reactions, AEs , and SAEs  
The use of a local laboratory may be allowed for safety follow up in case the central lab cannot be 
used.  
The Investigator  or delegate will perform a phone -call visit at each onsite planned visit to collect 
safety data and concomitant treatment. All data collected remotely will be properly documented in 
the subject’s medical record and the study CRF.  
For all assessments which  will not be performed remotely, the assessment windows will be 
extended until subjects may access the site.  
If onsite visit and home visit are not possible, a temporary treatment discontinuation may be 
considered. The Investigator or delegate will perfor m a phone -call visit at each onsite planned 
visit to collect safety data and concomitant treatment.  
Contingencies implemented due to emergency will be documented in the participant ’s medical 
record.  
10.10.3  Temporary discontinuation   
A temporary IMP discontinuation may be considered by [CONTACT_21509] a regional or national emergency declared by 
a governmental agency.  
Reinitiation of study drug can only occur once the investigator has determined, according to 
his/her best judgement, that the study drug did not contribute to the occurrence of the epi[INVESTIGATOR_21372] (eg, COVID -19). 
For all temporary intervention discontinuation s, duration should be recorded by [CONTACT_21510].  
10.10.[ADDRESS_20351] will be summarized (eg, study discontinuation or discontinuation/delay/omission of the 
intervention due to the emergency). Any additional analyses and metho ds required to evaluate the 
impact on efficacy (eg, missing data due to the emergency)  and safety will be detailed  in the SAP . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 119 10.11  APPENDIX 11: IMMUNOPHENOTYPI[INVESTIGATOR_1645] ( TOLEDYNAMIC SUBSTUDY )  
Title  
An immunological substudy to better understand the mechanism of action of the BTK inhibitor 
tolebrutinib in participants with multiple sclerosis and to correlate immunological changes with 
clinical/paraclinical responses (ToleDYNAMIC) . 
Introductio n/Study rationale  
Bruton’s tyrosine kinase mediates B cell receptor signaling and is also expressed in innate 
immune cells such as monocytes, macrophages , and microglial cells. BTK inhibitors exhibit well 
characterized effects in (autoreactive) B cells as one of the key target cell population in MS. 
However, nonclinical models also indicate indirect effects on T cell subsets due to the intricate, 
reciprocal  B cell and T cell crosstalk, which is particularly interesting in light of their role in the 
pathogenesis of MS.  
The second target population of BTK inhibitors is myeloid lineage cells. BTK inhibition alters 
macrophage phagocytic capacity and reduces sec retion of proinflammatory and cytotoxic 
cytokines and mediators. In the context of MS pathophysiology, these effects on innate immune 
cells have been proposed to contribute to control of progression. This concept is supported by 
[CONTACT_21511] “mixed active -inactive” MS lesions exhibiting absence of 
signs of relevant remyelination depi[INVESTIGATOR_21373] a pronounced rim of infiltrating macrophages, implicating 
this cell population in this “repair -hostile” environment.  
We propose to elucidate the i mpact of BTK inhibition via tolebrutinib on the peripheral immune 
regulatory network beyond B cells and to characterize its effects on functional properties and 
transcriptional signatures of peripheral blood monocyte populations in patients with PMS. In li ght 
of existing nonclinical data, it can be hypothesized that tolebrutinib exerts distinct effects on 
peripheral immune signatures exceeding its direct immune -modulatory effects on B cells and 
monocytes and which may restore immune -regulatory network funct ion. 
Objectives  
The major advantage of the multicenter substudy is that several key immunological questions can 
be addressed in context with available clinical/MRI data in order to gain knowledge about the 
potential correlation between key immunological c hanges and treatment response.  
In light of the limited amount of blood available and to ensure sufficient participant recruitment, 
we will focus on the following:  
1. Highly standardized functional multiparameter (13 colors per panel) flow cytometry of 
periphe ral blood of tolebrutinib -treated participants with PMS before and at different time 
points after onset of tolebrutinib treatment. We will focus on a characterization of T and B 
cell subsets as well as monocyte populations, ie,  
• T cells:  CD4, CD8, CD4 -CD8 -, CD4+CD8+, naive, central memory, effector memory, 
TEMRA, RTE, Treg  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 120 • CD4 memory:  Th1, Th2 , Th 17 , IL, Tfh , IFNγ , TNFα , GM -CSF, IL4, IL22, IL17A, GrA , 
GrB, GrK , GrM , perforin, MCAM  
• CD8 memory: Cytolytic activi ty, IFNγ, TNFα, GM -CSF, IL4, IL22, IL17A, GrA, GrB, 
GrK, GrM, perforin  
• Treg:  pTreg , tTreg , RTE Treg , CD39, DNAM -1, TIGIT  
• B cells:  naïve, class switch memory, Breg, unusual, transitional, marginal -zone -like, IgM 
only 
• Monocytes:  classical, intermediate, nonclassica l subsets  
Classical, intermediate, nonclassical:  
- Chemokine receptor expression (CCR2, CCR5, CX3CR1)  
- Activation markers (CD80, CD86, CD116, CD39)  
- Pro-inflammatory markers (CD69, CD54, CD68, CD40, CD64, CD32)  
- Anti-inflammatory markers (S100A9, CD93, CD36, C D163, PD -1, CD106, CD206, 
CD124, CD121b)  
- Adhesion and migratory capacities (CCR7, CD31)  
The frequency will be determined as well as activation status and functional properties such as 
cytokine production and cytolytic profile. Simultaneous assessment of p eripheral blood cell 
counts within the main study will allow for quantification of each immune cell subset in 
peripheral blood.  
2. The second set of experiments will focus on functional properties of peripheral blood 
monocytes. Cytokine profile of ex vivo and short -term stimulated CD14 monocytes will 
be determined using Luminex technology.  
• Isolated  CD14 monocytes:  cytokine /chemokine  production (IFNα, IFN γ, TNF α, IL6, 
IL1α, IL1 β, IL1RA, IL2, IL4, IL6, IL8, IL10, IL15, IL33, CCL2C)  
• Isolated CD14 monocytes:  capacity to phagocytose myelin as determined by [CONTACT_8315]  
• Production of reactive oxygen species by [CONTACT_398]14 monocytes  as determin ed by [CONTACT_8315]  
• Analysis of key metabolic properties of CD14 monocytes by [CONTACT_21512] B cells and CD14 
monocytes using unbiased RNA sequencing of magnetic -bead -sorted c ells will be determined. 
This approach will provide a detailed overview of therapy -induced changes within the T cell 
monocyte compartments to potentially identify immune cell subsets as well as transcriptional 
networks affected by [CONTACT_21513]. This approa ch may identify transcriptional markers which 
might be used in the future as biomarkers for treatment response.  
Statistical analysis will be described in a separate SAP.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20352] during the main study. There will be 3 s ampling points (baseline, 
Months 3 and 12) to collect approximately 40  mL of blood per sample/per visit for the 3 visits. 
A total of approximately 120 mL blood will be collected from each participant for this substudy.  
Study design  
• Inclusion/exclusion cri teria are those for the main study.  
• Multicenter substudy in participants with PMS sampled at baseline (before treatment) and 
Months 3 and 12 (after initiation of tolebrutinib).  
• Clinical endpoints and MRI measures are from the main study.  
• This substudy will  be performed in 80 participants total (40 participants from both 
PERSEUS and HERCULES, respectively). RNA sequencing will be performed in a subset 
of participants.  
• Blood sampling, handling , and shipment . 
• Each blood sample is approximately 40  mL (3 samples  of approximately 120  mL for the 
substudy).  
• Special procedures for collection, storage and shippi[INVESTIGATOR_21374].  
• Shipment to the central laboratory must be within [ADDRESS_20353] ing.  
• Bulk RNA -sequencing will be performed from frozen and subsequently thawed peripheral 
blood mononuclear cells and monocytes.  
Participating centers  
Selected sites.  
10.12  APPENDIX 12: ACTIGRAPHY SUBSTUDY   
A subset of participants may perform actigraphy (a noninvasive activity monitor) to assess disease 
symptoms and progression in the participant’s free -living environment. The objective of this 
assessment is to test the hypothesis that  the increased sensitivity and ecological validity of 
an actigraphy device will reflect changes in the participant’s condition more accurately and more 
comprehensively than occasional in -clinic assessments. If implemented based on pi[INVESTIGATOR_21375], 
the Spo nsor will provide participants with an actigraphy device. Participants will be required to 
wear the device duri ng waking hours for 14 days on and 14 days off every month from enrollment 
into the substudy until the end of the sub -study, as specified in the schedule of activities  
(Section  1.3). Additional details can be found in the Study Reference Manual.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 122 10.13  APPENDIX 1 3: ABBREVIATIONS   
 
ADL : activity of daily living  
AE: adverse event  
AESI:  adverse event of special interest  
ALP:  alkaline phosphatase  
ALT:  alanine transaminase  
aPTT:  activated partial thromboplastin time  
AST:  aspartate aminotransferase  
BTK:  Bruton’s tyrosine kinase  
CD: cluster of differentiation  
CDP:  confirmed disability progression  
CFR:  Code of Federal Regulation  
Chi3L1:  chitinase -3 like protein -1 
CIOMS:  Council for International Organization of Medical Sciences  
CNS:  central nervous system  
COVID -19: Coronavirus Disease 2019  
CPK:  creatine phosphokinase  
CSF:  cerebrospi[INVESTIGATOR_21376]:  clinical study report  
C-SSRS:  Columbia -suicide severity rating scale  
DDI:  drug-drug interaction  
DILI:  drug-induced liver injury  
DMC:  data monitoring committee  
DNA:  deoxyrebonucleic acid  
DNAM -1: DNAX accessory molecule 1  
DTP:  direct -to-patient  
EC: ethics committee  
eCRF : electronic case report form  
EDSS:  expanded disability status scale  
EU: European Union  
FSH:  follicle stimulating hormone  
GCP:  Good Clinical Practice  
Gd: gadolinium  
GM-CSF:  granulocyte -macrophage -colony stimulating factor  
GrA:  human granzyme A  
GrB:  human granzyme B  
GrK:  human granzyme K  
GrM:  human granzyme M  
HIV: human immunodeficiency virus  
HR: hazard ratio  
HRT:  hormonal replacement therapy  
ICF: informed  consent form  
ICH:  International Council for Harmonisation  
IEC:  Independent Ethics Committees  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 123 IFNγ:  Interferon γ  
IL: interleukin  
IMP:  investigational medicinal product  
INR:  international normalized ratio  
IRB:  Institutional Review Boards  
IRT: interactive response technology  
ITT: intent -to-treat 
IUD:  intrauterine device  
IUS:  intrauterine hormone -releasing system  
IV: intravenous  
IWRS : interactive web response system  
JCV:  John Cunningham virus  
LTS:  long-term safety  
MCAM:  melanoma cell adhesion molecule  
MedDRA:  Medical Dictionary for Regulatory Activities  
MMRM:  model with repeated measures  
MRI:  magnetic resonance imaging  
MS: multiple sclerosis  
MSFC -3: multiple sclerosis functional composite 3  
MTR:  magnetization transfer ratio  
NCI CTCAE:  National Cancer Institute Common Terminology Criteria for Adverse Event  
NEDA : no evidence of disease activity -3 
NfL:  neurofilament light chain  
NRSPMS:  nonrelapsing secondary progressive multiple sclerosis  
NSAIDs:  nonsteroidal anti -inflammatory drugs  
PCSA:  potentially clinically significant abnormality  
PD: pharmacodynamic(s)  
PK: pharmacokinetics  
PML:  progressive multifocal leukoencephalopathy  
PPMS:  primary progressive multiple sclerosis  
pTreg:  peripheral regulatory T cells  
RMS:  relapsing multiple sclerosis  
RRMS:  relapsing -remitting multiple sclerosis  
RTE:  recent thymic emigrant  
SAP:  statistical analysis plan  
SEL:  slowly evolving lesions  
SoA:  schedule of activities  
SPMS:  secondary progressive multiple sclerosis  
S[LOCATION_003]R:  suspected unexpected serious adverse reaction  
SWI:  susceptibility -weighted imaging  
TB: tuberculosis  
TEAE:  treatment -emergent adverse event  
Tfh: T follicular helper  
Th 17:  T helper 17 cells  
Th1:  T helper 1 cells  
Th2:  T helper 2 cells  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 124 TIGIT:  T cell immunoglobulin and immunoreceptor tyro sine-based inhibitory motif 
(ITIM) domain  
TNFα:  tumor necrosis factor α  
Treg:  regulatory T cell  
tTreg:  thymically derived Foxp3(+) regulatory T cells  
ULN:  upper limit of normal  
WBC : white blood cells  
WOCBP:  women of childbearing potential  
 
10.14  APPENDIX 1 4: PROTOCOL AMENDMENT HISTORY   
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
10.14.1  Amended protocol 01 (15 May 2020)   
This amended protocol (amendment 01) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the  
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary driver for this amended protocol consists of regulatory requirements including addition 
of a Relapse Adjudication Committee, change in stratification factor, removal of an endpoint and 
additi on of a benefit -risk evaluation of the study in the context of the COVID -19 pandemic.  
Protocol amendment summary of changes table  
Section # and 
Name  [CONTACT_11029]  
1.1 Synopsis  Expanded Disability Status Scale (EDSS )-plus endpoint removed. 
Time to onset of sustained 20% increase in the timed 25 foot walk  
(T25-FW) and the 9-hole peg test  (9-HPT) for at least 3  months 
maintained as secondary endpoints . Stratification by 
[CONTACT_21514]/presence of gadolinium (Gd) enhancing T1 lesions at 
baseline changed to stratification by [CONTACT_21406]. Geographic 
origin corrected to geographic region. Mention that investigational 
medicinal products (IMPs) are film coated  tablets. Relapse 
Adjudication Committee added. Post -trial access to study medication 
clarified. Statistical considerations updated for consistency with rest 
of document.  Accuracy. Clarity. 
Consistency. Health authority 
request.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 125 Section # and 
Name  [CONTACT_11029]  
1.3 Schedule of 
activitie s Removal of dispensation of IMP and matching placebo from 
premature end of treatment (pEOT) visit. Removal of investigational 
medicinal product (IMP) compliance check from randomization visit. 
Parameters of physical examination clarified. Clarification of  
tuberculosis (TB) testing. Timing of plasma and serum samples 
clarified. Participants who will enter long -term extension study  was 
clarified. Quarterly lipase testing added. Mention that additional 
safety assessments may be performed locally if required. Visit 
window for magnetic resonance imaging (MRI) performed after D1 
expanded. Clarification of potential uses of archival sample.  Accuracy. Clarity.  
2.1 Study rationale  Removal of paragraph on EDSS -Plus. Mention that relapse data will 
be adjudicated  EDSS -Plus is removed from 
secondary and 
tertiary/exploratory endpoints. 
Health authority request.  
2.3 Benefit/risk 
assessment  In potential benefits, “reduction in the accumulation of confirmed 
disability worsening” changed to “reduction in the  accumulation of 
confirmed disability progression” for clarity. Investigator assessment 
of relatedness of one adverse event (AE) of temporary alanine 
transaminase (ALT ) increase changed to “related” to reflect update in 
data. “No cardiac arrhythmia was observed” was changed to “No 
clinically significant cardiac arrhythmia was observed” for clarity. Text 
added to address regulatory requirements for COVID -19 risk and 
mitigation.  Clarity. Accuracy. Response  
to regulatory requirement.  
3 Objectives and 
endpoints  Adjudication added to relapse tertiary/exploratory endpoint. EDSS -
plus endpoint removed. Time to onset of sustained 20% increase in 
the T25 -FW and the [ADDRESS_20354] 3  months moved from 
tertiary/exploratory to secondary endpoints. Change from baseline to 
Months 12, 18, and 24 and to the end of study (EOS) in [LOCATION_004] 
Verbal Learning Test -II (CVLT -II) added in tertiary/exploratory 
endpoints.  Accuracy. Clarity. 
Consistency. Health authority 
request.  
3.1 Appropriateness 
of measurements  Removal of parag raph on EDSS -Plus. Mention that relapse data will 
be adjudicated  EDSS -Plus is removed from 
secondary and 
tertiary/exploratory endpoints. 
Health authority request.  
4.1 Overall design  Safety follow -up period clarified.  Clarity.  
4.2 Scientific 
rationale fo r study 
design  Clarification of statistical issue.  Clarity.  
4.3 Justification for 
dose  Text about external trials added.  Clarity. Addition of 
accidentally omitted text.  
5.1 Inclusion criteria  Move country specificities to Appendix 8.  Clarity.  
5.2 Exclusion criteria  In E01, wording “baseline” was change to “screening”.  
Removal of E18 as E09 is a similar criterion.  
In E06, timing of washout for concomitant medications changed from 
“before any baseline” to “before any randomization”, and table 
clarif ied. Clarity.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 126 Section # and 
Name  [CONTACT_11029]  
5.3.1 Meals and 
dietary restrictions  Timing of IMP administration clarified.  Clarity.  
6.1 Study 
intervention(s) 
administered  Mention that IMPs are film coated tablets. Direct -to-patient  (DTP) 
dispensation of IMP added as a possibility.  Accuracy. Flexibility for 
COVID -19. 
6.2 
Preparation/handling/ 
storage/accountability  Mention of responsibility in case of DTP shipment  Flexibility for COVID -19. 
6.3 Measures to 
minimize bias: 
randomization and 
blinding  Stratification by [CONTACT_21514]/presence of Gd enhancing T1 lesions at 
baseline changed to stratification by [CONTACT_21406]. Geographic 
origin corrected to geographic region.  Clarity. Health authority 
request.  
6.5 Concomitant 
therap y Mention that live (attenuated) vaccines are prohibited.  Clarity  
6.5.1 Rescue 
medicine  “A non -study treatment available for NRSPMS in their respective 
country” changed to “ a non -study treatment approved for NRSPMS 
in their respective country”. Clarificat ion that there can be no 
adjudicated relapse within [ADDRESS_20355] review of 
electrocardiograms (ECGs) clarified. Last visit for participants with 
definitive discontinuation an d participants who decide to discontinue 
open -label IMP clarified. Last visit for participants who decide to 
discontinue the IMP clarified. Participants who prematurely and 
permanently end treatment for a reason other than 6 -month CDP will 
not be eligible for open -label IMP  Clarity.  
7.1.2 Temporary 
discontinuation  Text added to address regulatory requirements for COVID -19 risk 
and mitigation.  Consistency.  
8 Study assessments 
and procedures  “Phone visits” changed to “telephone/remote visits” to allow for web -
based visits.  Ease of continuation of study 
during COVID -19 pandemic.  
[IP_ADDRESS] Confirmed 
disability progression  Definition of confirmed disability progression clarified.  Clarity.  
8.1.2 Magnetic 
resonance imaging  Details of MRI assessments added.  Clarity.  
[IP_ADDRESS]. Definition of 
MS relapse  Clarification of MS relapse confirmation definition. Crosslinks added.  Clarity.  
[IP_ADDRESS] EDSS plus  Section removed  EDSS -plus is not an endpoint 
anymore.  
[IP_ADDRESS] Assessment 
of no evidence of 
disease activity  Mention that MS relapse is adjudicated  Health Authority requirement.  
8.1.[ADDRESS_20356] be worn for 14 days after screening for 
baseline assessment.  Clarity.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 127 Section # and 
Name  [CONTACT_11029]  
8.2.[ADDRESS_20357] 
(AESI ) for ECG pertains to atrial fibrillation and atrial flutter only and 
that confirmation by a cardiologist is not required. Clarified that AESI 
reporting is intended for infections that are of severity Grade 3 or 
above by [CONTACT_21515] (NCI CTCAE).  Clarity.  
8.5 Pharmacokinetics  Blood samples of approximately 3 mL clarified as blood samples of 
approximately 2 to 3 mL.  Accuracy.  
8.6 
Pharmacodynamics  Clarification of the number of participants expected to participate in 
the pharmacodynamics part of the study.  Clarity.  
9.1 Statistical 
hypotheses  Addition of details on hypotheses.  Clarity. 
9.1 Statistical 
hypotheses  Details added for clarification.  Clarity.  
9.4.2 Primary 
endpoint  Clarification of definition of confirmed disability progression. 
Stratification by [CONTACT_21514]/presence of Gd enhancing T1 lesions at 
baseline changed to stratification by [CONTACT_21406]. Geographic 
origin corrected to geographic region. Subgroup analyses clarified.  Clarity. Health Authority 
request.  
9.4.3 Secondary 
endpoint(s)  Stratification by [CONTACT_21514]/presence of Gd enhancing T1 lesions at 
baseline cha nged to stratification by [CONTACT_21406]. Geographic 
origin corrected to geographic region  Clarity. Health Authority 
request.  
9.5 Interim analyses  The futility criteria or boundary will be predefined in the data 
monitoring committee (DMC ) charter.  Correction of error. This 
definition belongs in the DMC 
statistical analysis plan 
(SAP ). 
[IP_ADDRESS] Relapse 
Adjudication 
Committee  Section added. All relapses are to be adjudicated.  Clarity. Health Authority 
request.  
10.2 Appendix 2: 
Clinical laboratory 
tests  Removal of requiremen t of replicate sampling for local and central 
labs. Removal of requirement for central lab testing, if infeasible.  Simplification.  
10.8 Appendix 8: 
Country -specific 
requirements  Country specificities in inclusion criteria moved here.  Clarity  
Whole document  Minor format changes and typos correction.  Accuracy. Consistency.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 128 10.14.2  Amended protocol 02 ([ADDRESS_20358]  2020)   
This amended protocol 02 (amendment 02) is considered to be subst antial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary driver for this amended protocol is to respond to European Health Authorities’ 
requests. The amendment also added Phase 2b results with regard to SAR4 [ZIP_CODE] potential benefit 
for non -relapsing secondary progressive multiple sclerosis (NRSPMS).  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_21531].  Administrative change  
Section 1.1 Synopsis - 
objectives and endpoints, 
Section 1.3 Schedule of 
Activities (SoA), Section 3 
Objectives and Endpoints, 
and Section 8.5 
Pharmacokinetics  Addition of SAR442168 relevant  metabolite(s) when referring to the 
pharmacokinetic (PK) evaluation.  Clarity  
Section 1.1 Synopsis - 
Rationale, Section 2.1 
Study rationale  Updated text in these sections.  Health Authorities’ request  
1.3 Sch edule of Activities 
(SoA)  Addition of hematology, biochemistry, pregnancy test, and Columbia -
suicide severity rating scale (C -SSRS) to the follow -up visit.  Health Authorities’ request  
 Time period for randomization visit relaxed. Additional safety 
assessments allowed if locally required.  Health Authorities: 
Coronavirus disease 2019 
(COVID -19) 
 Repeated vital signs assessment row and checkmark for the same 
deleted.  Correction  
 Due to r evision of footnotes, sequencing of footnotes has been 
updated  Updation  
1.3 Schedule of Activities 
(SoA), 10.4 Appendix 4 
Contraceptive guidance 
and collection of 
pregnancy information  Telephone reporting of home pregnancy tests allowed.  Health Authorities: 
COVID -19 
2.3 Benefit/risk 
assessment  Adverse events (AEs) details updated.  
Recent information on Bruton’s tyrosine kinase (BTK) inhibitors and 
COVID -19 added.  Clarity  
Health Authori ties: 
COVID -19 
4.1 Overall design  "whether or not remaining on IMP" was added to EOS definition  Clarity  
4.2.2 Justification for the 
use of placebo  Added a new sub -heading - Justification for the use of placebo, and 
relevant text.  Health Authorities’ request, 
clarity  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 129 Section # and Name  [CONTACT_11029]  
5.1 Inclusion criteria  I09B was updated by [CONTACT_1583] “women of childbearing potential 
(WOCBP) must use reliable means of contraception as described in 
Appendix 4 (Section 10.4) at a minimum. If local requirements are 
more string ent than what is described in Section 10.4, they should be 
followed”.  Health Authorities’ request  
5.2 Exclusion criteria  E04: Conditions that may predispose the patient to excessive 
bleeding clarified.  
E08: Investigator’s role in stoppi[INVESTIGATOR_21377] t herapi[INVESTIGATOR_21378].  Health Authorities’ request  
 E18: Deleted the placeholder for already deleted exclusion criteria 
E18 Clarity  
 
6.3 Measures to minimize 
bias: randomization and 
blinding  Contact[CONTACT_21516].  Health Authorities’ request  
Data access of “Treating Investigator” clarified.  Health Authorities’ request  
6.5 Concomitant therapy  “Therapi[INVESTIGATOR_21346] E06 (Section 5.2) 
are not permitted after randomization while the patient is on study 
treatment” was added.  Health Authorities’ request. 
Clarity. To address the 
issues around use of 
ocrelizumab and siponi mod 
both prior to enrolment and 
during the trial.  
7.1.1 Definitive 
discontinuation  Role of Investigator in treating participant after definitive 
discontinuation clarified. Progressive multifocal leukoencephalopathy 
(PML) added to criteria for definitive discontinuation.  Health Authorities’ request  
7.1.2 Temporary 
discontinuation,  
7.1.2 .1 Rechallenge,  
8.0 Study assessments 
and procedures,  
10.1.3 Informed consent 
process, and  
10.12 Appendix 12 
Contingency Measures for 
a regional or national 
emergency that is 
declared by a 
governmental agency.  Contingency measures for a regional or nation al emergency were 
added.  Include flexibility and ease of 
continuation of study during 
regional or national 
emergency such as 
COVID -19. 
7.1.2 Temporary 
discontinuation  Suicidal risk as per C -SSRS added.  Clarity  
8.1.2 Magnetic resonance 
imaging  Added prov ision for study manual to be provided to all sites for MRI 
related procedure.  Clarity  
 Update of the disclosure of MRI reports to the Treating Investigator.  Health Authorities’ request  
8.2.5 Suicidal ideation and 
behavior risk monitoring  Columbia -suicide severity rating scale (C -SSRS ) criteria for 
interruption of study drug clarified.  Health Authorities’ request  
8.3.4 Regulatory reporting 
requirements for SAEs  Requirements for reporting of suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) clarified.  Health Authorities’ request  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 130 Section # and Name  [CONTACT_11029]  
10.6 Liver and other 
safety: suggested actions 
and follow -up 
assessments  Diagnostic workup for PML suspi[INVESTIGATOR_21379].  Health Authori ties’ request  
10.8 Appendix 8: Country -
specific requirements  A new sub -heading was added "10.8.1 Contraception requirements 
in [LOCATION_006], [LOCATION_013] and Denmark"  Updation  
10.11 Appendix 11  Protocol amendment history with the change that the section was 
updated with amended protocol01 history  Updation  
Throughout  Substitution of “long term safety (LTS)” for “long term extension 
(LTE)” to describe the study that participants will be allowed to roll 
over to; correction of small errors (eg,  comma errors, dup lication of 
words); slight rewordings for clarity, addition of abbreviations, covid -
[ADDRESS_20359] 
been changed throughout the document.  Correction of errors, clarity  
10.14.3  Amended protocol 03 (03 November  2020)   
This amended protocol 03 (amendment 03) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary driver for this amended protocol is to respond to the feedback from Investigators with 
regard to the inclusion/exclusion criteria.  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.2 Schema  Addition of footnote to clarify that “Month -1 (D-28 – 
D-1)” refers to screening period as "Day -28 to Day -1"; 
“Month 0 (D1)” refers to randomization on Day 1.  Clarification  
 M1 corrected to M0. MRI visit at M0 moved to M -1. 
“Long -term extension study ” changed to “Long -term 
safety study ”.  Correction of error  
1.3 Schedule of activities (SoA)  Timing of visit assessments clarified. Reference to E01 
added in footnote “I”. Timing of MRI scans clarified 
(footnote “p” added and duplicated text removed from 
footnote “o”). Sequencing of footnotes has changed due 
to the addition of footnote “p”.  Clarification  
3 Objectives and endpoints  Tertiary/exploratory endpoints: Clarification of the MTR 
recovery and slowly evolving lesions (SELs) endpoints.  Clarification  
5.1 Inclusion criteria  I07: Deletion of existing criteria.  Update and clarification  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 131 Section # and Name  [CONTACT_11029]  
5.2 Exclusion criteria  E01: Clarification of repetition of TB testing. Clarification 
of hepatitis testing.  Clarification.  
 E06: Changes of the wash -out period header of the 
table. Removal of requirement for ascertainment of 
B-cell levels after washout.  Clarification. To allow earlier 
treatment that may potentially 
reduce the progression of 
disability and it is routine 
practice to continue certain MS 
treatments for participant s on 
anti-CD20 antibody treatments 
with low B -cell counts.  
 E15: Potential part icipants unable to complete 
electronic clinical outcome assessments excluded.  Copyright issue with paper 
clinical outcome assessment 
forms.  
Section 5.[ADDRESS_20360]  Acute hypersensitivity/ana phylaxis removed from list of 
adverse events of special interest.  Found to be unnecessary 
because of lack of safety signal 
in previous studies.  
8.3.[ADDRESS_20361] -treatment 
epochs.  Clarification.  
[IP_ADDRESS] Eligibility Adjudication 
Committee  Clarification of the assessment of disability progression.  Clarifica tion. 
10.1.6 Dissemination of clinical study 
data Text on disclosure of information added.  Change in company policy.  
10.2 Appendix 2: Clinical laboratory 
tests  Clarification of repetition of TB testing and reference to 
E01 added.  Clarification.  
 Template wording regarding hepatic impairment and 
cirrhosis removed.  Template wording not applicable 
to this study.  
10.6 Liver and other safety: 
suggested actions and follow -up 
assessments  PML assessment clarified.  Clarification.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 132 Section # and Name  [CONTACT_11029]  
10.11 Appendix 11: Protocol 
amendment history  Protocol amendment history updated.  Update.  
10.12 Appendix 12: Contingency 
measures for a regional or national 
emergency that is declared by 
a governmental agency  Additional measures added.  Contingency measures for 
COVID -19. 
Throughout the document  Correction of small errors (eg,  comma errors, 
duplication of words); slight rewordings for clarity, 
addition of abbreviations.  
New references have b een added and sequence 
numbering has been changed throughout the 
document. Table of contents has been updated.  
In-text references updated in relation to update of 
sections.  Correction of errors, clarity.  
10.14.4  Amended protocol 04 (26  July 2021)   
This amended protocol (amendment 04) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary reason for this amendment is the availability of new information from drug -drug 
interaction studies.  
Protocol amendment summary of changes  
Section # and Name  [CONTACT_21532]  
3 Objectives and endpoints  Changed a secondary endpoint from 
“Change in lymphocyte phenotype subsets in 
whole blood at the EOS compared to 
baseline” to “Change in lymphocyte 
phenotypi[INVESTIGATOR_21380] a subset of 
participants.”  Lymphocyte phenotypi[INVESTIGATOR_21381] 04.  
1.3 Schedule of Activities, footnotes  The footnotes were updated as follows:   
 • Footnote a: To allow a window of 
1 additional week (7 days) for 
screening magnetic resonance imaging 
(MRI) if required to be rescheduled or 
repeated (eg, in case of technical 
issues).  To allow more flexibility for screening 
MRI and safety laboratory tests.  
 • Footnote d: To allow safety laboratory 
tests at Months 1, 2, 4, and [ADDRESS_20362] assessment.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 133 Section # and Name  [CONTACT_21533]  
 • Footnote e: To clarify the study 
procedures/assessments to be 
performed if a participant prematurely 
permanently discontinues treatment 
with the IMP.  Clarity.  
 • Footnote i: Text added: Screening 
tests for TB are described in Appendix 
2 (Section 10.2).  Clarity.  
 • Footnote k: Text added: Lipase will be 
tested at the Screening Visit, then 
quarterly. Also clarified that additional 
safety assessments can be performed 
at local laboratories, if required by [CONTACT_13125].  Clarity.  
 • Footnote l: Text updated as: A seru m 
ß-hCG pregnancy test will be analyzed 
at a central laboratory at screening and 
urine pregnancy tests before the first 
dose of investigational medicinal 
product (IMP) and at scheduled times 
during the study.  Clarification of pregnancy tests 
required durin g the study.  
 • Footnote u: Clarified the details of 
pharmacodynamic/biomarker samples 
are not timed at pEOT and EOS.  Timed pharmacodynamic/biomarker 
sampling is only needed at visits when 
pharmacokinetic (PK) samples are 
also collected at these same time 
points.  
 • New footnote y added to add 
requirement that samples for hematology  
and biochemistry tests on Day 1 
(randomization) must be collected prior 
to administration of the first IMP dose.  To ensure collection of baseline 
(pre-IMP) values for the safety 
laboratory tests.  
 • New footnote z added to clarify 
immunophenotypi[INVESTIGATOR_007]/RNA sequencing 
samples shippi[INVESTIGATOR_21382].  Clarity.  
1.3 Schedule of activities, footnote e  
8.5 Pharmacokinetics  To add the collection of a pharmacokinetic 
sample at premature end of treatment 
(pEOT) visit, if the visit can be scheduled 
within a maximum [ADDRESS_20363] 
IMP dose.  To clarify that the PK sample should 
be collected in case of pEOT only if 
the visit can be scheduled within 
24 hours due to short t 1/[ADDRESS_20364] 
IMP dose.  
1.3 Schedule of Activities  Immunophenotypi[INVESTIGATOR_007]/RNA sequencing 
(ToleDYNAMIC/optional substudy at 
selected sites) added.  Additional substudy to investigate 
immunological changes over the 
treatment duration . 
1.3 Schedule of Activities  
8.6 Pharmacodynamics  Updated footnote aa for lymphocyte 
phenotypi[INVESTIGATOR_21383]: Blood sample 
collection for lymphocyte phenotypi[INVESTIGATOR_21384] a subset 
of randomized participants. Participants who 
did not have a baseline sample collected, will 
no longe r have this test performed; 
participants who had a baseline sample 
collected will have a second sample 
collected at EOT/pEOT.  Lymphocytes phenotypi[INVESTIGATOR_21385] 
a subset of participants. Sample time 
points have also been r educed. 
Approximately up to [ADDRESS_20365] 
at end of treatment.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 134 Section # and Name  [CONTACT_21533]  
3. Objectives and endpoints  Updated the language of a tertiary/exploratory  
endpoint to add the assessment of 
cumulative number of new T1 -hypointense 
lesions.  To clarify analysis of T1 hypointense 
lesions.  
4.[ADDRESS_20366] completed the study if 
he/she has completed all periods of the 
study including the EOS visit, whether 
remaining on IMP or not.  Clarity.  
5.1 Inclusion criteria  Inclusion criterion 09: Clarified that a woman 
of childbearing potential must have a 
negative highly sensitive pregnancy test at 
screening and before the first dose of study 
intervention.  Clarity.  
5.2 Exclusion criteria  Exclusion criterion 01: Updated the details of 
tuberculosis and hepatitis tests.  Clarification of these screening 
procedures and harmonization with the 
other studies in the Phase 3 multiple 
sclerosis (MS) program participants.  
 Exclusion criterion 02: Clarified that the 
Columbia Suicide Severity Rating Scale 
baseline/screening version will be used for 
assessment of suicidal ideation  Clarity.  
 Exclusion criterion 03: Updated language to 
clarify Investigator’s judgement to be 
clinically significant in the context of this trial.  Clarity.  
 Exclusion criterion 05: Removed standalone 
albumin criterion.  Clarity.  
 Exclusion criterion 06: Added plasma 
exchange with a 1 -month washout period 
required prior to randomization with MRI and 
clinical assessment for PML. Updated 
washout period for fingolimod and 
natalizumab and in addition provided the 
washout period for ofatumumab and 
ozanimod.  Clarification to ensure washout 
requirement is based on the 5 half -life 
rule for drug elimination in participants.  
5.3.1 Meals and dietary restrictions  Clarification of IMP administration details to 
specify that a gap of a minimum of 12 hours 
between 2 doses should be maintained in 
case the mealtime needs to be changed for 
IMP administration.  Clarification of the minimum time 
between 2 IMP doses.  
 Removed the restrictions related to 
consumption of grapefruit or grapefruit juice.  Update based on outcomes from PK 
results of drug-drug interaction (DDI ) 
studies, investigating concomitant use 
of SAR442168  with drugs such as 
itraconazole.  
6. Study intervention  Updated language to remove device from 
the details . Correction as no device for study 
intervention.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 135 Section # and Name  [CONTACT_21533]  
6.4 Measures to minimize bias: 
Randomization and blinding  Added text: A participant cannot be 
randomized more than once in the study.  Clarity.  
1.3 Schedule of activities  
6.5 Study intervention compliance  Added details of paper diary provision to all 
participants, to capture all study -related 
details.  Clarity.  
6.6 Concomitant therapy  Added the concomitant use of short -term use 
(3 to 5 days) of glucocorticoids (eg, for MS 
relapse treatment or an acute illness) and 
local corticosteroids (eg, topi[INVESTIGATOR_2855], nasal, 
ocular, otic, intra -articular).  Clarification for use of topi[INVESTIGATOR_21386] -term 
corticosteroids.  
 Updated the language related to use of 
NSAIDs and symptomatic t reatment of MS.  Clarity.  
 Added allowed daily maximum dose of 
aspi[INVESTIGATOR_248] 81 mg/day.  With the extensive safety monitoring 
during the study and with no bleeding 
risk identified so far for Tolebrutinib , 
the Sponsor has relaxed this 
restriction to improve patien t 
engagement.  
5.2 Exclusion criterion 7  
6.6 Concomitant therapy  
10.9 Appendix 9: Examples of drugs 
with a potential to change 
SAR442168  metabolism or 
absorption  Updated for antacid drugs:  
Removed the restrictions related to antacid 
drugs as concomitant use of proton -pump 
inhibitors (PPI), H2 receptor antagonists, and 
antacids is allowed.  Update based on outcomes from PK 
results of drug -drug interaction 
studies, investigating concomitant use 
of SAR442168  with drugs such as 
itraconazole, gemfib rozil, rifampi[INVESTIGATOR_21387].  
 Updated guidance for CYP 
inhibitors/inducers: Potent and moderate 
inducers of CYP3A or potent inhibitors of 
CYP2C8 hepatic enzymes are not permitted 
throughout the study.  New information from DDI studies.  
 Clarified concomitant use of potent CYP3A 
inhibitors is allowed.  New information from DDI studies.  
6.6.[ADDRESS_20367] reduced 
MRI schedules.  
 Removed the Data Monitoring Committee 
(DMC) review of data to determine whether 
AEs should preclude continued treatment 
with study intervention.  The DMC has no responsibility to 
review individual data and advice for 
IMP discontinuation for a participant.  
 To add collection of a pharmacokinetic 
sample at premature end of treatment 
(pEOT) visit, if the visit can be scheduled 
within a maximum [ADDRESS_20368] 
IMP dose.  To clarify that the PK sample should 
be collected in case of pEOT only if 
the visit can be scheduled within 
24 hours due to short t 1/[ADDRESS_20369] 
IMP dose.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 136 Section # and Name  [CONTACT_21533]  
7.1.[ADDRESS_20370] on MRI findings.  
[IP_ADDRESS] Definition of multiple sclerosis 
relapse  Clarified that MS relapse confirmation will be 
done by [CONTACT_21517].  Clarity.  
8.2.2 Vital signs  Clarified that blood pressure and heart rate 
measurements will be assessed in a supi[INVESTIGATOR_21388].  
8.2.3 Electrocardiog rams  Added allowance of manual calculation of 
QT interval corrected using Fridericia’s 
formula ( QTcF).  To allow some flexibility as some 
automated electrocardiograms do not 
provide these parameters. All other 
electrocardiogram parameters will be 
automatica lly provided.  
8.3.8 reporting of safety findings from 
magnetic resonance imaging  Text updated to “In case of clinically relevant 
findings, relevant information needs to be 
provided to the Treating Investigator for 
appropriate safety reporting and also to 
ensure the appropriate management of the 
participant’s identified safety finding.”  Clarity.  
8.3.[ADDRESS_20371].  
 Thrombocytopenia, platelet count updated 
from <100  000/mm3 to <75  000/mm3 Modified to align with CTCAE 
guidelines for thrombocytopenia  
8.[ADDRESS_20372] documented IMP 
dose (rather than the last dose of 
SAR442168 ). Correction of error.  
8.6 Pharmacokinetics  Updated the section for number of PK 
samples: The five scheduled samples will be 
collected. Additional PK samples may be 
collected (eg, for retest or if clinically 
indicated).  Clarity; no change in number of 
samples.  
10.2 Appendix 2: Clinical laboratory 
test Added details of the serology tests for 
hepatitis B and C.  To harmonize with other protocols in 
Phase  [ADDRESS_20373].  
 Removed the cross -reference to unblinding 
section (Section 6.3).  Clarification of error.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 137 Section # and Name  [CONTACT_21533]  
10.4 Appendix 4: Contraceptive 
guidance and collection of pregnancy 
Information  Clarified the definition of high 
follicle -stimulating hormone level: >30  IU/L 
or as per laboratory reference ranges.  Clarification of follicle -stimulating 
hormone  level for postmenopausal 
status confirmation as not all 
laboratories use the threshold of 
30 IU/L.  
10.6 Appendix 6: Liver and other 
safety: required actions and follow up 
assessments  Table 6 was updated for clinical history 
manifestations.  Simplification.  
 Updated ‘Increase in ALT’ flowchart.  To provide clear guidelines for safety 
of participants in case of elevated ALT 
or reduced platelet counts.  
 Updated algorithm for thrombocytopenia.  To align with CTCAE guidelines for 
thrombocytopenia.  
10.8.[ADDRESS_20374] from “efficacy assessment” to 
“other safety assessments.  Correction of error.  
10.11 Appendix 11 
Immunophenotypi[INVESTIGATOR_007]/ToleDYNAMIC 
substudy  Added appendix for immunophenotypi[INVESTIGATOR_21389].  Additional substudy to investigate 
immunological changes over the 
treatment duration  
Throughout the document  Correction of small errors (eg, c omma errors, 
duplication of words); slight rewordings for 
clarity, addition of abbreviations.  
New references have been added and 
sequence numbering has been changed 
throughout the document. Table of contents 
has been updated.  
In-text references updated in  relation to 
update of sections.  Correction of errors, clarity.  
10.14.5  Amended protocol 05 (21 December 2021)   
This amended protocol (amendment 05) was considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary reason for this amendment was to facilitate operational f easibility and reduce 
complexity, without compromising study integrity.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 138 Protocol amendment summary of changes table  
Section # and Name  [CONTACT_21534] [CONTACT_21518] 02.  Correction of error.  
1.3 Schedule of activities  PK sampling added to pEOT visit.  
Footnote a: additional week of flexibility 
allowed for broadened scheduling.  
Footnote c: added references to Section 7.1 
and the Study Reference Manual.  
Footnote t updated, added to M9 PK 
sampling.  
Footnote u: clarification of pharmacodynamics 
and biomarkers sampling.  Correction of error.  
Additional flexibility in case of 
logistical issues.  
Clarification.  
5.2 Exclusion criteria  E 01: Text inserted to allow for rescreening 
after TB treatment.  Flexibility.  
6.4 Measures to minimize bias: 
randomization and blinding  
8.[ADDRESS_20375]  
8.1.6 Cognitive tests  Requirement for Examining Investigator/rater 
to perform all clinical efficacy tests removed. 
Blinding requirements revised for certain data 
such as participant visit number.  Update to facilitate operational 
feasibility and reduce complexity , 
without compromising study 
integrity.  
6.5 Study intervention compliance  Proper placement of tear -off label removed.  Correction of error. This study has 
no tear -off label.  
6.6 Concomitant therapy  Updated the language related to use of 
NSAIDs.  Clarification.  
[IP_ADDRESS] Confirmed disability 
progression  Clarification of timing of observation of EDSS 
scores used for confirmed disability 
progression.  Clarification.  
8.1.2 Magnetic resonance imaging  Clarification that full MRI report viewing 
restrictio n to one/year is applicable during the 
intervention period.  Clarification.  
8.1.8 Actigraphy  Section 8.1.8 moved to appendices.  
 
Reference to Study Reference Manual added. 
Timing of requirement for wearing device 
clarified.  Compliance with requirement that 
substudies be listed as appendices.  
Clarification.  
8.2.1 Physical examinations  Clarification of reporting of AEs.  Clarification.  
Throughout the document  Reformatting of existing content when 
necessary.  
Minor, editorial, stylistic changes as 
necessary.  
Update table of contents, section numbers, 
references as necessary.  Update in accordance with 
Sponsor’s standards.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 139 10.14.6  Amended Protocol 06 (23 May 2022)   
This amended protocol (amendment 06) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The primary driver for this amended protocol is to update liver related exclusion criteria and 
monitoring to mitigate risk of drug -induced liver injury.  
Protocol amendment summary of change s table  
Section # and Name  [CONTACT_21535]’s legal address updated.  Update.  
1.1 Synopsis  
10.1.5. Committees structure  Independent Hepatology Assessment Committee 
subsection added.  To evaluate on an ongoing 
basis cases of potential liver 
injury.  
1.3 Schedule of activities (SoA)  
5.2 Exclusion criteria (E 05)  
10.2 Appendix 2: Clinical laboratory 
tests (Table 5)  Iron panel at screening and corresponding exclusion 
criteria for genetic liver diseases added.  To mi tigate the risk of DILI.  
Abbreviations under the SoA and Table 5 updated.  Update.  
2.3 Benefit/Risk Assessment  Text related to drug -induced liver injury identified in 
an ongoing Phase 3 trial added.  Update.  
5.2 Exclusion criteria (E 02)  
5.3.2 Caffeine, alcohol, and tobacco  Exclusion criteria for alcohol consumption added. 
Related recommendation for alcohol consumption 
during study and PK/PD visits updated.  To mitigate the risk of DILI.  
1.3 Schedule of activ ities (SoA)  
5.2 Exclusion criteria (E 05)  
10.6 Appendix 6: Liver and other 
safety: actions and follow -up 
assessments  Liver and safety monitoring plan updated.  
Hepatic monitoring and hepatic exclusion criteria 
added.  
ALT algorithm and related instructions updated  
 To mitigate the risk of DILI.  
Updated monitoring request 
as per new exclusion 
threshold for ALT level.  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
Throughout the document  Reformatting of existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
references, abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
10.14.7  Amended protocol 07 (13 September 2022)   
This amended protocol (amendment 07) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 140 OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is to further reduce the risk of drug -induced liver injury 
(DILI) by [CONTACT_21519].  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_21536].  Update.  
1.3 Schedule of activities (SOA)  
 Increased liver laboratory monitoring frequency in 
the first year after the start of the IMP. Footnote ‘l’ 
updated.  
Albumin’ added in footnote ‘k’.  
Footnote ‘s’ next to ‘Pharmacokinetics’, 
‘Pharmacogenetics’, and 
‘Pharmacodynamics/biomarkers’ removed.  To reduce the risk of DILI.  
 
Correction of error.  
Correction of error.  
6.6.1 Rescue medicine  Increased liver laboratory monitoring added for 
participants switching to open -label SAR442168  
treatment after 6 -month CDP confirmation.  To reduce the risk of DILI.  
 
10.6 Appendix 6: Liver and other 
safety: actions and follow -up 
assessments  Increase in ALT algorithm flowchart and related 
instructions updated  Update.  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
Throughout the document  Reformatting of existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
references, abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
10.14.8  Amended protocol 08 (14 December 2022)   
This amended protocol (amendment 08) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is to clarify information about drug -induced liver 
injury (DILI) and update the ALT increase algorithm in relation to the risk of DILI.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 141 Protocol am endment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.2 Schema  Number of participants removed and replaced by 
[CONTACT_21520] 1 - Graphical study design.  Clarification.  
9.2 Sample size determination  Updated to clarify that with a reduced sample size, 
study power can be maintained by [CONTACT_21521] -up duration.  Sample size is adjusted 
based on actual recruitment 
and event rates. The target 
number of events is 
unchanged.  
1.3 Schedule of activities (SOA)  Removal of actigraphy wording from footnote ‘r’.  Update.  
10.12 Appendix 12: Actigraphy 
substudy  Updated to allow performing actigraphy in 
participants from enrollment into the substudy 
instead of screening.   
2.3 Benefit/risk assessment  Updated information about drug -induced liver injury.  Update.  
10.1.6 Dissemination of clinical study 
data Addition of ‘euclinicaltrials.eu’ in the list of websites 
where [COMPANY_011] shares information about clinical trials.  
‘Clinicalstudydatarequest.com’ replaced with 
‘vivli.org’.  Update.  
10.6 Appendix 6: Liver and other 
safety: actions and follow -up 
assessments  Related instructions of the increase in ALT algorithm 
updated.  Update.  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
Throughout the document  Reformatting of existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
references, abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
10.14.9  Amended protocol 09 (12 July 2023)   
This amended protocol (amendment 09) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is to incorporate country -specific guidelines for [LOCATION_009].  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 142 Protocol amendment summary of changes table  
Section # and Name  [CONTACT_21537] [CONTACT_21522] 02.  Correction of error.  
10.8.[ADDRESS_20376].  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
11 References  Updated.  Update.  
Throughout the document  Reformatted existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
references, abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
10.14.10  Amended protocol  10 (28 September 2023)   
This amended protocol (amendment 10) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is to clarify the language and requirements for the use 
of open -label SAR442168 in participants who have achieved 6 -month confirmed disability 
progression, and to update the testing requirements in the “Increase in ALT algorithm” in 
accordance with the Council for International Organization of Medical Sciences (CIOMS ) 
working group on DILI consensus report.   
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis  Changed the subtitle of “Post -trial access to study 
medication” to “Long -term safety study”.  Clarification.  
1.1 Synopsis, 1.3 Schedule of 
activities (SoA), and 6.8 Intervention 
after the end of the study  Revised “will be offered” to “may be offered”.  Clarification.  
1.1 Synopsis and 9.4.2 Primary 
endpoint  Added “baseline EDSS score” and “baseline 
Gd-enhancing T1 lesions (0, ≥1)” as a covariate of 
the Cox proportional hazards model.  
Updated the censoring and imputation algorithm for 
analyzing the time to onset of 6 -month CDP.  Update.  
 
 
Update primary ITT analyses  
based on the feedback from 
the health authority.  
1.1 Synopsis and 9.4.3 Secondary 
endpoint(s)  Added “baseline EDSS score” and “baseline number 
of T2 lesions” as covariates and update the offset 
variable based on the different duration of times 
between MR I scans.   Update secondary endpoint 
analyses.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 143 Section # and Name  [CONTACT_11029]  
1.3 Schedule of activities (SoA)  Updated footnote ‘e’ to include reference to the Study 
Manual.  
Updated footnote ‘l’ to include permitted time window 
for liver function tests.  Clarification.  
2.2 Background  
2.3 Benefit/risk assessment  Changed “T2 phase rims” to “paramagnetic rim 
lesions”.  Update.  
2.3 Benefit/risk assessment  Removed “all” for the identified risk for tolebrutinib 
and removed “to mitigate risk of hepatic injury”.  Update to keep cons istency 
with the Investigator’s 
Brochure.  
Updated “drug -induced liver injury (DILI)” to “DILI, 
including severe DILI (risk of liver transplantation or 
death), as an identified risk”.   
4.1 Overall Design  Replaced “rescued” with “initiated”. Removed “as 
rescued”.  Clarification.  
6.6.1 Open -label treatment  
 Replaced the term ‘rescue treatment’ with ‘open -label 
treatment’. Replaced the term “rescue medication” 
with “relapse treatment”.  Clarification.  
Updated requirements related to the exclusion criteria 
for participants switching to open -label treatment.  Clarification.  
 
7.1.1 Definitive discontinuation  Replaced “should be considered” with “is required”.  Clarification.  
8.5 Pharmacokinetics  Clarified PK sample collection/storage requirements 
and recommendations for liver and other safety 
events. Added cross -reference to Section 10.6 for 
more details.  Clarification.  
8.11 Use of biological samples and 
data for future research  Added details about the future use of  participant’s 
biological samples and data.  To keep consistency with ICF 
and Sponsor standards 
related to data privacy 
guidelines.  
9.4.2 Primary endpoint  Updated the subgroup analyses on the primary 
endpoint, including geographic region, baseline 
EDSS sco re, prior disease modifying therapy use, 
and duration since relapsing -remitting multiple 
sclerosis (RRMS) symptom onset.   Clarification on the subgroup 
factors.  
9.4.3 Secondary endpoint(s)  Updated the handling of the impact of deviation from 
normality.  
Updated the estimate as annualized rate based on 
the different duration of times between MRI scans.  Clarification.  
 
Update the secondary 
endpoint analyses.  
10.1.3 Informed consent process  Clarification of informed consent process.  To keep cons istency with ICF 
and Sponsor standards 
related to data privacy 
guidelines . 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 144 Section # and Name  [CONTACT_11029]  
10.1.4 Data protection  Sponsor’s data privacy and protection responsibilities 
clarified. Data protection for professionals involved in 
the study clarified.  To be compliant with dat a 
privacy guidelines . 
10.3.3 Recording and follow up of AE 
and/or SAE  Updated requirement for reporting SAEs in case of 
life-threatening or death events.  Clarification.  
10.6 Appendix 6: Liver and other 
safety: actions and follow -up 
assessments  Increase in ALT algorithm related assessments 
updated.  Update, for consistency with 
the CIOMS consensus 
report.  
10.8.[ADDRESS_20377].  
10.9 Appendix 9: Example of drugs 
with a potential to change 
SAR442168 metabolism or 
absorption  Removed “(per the lists of the Drug Interaction 
Database Program of the University of Washington)” 
and “modafinil”.  Correction of error as, 
according to the labels, 
modafinil is a weak CYP3A 
inducer, and therefore not 
prohibited; also, only keepi[INVESTIGATOR_21390] e 
sites to refer to the drug label 
for metabolic interactions.  
10.14 Appendix 14: Protocol 
amendment history  Updated.  Update.  
11 References  Updated.  Update.  
Throughout the document  Reformatting of existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
references, abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
Replaced the word ‘rescue treatment’ with ‘open -label 
treatment’.  Clarification.  
10.14.11  Amended protocol 11 (20 November 2023)   
This amended protocol (amendment 11) is considered to be substantial based on the criteria set 
forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
 
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 145 OVERALL RATIONALE FOR THE AMENDMENT  
The rationale for this protocol amendment is to clarify the liver function monitoring requirements, 
update the testing requirements  in the “Increase in ALT algorithm”, and update the concomitant 
medications that are prohibited during the conduct of the study as per health authority request.  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_11029]  
1.1 Synopsis, 9.4.3 Secondary 
endpoints  Clarification of statistical descriptions.  Clarification.  
1.3 Schedule of activities (SOA)  Safety follow -up visit period changed from [ADDRESS_20378] monitoring provided.  Update.  
10.6 Appendix 6: Liver and other 
safety: actions and follow up 
assessments  Liver function test monitoring guidance provided. 
Increase in ALT algorithm related assessments 
updated. Rechallenge restrictions updated.  Update.  
10.8.[ADDRESS_20379] the prohibited use of 
CYP3A and CYP2C8 inhibitors and the restriction of 
grapefruit/grapefruit juice (a CYP3A4 inhibitor).  Update.  
10.9 Appendix 9 : Example of drugs 
with a potential to change 
SAR442168 metabolism or 
absorption  Update to provide guidance to US, Israel, and any 
other sites that may be under FDA partial clinical 
hold.  Update to provide guidance.  
Throughout the document  Reformatting of  existing content when necessary. 
Minor, editorial, stylistic changes as necessary. 
Updated table of contents, section numbers, 
abbreviations as necessary.  Update in accordance with 
Sponsor’s standards.  
 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 146 11 REFERENCES   
1. Kappos L, Bar -Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. Efficacy of siponimod in 
secondary progressive mu ltiple sclerosis: results of the Phase 3 Study (CT.002). Neurology. 
2017;88 (Suppl 16):CT.002.  
2. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar -Or A, Comi G, et al. Ocrelizumab 
versus place bo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209 -20. 
3. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate 
endpoints for EDSS worsening in multiple sclerosis a meta -analytic approach. Neurology. 
2010;75(4):302 -9. 
4. Kappos L, Bar -Or A, Cree BAC, Fox RJ, Giovanni G, Gold R, et al. Siponimod versus 
placebo in secondary  progressive multiple sclerosis (EXPAND): a double -blind, randomised, 
phase 3 study. Lancet. 2018;391([ZIP_CODE]):1263 -73. 
5. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et a l. Diagnosis of 
multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162 -
73. 
6. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral  
fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, 
double -blind, placebo -controlled trial. Lancet. 2016;387([ZIP_CODE]):[ADDRESS_20380] of natalizumab 
on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, 
randomised, double -blind, placebo -controlled trial with an open -label extension. Lancet 
Neurol. 2018;17(5) :405-15. 
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status 
scale (EDSS). Neurology. 1983;33(11):1444 -52. 
9. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical 
investigation of medicinal products for the treatment of multiple sclerosis. 2015.  
10. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining 
the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278 -86. 
11. Lublin FD , Reingold SC. Defining the clinical course of multiple sclerosis: results of an 
international survey. National Multiple Sclerosis Society ([LOCATION_003]) Advisory Committee on 
Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907 -11. 
12. Hauser SL, Bar -Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab 
versus interferon Beta -1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):[ADDRESS_20381] Neurol. 2006;2(4):201 -11. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 147 14. Frischer JM, Bramow S, Dal -Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. 
The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 
2009;132(5):1175 -89. 
15. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand 
up? Nat Rev Neurosci. 2012;13(7):507 -14. 
16. Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, et al. Chronic white 
matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. 
Brain. 2019;142(9):2787 -99. 
17. Absinta M, Sati P, Masuzzo F, Nair G, Sethi V, Kolb H, et al. Errors in table and supplemental 
figure. Erratum for association of chronic active multiple sclerosis lesions with disability in 
vivo. [JAMA Neurol. 2019] . JAMA Neurol. 2019;76(12):1520.  
18. Giovannoni G, Hawkes C, Lechner -Scott J, Levy M, Waubant E, Gold J. The COVID -[ADDRESS_20382]. 
2020;39:102073.  
19. Navarro J, Pérez -Ruiz M. Antiviral Immunity. Curr Immunol Rev. 2011;7:19 -24. 
20. Roschewski M, Lionak is MS, Sharman JP, Roswarski J, Goy A, Monticelli, et al. Inhibition of 
Bruton tyrosine kinase in patients with severe COVID -19. Sci Immunol. 
2020;5(48):eabd0110.  
21. National Library of Medi cine. Identifier [STUDY_ID_REMOVED], A phase 2, open -label, randomized 
study of the efficacy and safety of acalabrutinib with best supportive care versus best 
supportive care in subjects hospi[INVESTIGATOR_21391] -19. [Online]. 2020 May 8 [cited 2020 
Aug 12]; [about  5 screens]. Available from: 
URL:https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=acalabrutinib&cond=Covid19&
draw=2&rank=1  
22. National Library of Medicine. Identifier [STUDY_ID_REMOVED], A phase  2, open -label, randomized 
study of the efficacy and safety of acalabrutinib with best supportive care versus best 
supportive care in subjects hospi[INVESTIGATOR_21391] -19. [Online]. 2020 Apr 15 [cited 2020 
Aug 12]; [about 5 screens]. Available from: 
URL:htt ps://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=acalabrutinib&cond=Covid19&
draw=2&rank=2  
23. National Library of Medicine. Identifier [STUDY_ID_REMOVED], IbrutiNib in SARS CoV -2 induced 
pulmonary i njury and respi[INVESTIGATOR_1399] (iNSPI[INVESTIGATOR_21392]). [Online]. 2020 May 5 [cited 2020 Aug 
12]; [about 5 screens]. Available from: 
URL:https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=ibrutinib&cond=covid19&draw
=2&rank=1  
24. National Library of Medicine. Identifier [STUDY_ID_REMOVED], Randomized trial of ibrutinib versus 
standard treatment for COVID -19 illness requiring hospi[INVESTIGATOR_21393] -in. 
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 148 [Online]. 2020 Jun 19 [cited 2020 Aug 12]; [about 5 sc reens]. Available from: 
URL:https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=ibrutinib&cond=covid19&draw
=2&rank=2  
25. Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, et  al. Clinical 
relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a 
clinical routine. Expert Rev Neurother. 2016;16(7):777 -93. 
26. Acquadro C, Berzon R, Du bois D, Leidy NK, Marquis P, Revicki D, et al. Incorporating the 
patient’s perspective into drug development and communication: an ad hoc task force report of 
the Patient -Reported Outcomes (PRO) harmonization group meeting at the Food and Drug 
Administrati on, February 16, 2001. Value Health. 2003;6(5):522 -31. 
27. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic 
opportunity in multiple sclerosis: evidence f rom monoclonal antibody therapy. J Neurol. 
2006;253(1):98 -108. 
28. Hauser SL, Bar -Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab 
versus interferon beta -1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221 -34. 
29. European Medicines Agency. EMA's final opi[INVESTIGATOR_21394]. EMA/4 [ZIP_CODE]/2017. [Online]. 2017 Jul [cited 2020 Aug 12]; 
Available from: URL: https://www.ema.europa.eu/en/documents/press -release/emas -final-
opi[INVESTIGATOR_1649] -confirms -restrictions -use-linear -gadolinium -agents -body -scans_en.pdf  
30. National MS Society. Timed [ADDRESS_20383]. [Online]. [cited 2021 Dec 21]; Available from: 
URL:https://www.nationalmssociety.org/For -Professionals/Researchers/Resources -for-MS-
Researchers/Research -Tools/Clinical -Study -Measures/T imed -25-Foot-Walk -(T25 -FW) 
31. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional 
measures in MS: what is a reliable change? Neurology. 2002;58(8):1294 -6. 
32. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional 
Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. 
National MS Society Clinical Ou tcomes Assessment Task Force. Mult Scler. 1999;5(4):[ADDRESS_20384], Grattan L, Panitch HS, Johnson KP. The brief repeatable battery of 
neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult Scler. 
1995;1(3):[ADDRESS_20385] as a cognition  performance outcome measure for multiple 
sclerosis.Mult Scler. 2017;23(5):[ADDRESS_20386]. 2nd ed (CVLT -
II). San Antonio: P sychological Corporation; 2000.  
VV-CLIN-0579238 21.0
Amended Clinical Trial Protocol 12   
SAR442168 -EFC16645  - tolebrutinib  20-Dec-2023  
Version number: [ADDRESS_20387] RH. 
Psychometrics and normative data for the Multiple Sclerosis Functional Com posite: replacing 
the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010;16(2):228 -37. 
37. Banwell B, Giovannoni G, Hawkes C, Lubin F. Editors’ welcome and a working definition for 
a multiple sclerosis cure. Mult Scler Relat Disord. 2013;2(2):[ADDRESS_20388], Harooni R, Myers LW, Ellison GW. A health -related quality of life 
measure for multiple sclerosis. Q ual Life Res. 1995;4(3):[ADDRESS_20389], Genovese BJ, Myers LW, Ellison GW. Comparison of a generic to 
disease -targeted health -related quality -of-life measures for multiple sc lerosis. J Clin 
Epi[INVESTIGATOR_5541]. 1997;50(5):[ADDRESS_20390] AS, Neary MP, Cella D. Estimation of minimally important differences in EQ -5D 
utility and VAS scores in cancer. Health Qual Life Outco mes. 2007;5:70.  
41. Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart -Jones H, et al. How people 
with multiple sclerosis rate their quality of life: an EQ -5D survey via the [LOCATION_006] MS Reg ister. 
PLoS ONE. 2013;8(6):e65640.  
42. Food and Drug Administration. Collection of Race and Ethnicity Data in Clinical Trials: 
Guidance for Industry and Food and Drug Administration Staff. 201 6. 
43. International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: Ethnic factors in the 
acceptability of foreign clinical data E5(R1). 1998.  
44. Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic 
criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 
2013;80(15):1430 -8. 
45. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab 
treatment for multiple sclerosis: rec ommendations for patient selection and monitoring. Lancet 
Neurol. 2007;6(5):431 -41. 
46. U.S. Food and Drug Administration. Drug Induced Liver Injury Rank (DILIrank) Dataset. 
2023 Feb 09 [cited  2023 Jul 07]. Available from: URL:https://www.fda.gov/science -
research/liver -toxicity -knowledge -base-ltkb/drug -induced -liver-injury -rank-dilirank -dataset  
47. Chen M, Suzuki A, Thakkar S, Yu K , Hu C, Tong W. DILIrank: the largest reference drug list 
ranked by [CONTACT_21523][INVESTIGATOR_21395] -induced liver injury in humans. Drug Discov Today. 
2016;21(4):648 -53. 
48. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug -
induced liver injury. J Hepatol. 2019;70(6):1222 -61. 
VV-CLIN-0579238 21.0
Signature [CONTACT_11032]-CLIN-0579238 v21.0
efc16645-16-1-1-amended-protocol12
Approve & eSign
Approve & eSign
VV-CLIN-0579238 21.0
